<PAGE>
<PAGE>
________________________________________________________________________________
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED OCTOBER 31, 1995 COMMISSION FILE NO. 1-8597
------------------------
THE COOPER COMPANIES, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
------------------------
<TABLE>
<S> <C>
DELAWARE 94-2657368
(STATE OR OTHER JURISDICTION (I.R.S. EMPLOYER
OF INCORPORATION) IDENTIFICATION NO.)
6140 STONERIDGE MALL ROAD, SUITE 590 94588
PLEASANTON, CALIFORNIA (ZIP CODE)
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
510-460-3600
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
</TABLE>
------------------------
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
<TABLE>
<CAPTION>
NAME OF EACH EXCHANGE
TITLE OF EACH CLASS ON WHICH REGISTERED
- ------------------------------------------------ ------------------------------------------------
<S> <C>
Common Stock, $.10 Par Value, and
associated Rights New York Stock Exchange
10 5/8% Convertible Subordinated Reset Pacific Stock Exchange
Debentures due 2005 New York Stock Exchange
10% Senior Subordinated Secured Notes Pacific Stock Exchange
due 2003 Pacific Stock Exchange
</TABLE>
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:
None
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months, and (2) has been subject to such filing
requirements for the past 90 days. Yes [x] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [x]
Aggregate market value of the voting stock held by non-affiliates of the
registrant as of December 31, 1995: Common Stock, $.10 Par Value -- $66,383,460.
Number of shares outstanding of the registrant's common stock, as of
December 31, 1995: 11,582,186.
DOCUMENTS INCORPORATED BY REFERENCE:
The Proxy Statement for the registrant's 1996 Annual Meeting of
Stockholders is incorporated by reference into Part III of this Form 10-K.
________________________________________________________________________________
<PAGE>
<PAGE>
PART I
ITEM 1. BUSINESS.
INTRODUCTION
The Cooper Companies, Inc. ('TCC' or the 'Company'), through its
subsidiaries, develops, manufactures and markets healthcare products, including
a range of contact lenses and diagnostic and surgical instruments and
accessories, and provides healthcare services through the ownership and
operation of certain psychiatric facilities. TCC is a Delaware corporation which
was organized on March 4, 1980.
COOPERVISION
CooperVision, Inc. ('CooperVision' or 'CVI') develops, manufactures and
markets a range of contact lenses in the United States and Canada. Approximately
75% of the lenses sold are conventional daily or flexible wear lenses and
approximately 25% constitute planned replacement lenses.
CooperVision's major brand name lenses are Hydrasoft'r', Preference'r',
Vantage'r', Permaflex'r', Permalens'r' and Cooper Clear'tm'. These and other
products enable CooperVision to fit the needs of a diverse group of wearers by
offering lenses formulated from a variety of polymers containing varying amounts
of water and different degrees of oxygen permeability, and having different
design parameters, diameters, base curves and lens edges. Certain lenses offer
special features such as protection against ultraviolet light, color tint,
astigmatic correction or aphakic correction.
Preference'r', which was introduced in fiscal 1992, is a planned
replacement product manufactured from the Tetrafilcon A polymer. Three clinical
studies, conducted at 31 investigative sites using 603 patients, have
demonstrated Preference's superior performance in connection with deposit
resistance, visual acuity and handling.
In April 1993, CooperVision acquired CoastVision, Inc. ('CoastVision'), a
contact lens company which designs, manufactures and markets high quality soft
toric lenses (the majority of which are custom made) designed to correct
astigmatism. The acquisition has enabled CooperVision to expand into an
additional niche in the contact lens market and to enlarge its customer base.
In October 1994, CooperVision introduced Preference Toric'tm', a toric
planned replacement product. Preference Toric'tm' combines the benefits of the
Tetrafilcon A polymer with the low cost 'fips' manufacturing techniques and
design characteristics of the Hydrasoft'r' toric lens. This new product enables
CooperVision to compete in the fast-growing toric planned replacement market
segment.
CooperVision Pharmaceuticals, now reorganized as part of CooperVision, has
completed all of the clinical trials conducted during the past four years with
respect to CalOptic'tm', its proprietary calcium channel blocker compound being
developed for the topical treatment of glaucoma. Those clinical trials
demonstrated safety and efficacy, but also indicated that considerable further
research would be necessary to establish the compound's full potential and to
obtain regulatory approvals to market the product. Exploratory discussions with
prospective partners are continuing in an attempt to share the risks and costs
of the necessary further research, as well as the potential profits that may
ultimately be obtained if the product is approved for sale.
CooperVision is continuing to explore opportunities to expand and diversify
its business into additional niche markets.
COOPERSURGICAL
CooperSurgical, Inc. ('CooperSurgical') was established in November 1990 to
compete in niche segments of the rapidly expanding worldwide market for
diagnostic and surgical instruments, accessories and disposable devices. During
the past few years, increasing emphasis has been given to developing,
manufacturing and distributing diagnostic and surgical instruments, disposable
devices and equipment used selectively in both traditional and minimally
invasive surgical procedures, especially
1
<PAGE>
<PAGE>
those performed by gynecologists. By the end of fiscal 1995, approximately 75%
of CooperSurgical's net revenue related to women's healthcare products.
CooperSurgical's loop electrosurgical excision procedure products, marketed
under the LEEP'tm' brand name, are primarily used for the removal of cervical
and vaginal pre-cancerous tissue and benign external lesions. Unlike laser
ablation, which tends to destroy tissue, the electrosurgery procedure removes
affected tissue with minimal charring, thereby improving the opportunity to
obtain an accurate histological analysis of the patient's condition by producing
a viable tissue specimen for biopsy purposes. In addition, the loop
electrosurgical excision procedure is less painful to the patient than laser
ablation and is easily learned by practitioners. Because this procedure enables
a gynecologist to both diagnose and treat a patient in one office visit,
patients incur lower costs.
CooperSurgical's LEEP System 6000'r' branded products include an
electrosurgical generator, sterile single application LEEP Electrodes'tm', the
CooperSurgical Smoke Evacuation System 6080'tm', a single application LEEP
RediKit'r', a series of educational video tapes and a line of autoclavable
coated LEEP'tm' surgical instruments. LEEP System 1000'tm' branded products have
been introduced for use abroad.
CooperSurgical's Euro-Med mail order business offers over 400 products for
use in gynecologic and general surgical procedures. Over 60% of these products
are exclusive to Euro-Med, including its 'signature' instrument series, cervical
biopsy punches, clear plastic instruments used for unobstructed viewing,
titanium instruments used in laser surgeries, colposcopy procedure kits and
instrument care and sterilization systems.
CooperSurgical's Frigitronics'r' instruments for cryosurgery are used
primarily in dermatologic procedures to treat skin cancers, in ophthalmic
procedures to treat retinal detachments and remove cataracts, and in certain
gynecologic, cardiovascular and general surgical procedures. The primary
products bearing the Frigitronics brand name are the Model 310 Zoom Colposcope,
the CCS-200 Cardiac Cryosurgical System, the Model 2000 Ophthalmic Cryosurgical
System and the Cryo-Plus System for gynecologic office procedures.
In May 1995, CooperSurgical terminated its agreement with InnerDyne, Inc.
to develop their endometrial ablation technology to control excessive uterine
bleeding.
In June 1995, CooperSurgical acquired a proprietary line of products that
facilitate the performance of gynecological procedures where uterine
manipulation is required. Compared to competing products, the new CooperSurgical
products offer the gynecologist substantially improved pelvic exposure, access
and traction during laparoscopic surgery, and facilitate dye injection during
fertility studies. Since acquiring this product line, CooperSurgical has
completed development of a proprietary line extension designed to enable
gynecologists to perform minimally invasive hysterectomies, which will be
launched after market clearance by the FDA.
Outside the U.S., CooperSurgical received regulatory approval during 1995
for its operating room laparoscopy products in Japan.
HOSPITAL GROUP OF AMERICA
In May 1992, TCC acquired Hospital Group of America, Inc. ('HGA'), which
owns and operates three psychiatric facilities: Hartgrove Hospital in Chicago,
Illinois (which currently has 119 licensed beds), Hampton Hospital in Rancocas,
New Jersey (which currently has 100 licensed beds) and MeadowWood Hospital in
New Castle, Delaware (which currently has 50 licensed beds). Also in May 1992, a
subsidiary of the Company entered into a management services agreement under
which it assumed the management of three additional psychiatric facilities. The
management services agreement, which provided for monthly payments to the
Company of $166,667, expired by its terms in May 1995. Also in May 1995, HGA
settled a purchase price adjustment and other disputes that had been pending
since 1992 with the former owner of its hospitals.
HGA's psychiatric facilities provide intensive and structured treatment for
children, adolescents and adults suffering from a variety of mental illnesses
and/or chemical dependencies, including treatment for women, older adults,
survivors of psychological trauma and alcohol and substance abusers. Services
2
<PAGE>
<PAGE>
include comprehensive psychiatric and chemical dependency evaluations, inpatient
and outpatient treatment and partial hospitalization.
In response to market demands for an expanded continuum of care, HGA is in
the process of expanding its outpatient and partial hospitalization programs.
Several of those facilities offer day-treatment to children and adolescents,
others offer treatment to chronically mentally ill adults and others offer
outpatient counseling. During 1995, the number of day-treatment sites was
increased to eight at Hartgrove Hospital and to four at MeadowWood Hospital.
Additional programs are expected to commence operations in 1996.
The following is a comparison of certain statistical data relating to
inpatient treatment for fiscal years 1993, 1994 and 1995 for the psychiatric
facilities owned by HGA:
<TABLE>
<CAPTION>
FISCAL YEAR ENDED OCTOBER
31,
----------------------------
1995 1994 1993
------ ------ ------
<S> <C> <C> <C>
Total patient days.................................................... 62,556 71,882 72,054
Admissions............................................................ 4,782 4,787 4,310
Average length of stay (in days)...................................... 12.9 15.0 16.8
Average occupancy..................................................... 63.7% 73.2% 76.2%
</TABLE>
During the three-year period for which information is provided, total
patient days, average length of stay, and average occupancy have declined. This
trend is due, in part, to pressure from managed care groups to limit the length
of hospital stays.
Each psychiatric facility is accredited by the Joint Commission of
Accreditation of Healthcare Organizations (JCAHO), a national organization which
periodically undertakes a comprehensive review of a facility's staff, programs,
physical plant and policies and procedures for purposes of accreditation of such
healthcare facility. Accreditation generally is required for patients to receive
insurance company reimbursement and for participation by the facility in
government sponsored provider programs.
Until December 31, 1995, a medical group not affiliated with HGA was
responsible for providing both clinical and clinical administrative services at
Hampton Hospital. In December 1995, the Company announced the settlement of a
dispute with the management of that medical group. (See Note 14.(1))
Patient and Third Party Payments. HGA receives payment for its psychiatric
services either from patients, from their health insurers or through the
Medicare, Medicaid and Civilian Health and Medical Program of Uniformed Services
('CHAMPUS') governmental programs. Medicare is a federal program which entitles
persons 65 and over to a lifetime benefit of up to 190 days as an inpatient in
an acute psychiatric facility. Persons defined as disabled, regardless of age,
also receive this benefit. Medicaid is a joint federal and state program
available to persons with limited financial resources. CHAMPUS is a federal
program which provides health insurance for active and retired military
personnel and their dependents.
While other programs may exist or be adopted in different jurisdictions,
the following four categories reflect the primary methods by which HGA's
facilities receive payment for services:
(a) Standard reimbursement, consisting of payment by patients and
their health insurers, is based on a facility's schedule of rates and is
not subject to negotiation with insurance companies, competitive bidding or
governmental limitation.
(b) Negotiated rate reimbursement is at prices established in advance
by negotiation or competitive bidding for contracts with insurers and other
payors such as managed care companies, health maintenance organizations
('HMO'), preferred provider organizations ('PPO') and similar organizations
which can provide a reasonable number of referrals.
(c) Cost-based reimbursement is predicated on the allowable cost of
services, plus, in certain cases, an incentive payment where costs fall
below a target rate. It is used by Medicare, Medicaid
- ------------
(1) All references to Note numbers shall constitute the incorporation by
reference of the text of the specific Note contained in the Notes to
Consolidated Financial Statements of the Company and its subsidiaries
located in Item 8, into the Item number in which it appears.
3
<PAGE>
<PAGE>
and certain Blue Cross insurance programs to provide reimbursement in
amounts generally lower than the standard or negotiated schedule of rates
in effect at an HGA facility.
(d) CHAMPUS reimbursement is at either (1) regionally set rates, (2) a
national rate adjusted upward periodically on the basis of the Medicare
Market Basket Index or (3) a fixed discount rate per day at certain
facilities where CHAMPUS contracts with a benefit administration group.
The Medicare, Medicaid and CHAMPUS programs are subject to statutory and
regulatory changes and interpretations, utilization reviews and governmental
funding restrictions, all of which may materially increase or decrease program
payments and the cost of providing services, as well as the timing of payments
to the facilities.
Limits on Reimbursement. Changes in government reimbursement programs have
resulted in limitations on increases in, and in some cases in reduced levels of
reimbursement for healthcare services, and additional changes are anticipated.
Such changes are likely to result in further limitations on reimbursement
levels. In addition, private payors, including managed care payors, increasingly
are demanding discounted fee structures. Inpatient hospital utilization, average
lengths of stay and occupancy rates continue to be negatively affected by
payor-required pre-admission authorization and utilization review and by payor
pressure to maximize outpatient and alternative healthcare delivery services for
less acutely ill patients. In addition, efforts to impose reduced allowances,
greater discounts and more stringent cost controls by government and other
payors are expected to continue. Although the Company is unable to predict the
effect these changes will have on its operations, as the number of patients
covered by managed care payors increases, significant limits on the scope of
services reimbursed and on reimbursement rates and fees could have a further
adverse effect on HGA's business and earnings.
RESEARCH AND DEVELOPMENT
During the fiscal years ended October 31, 1995, 1994 and 1993, expenditures
for Company-sponsored research and development were $2,914,000, $4,407,000 and
$3,209,000, respectively. During fiscal 1995, approximately 43% of those
expenditures was incurred by CooperVision Pharmaceuticals, primarily in
connection with completing the CalOptic'tm' clinical trials, 29% was incurred by
CooperVision and the balance was incurred by CooperSurgical. No
customer-sponsored research and development has been conducted.
The Company employs 16 people in its research and development and
manufacturing engineering departments. Product development and clinical research
for CooperVision products are supported by outside specialists in lens design,
formulation science, polymer chemistry, microbiology and biochemistry. Product
research and development for CooperSurgical is conducted in-house and by outside
surgical specialists, including members of both the CooperSurgical and Euro-Med
surgical advisory boards.
GOVERNMENT REGULATION
Healthcare Products. The development, testing, production and marketing of
the Company's healthcare products are subject to the authority of the U.S. Food
and Drug Administration ('FDA') and other federal agencies as well as foreign
ministries of health. The Federal Food, Drug and Cosmetic Act and other statutes
and regulations govern the testing, manufacturing, labeling, storage,
advertising and promotion of such products. Noncompliance with applicable
regulations can result in fines, product recall or seizure, suspension of
production and criminal prosecution.
The Company is currently developing and marketing medical devices, which
are subject to different levels of FDA regulation depending upon the
classification of the device. Class III devices, such as flexible and extended
wear contact lenses, require extensive premarket testing and approval
procedures, while Class I and II devices are subject to substantially lower
levels of regulation.
A multi-step procedure must be completed before a new contact lens can be
sold commercially. Data must be compiled on the chemistry and toxicology of the
lens, its microbiological profile and the proposed manufacturing process. All
data generated must be submitted to the FDA in support of an application for an
Investigational Device Exemption. Once granted, clinical trials may be initiated
4
<PAGE>
<PAGE>
subject to the review and approval of an Institutional Review Board and, where a
lens is determined to be a significant risk device, the FDA. Upon completion of
clinical trials, a Premarket Approval Application must be submitted and approved
by the FDA before commercialization may begin.
The Company, in connection with some of its new surgical products, can
submit premarket notification to the FDA under an expedited procedure known as a
510(k) application, which is available for any product that can be demonstrated
to be substantially equivalent to a device marketed prior to May 28, 1976. If
the new product is not substantially equivalent to a pre-existing device or if
the FDA were to reject a claim of substantial equivalence, extensive preclinical
and clinical testing would be required, additional costs would be incurred and a
substantial delay would occur before the product could be brought to market.
FDA and state regulations also require adherence to applicable 'good
manufacturing practices' ('GMP'), which mandate detailed quality assurance and
record-keeping procedures. In conjunction therewith, the Company is subject to
unscheduled periodic regulatory inspections. The Company believes it is in
substantial compliance with GMP regulations.
The Company also is subject to foreign regulatory authorities governing
human clinical trials and pharmaceutical/medical device sales that vary widely
from country to country. Whether or not FDA approval has been obtained, approval
of a product by comparable regulatory authorities of foreign countries must be
obtained before products may be marketed in those countries. The approval
process varies from country to country, and the time required may be longer or
shorter than that required for FDA approval.
The procedures described above involve the expenditure of considerable
resources and usually result in a substantial time lag between the development
of a new product and its introduction into the marketplace. There can be no
assurance that all necessary approvals will be obtained, or that they will be
obtained in a time frame that allows the product to be introduced for commercial
sale in a timely manner. Furthermore, product approvals may be withdrawn if
compliance with regulatory standards is not maintained or if problems occur
after marketing has begun.
Healthcare Services. The healthcare services industry is subject to
substantial federal, state and local regulation. Government regulation affects
the Company's business by controlling the use of its properties and controlling
reimbursement for services provided. Licensing, certification and other
applicable governmental regulations vary from jurisdiction to jurisdiction and
are revised periodically.
The Company's facilities must comply with the licensing requirements of
federal, state and local health agencies and with the requirements of municipal
building codes, health codes and local fire department codes. In granting and
renewing a facility's license, a state health agency considers, among other
things, the condition of the physical buildings and equipment, the
qualifications of the administrative personnel and professional staff, the
quality of professional and other services and the continuing compliance of such
facility with applicable laws and regulations.
The states in which the Company operates hospital facilities have in effect
certificate of need statutes. State certificate of need statutes provide,
generally, that prior to the construction of new healthcare facilities, the
addition of new beds or the introduction of a new service, a state agency must
determine that a need exists for those facilities, beds or services. A
certificate of need is generally issued for a specific maximum amount of
expenditures or number of beds or types of services to be provided, and the
holder is generally required to implement the approved project within a specific
time period. Certificate of need issuances for new facilities are extremely
competitive, often with several applicants for a single certificate of need.
All of HGA's facilities are certified or approved as providers under one or
more of the Medicaid or Medicare programs. In order to receive Medicare
reimbursement, each facility must meet the applicable conditions promulgated by
the United States Department of Health and Human Services relating to the type
of facility, its equipment, its personnel and its standards of patient care.
The Social Security Act contains a number of provisions designed to ensure
that services rendered to Medicare and Medicaid patients are medically necessary
and meet professionally recognized standards. Those provisions include a
requirement that admissions of Medicare and Medicaid patients to healthcare
facilities must be reviewed in a timely manner to determine the medical
necessity of the
5
<PAGE>
<PAGE>
admissions. In addition, the Peer Review Improvement Act of 1982 provides that a
healthcare facility may be required by the federal government to reimburse the
government for the cost of Medicare-paid services determined by a peer review
organization to have been medically unnecessary.
Various state and federal laws regulate the relationships between providers
of healthcare services and physicians. Among these laws are the Medicare and
Medicaid Anti-Fraud and Abuse Amendments to the Social Security Act, which
prohibit individuals or entities participating in the Medicare or Medicaid
programs from knowingly and willfully offering, paying, soliciting or receiving
'remuneration' (which includes anything of value) in order to induce referrals
for items or services reimbursed under those programs. Sanctions for violating
the Amendments include criminal penalties and civil sanctions, including fines
and possible exclusion from the Medicare and Medicaid programs. In addition,
Section 1877 of the Social Security Act was amended, effective January 1, 1995,
to significantly broaden the prohibitions against physicians making referrals
under Medicare and Medicaid programs to providers with which the physicians have
financial arrangements. Many states have adopted, or are considering, similar
legislative proposals, some of which (including statutes in effect in New Jersey
and Illinois) extend beyond the Medicare and Medicaid programs to all healthcare
services.
In addition, specific laws exist that regulate certain aspects of the
Company's business, such as the commitment of patients to psychiatric hospitals
and disclosure of information regarding patients being treated for chemical
dependency. Many states have adopted a 'patient's bill of rights' which sets
forth standards for dealing with issues such as use of the least restrictive
treatment, patient confidentiality, patient access to telephones, mail and legal
counsel and requiring the patient to be treated with dignity.
Healthcare Reform. In recent years, an increasing number of legislative
initiatives have been introduced or proposed in Congress and in state
legislatures that would effect major changes in the healthcare system, either
nationally or at the state level. Among the proposals under consideration are
price controls on hospitals, insurance market reforms to increase the
availability of group health insurance to small businesses, requirements that
all businesses offer health insurance coverage to their employees and the
creation of a government health insurance plan or plans that would cover all
citizens. There continue to be efforts at the federal level to introduce various
insurance market reforms, expanded fraud and abuse and anti-referral legislation
and further reductions in Medicare and Medicaid reimbursement. A broad range of
both similar and more comprehensive healthcare reform initiatives is likely to
be considered at the state level. It is uncertain which, if any, of these or
other proposals will be adopted. The Company cannot predict the effect such
reforms or the prospect of their enactment may have on the business of the
Company and its subsidiaries.
RAW MATERIALS
In general, raw materials required by CooperVision consist of various
polymers as well as packaging materials. Alternative sources of all of these
materials are available. Raw materials used by CooperSurgical or its suppliers
are generally available from a variety of sources. Products manufactured for
CooperSurgical are generally available from more than one source. However,
because some products require specialized manufacturing procedures,
CooperSurgical could experience inventory shortages if an alternative
manufacturer had to be secured on short notice.
MANUFACTURING
CooperVision manufactures products in the United States and Canada.
CooperSurgical manufactures products in the United States and Europe.
Pursuant to a supply agreement entered into in May 1989 and subsequently
amended between the Company and Pilkington plc, the buyer of the Company's
contact lens business outside of the United States and Canada, CooperVision
purchases certain of its lenses from Pilkington plc (see Note 14). These
purchased lenses represented approximately 10%, 13% and 28% of the total number
of lenses sold by the Company in fiscal 1995, 1994 and 1993, respectively.
6
<PAGE>
<PAGE>
MARKETING AND DISTRIBUTION
Healthcare Products. In the United States and Canada, CooperVision markets
its products through its field sales representatives, who call on
ophthalmologists, optometrists, opticians and optical chains. In the United
States, field sales representatives also call on distributors.
CooperSurgical's LEEP'tm', Frigitronics'r' and hysteroscopy products are
marketed worldwide by a network of independent sales representatives and
distributors. Euro-Med'r' instruments, as well as certain LEEP'tm' disposable
products, are marketed in the United States through direct mail catalog
programs.
Healthcare Services. HGA's marketing concept aims to position each
psychiatric facility as the provider of the highest quality mental health
services in its marketplace. HGA employs a combination of general advertising,
toll-free 'help lines,' community education programs and facility-based
continuing education programs to underscore the facility's value as a mental
health resource center. HGA's marketing emphasizes discrete programs for select
illnesses or disorders because of its belief that marketing with program
differentiation will be valuable to a referral source seeking treatment for
specific disorders. Referral sources include psychiatrists, other physicians,
psychologists, social workers, school guidance counselors, police, courts,
clergy, care-provider organizations and former patients.
PATENTS, TRADEMARKS AND LICENSING AGREEMENTS
TCC owns or licenses a variety of domestic and foreign patents which, in
the aggregate, are material to its businesses. Unexpired terms of TCC's United
States patents range from less than one year to a maximum of 20 years.
As indicated in the references to such products in this Item 1, the names
of certain of TCC's products are protected by trademark registrations in the
United States Patent and Trademark Office and, in some instances, in foreign
trademark offices as well. Applications are pending for additional trademark
registrations. TCC considers these trademarks to be valuable because of their
contribution to the market identification of its various products.
DEPENDENCE UPON CUSTOMERS
No material portion of TCC's businesses is dependent upon any one customer
or upon any one affiliated group of customers. However, approximately 21% and
29%, respectively, of HGA's fiscal 1995 net patient revenue was generated by
Medicaid and Medicare.
GOVERNMENT CONTRACTS
No material portion of TCC's businesses is subject to renegotiation of
profits or termination of contracts or subcontracts at the election of the
United States government.
COMPETITION
Each of TCC's businesses operates within a highly competitive environment.
Competition in the healthcare industry revolves around the search for
technological and therapeutic innovations in the prevention, diagnosis and
treatment of illness or disease. TCC competes primarily on the basis of product
quality, program differentiation, technological benefit, service and
reliability, as perceived by medical professionals.
Healthcare Products. Numerous companies are engaged in the development and
manufacture of contact lenses. CooperVision competes primarily on the basis of
product quality, service and reputation among medical professionals and by its
participation in specialty niche markets. It has been, and continues to be, the
sponsor of clinical lens studies intended to generate information leading to the
improvement of CooperVision's lenses from a medical point of view. Major
competitors have greater financial resources and larger research and development
and sales forces than CooperVision. Furthermore, many of these competitors offer
a greater range of contact lenses, plus a variety of other
7
<PAGE>
<PAGE>
eyecare products, including lens care products and ophthalmic pharmaceuticals,
which may give them a competitive advantage in marketing their lenses to high
volume contract accounts.
In the surgical segment, competitive factors are technological and
scientific advances, product quality, price and effective communication of
product information to physicians and hospitals. CooperSurgical believes that it
benefits, in part, from the technological advantages of certain of its products
and from the ongoing development of new medical procedures, which creates a
market for equipment and instruments specifically tailored for use in such new
procedures. CooperSurgical competes by focusing on distinct niche markets and
supplying medical personnel working in those markets with equipment, instruments
and disposable products that are high in quality and that, with respect to
certain procedures, enable a medical practitioner to obtain from one source all
of the equipment, instruments and disposable products required to perform such
procedure. As CooperSurgical develops products to be used in the performance of
new medical procedures, it offers training to medical professionals in the
performance of such procedures. CooperSurgical competes with a number of
manufacturers in each of its niche markets, including larger manufacturers that
have greater financial and personnel resources and sell a substantially larger
number of product lines.
Healthcare Services. In most areas in which HGA operates, there are other
psychiatric facilities that provide services comparable to those offered by
HGA's facilities. Some of those facilities are owned by governmental
organizations, not-for-profit organizations or investor-owned companies having
substantially greater resources than HGA and, in some cases, tax-exempt status.
Psychiatric facilities frequently draw patients from areas outside their
immediate locale, therefore, HGA's psychiatric facilities compete with both
local and distant facilities. In addition, psychiatric facilities compete with
psychiatric units in acute care hospitals. HGA's strategy is to develop high
quality programs designed to target specific disorders and to retain a highly
qualified professional staff.
BACKLOG
TCC does not consider backlog to be a material factor in its businesses.
SEASONALITY
HGA's psychiatric facilities experience a decline in occupancy rates during
the summer months when school is not in session and during the year-end holiday
season. No other material portion of TCC's businesses is seasonal.
COMPLIANCE WITH ENVIRONMENTAL LAWS
Federal, state and local provisions regulating the discharge of materials
into the environment, or otherwise relating to the protection of the
environment, do not currently have a material effect upon TCC's capital
expenditures, earnings or competitive position.
WORKING CAPITAL
TCC's businesses have not required any material working capital
arrangements in the past five years. In light of the substantial reduction in
TCC's current asset base and the potential cash outflow which may occur in
connection with the acquisition of new products, the Company has obtained a line
of credit from a commercial lender and is pursuing a variety of other
alternatives to obtain funds. See Item 7 'Management's Discussion and Analysis
of Financial Condition' and 'Results of Operations -- Capital Resources and
Liquidity.'
FINANCIAL INFORMATION ABOUT BUSINESS SEGMENTS, GEOGRAPHIC AREAS, FOREIGN
OPERATIONS AND EXPORT SALES
Note 16 sets forth financial information with respect to TCC's business
segments and sales in different geographic areas.
8
<PAGE>
<PAGE>
EMPLOYEES
On October 31, 1995, TCC and its subsidiaries employed approximately 1,000
persons. In addition, HGA's psychiatric facilities are staffed by licensed
physicians who have been admitted to the medical staff of an individual
facility. Certain of those physicians are not employees of HGA. TCC believes
that its relations with its employees are good.
EXECUTIVE OFFICERS OF THE COMPANY
Set forth below is information regarding the current executive officers of
the Company or its principal subsidiaries who are not also directors:
<TABLE>
<CAPTION>
NAME AGE OFFICE
- ------------------------------- --- --------------------------------------------------------------------------
<S> <C> <C>
Gregory A. Fryling............. 41 Vice President, Business Development, President of CooperVision
Pharmaceuticals, Inc.
Robert S. Holcombe............. 53 Senior Vice President and General Counsel
Marisa F. Jacobs............... 38 Secretary and Associate General Counsel
Carol R. Kaufman............... 46 Vice President and Chief Administrative Officer
Audrey A. Murray............... 51 Vice President of Risk Management and Employee Benefits
Nicholas J. Pichotta........... 51 President and Chief Executive Officer of CooperSurgical, Inc.
Mark R. Russell................ 46 President and Chief Executive Officer of Hospital Group of America, Inc.
Robert S. Weiss................ 49 Executive Vice President, Treasurer and Chief Financial Officer
Stephen C. Whiteford........... 55 Vice President and Corporate Controller
</TABLE>
Gregory A. Fryling has served as Vice President, Business Development since
January 1993 and has been serving as President of CooperVision Pharmaceuticals,
Inc. since May 1994. He has been an officer of various subsidiaries including
Vice President and Controller of The Cooper Healthcare Group from January 1990
through December 1992 and Vice President and Controller of CooperVision from
October 1988 through December 1989. He also served as Vice President and
Controller of Cooper Life Sciences ('CLS') (then, a manufacturer of surgical
laser and ultrasonic devices) from September 1986 to September 1988.
Robert S. Holcombe has served as Senior Vice President since October 1992
and as General Counsel since December 1989. He served as Vice President from
December 1989 until October 1992. From October 1988 through June 1989 he served
as Assistant General Counsel, and from June 1987 through September 1988, as
General Attorney of Emhart Corporation (a manufacturer of consumer and
industrial products and provider of computer based services). From September
1979 until May 1987, he served as Vice President and General Counsel of Planning
Research Corporation (a professional services firm).
Marisa F. Jacobs has served as Secretary since April 1992 and as Associate
General Counsel since November 1989. From July 1987 until October 1989, she
served as Senior Vice President of Prism Associates, Inc. (a business consulting
firm of which she was a co-founder). From September 1981 to October 1987, she
was an associate with the law firm of Reavis & McGrath (now Fulbright & Jaworski
L.L.P.).
Carol R. Kaufman has served as Vice President and Chief Administrative
Officer since October 1995. From January 1989 through September 1995, she served
as Vice President, Chief Administrative Officer and Secretary of Cooper
Development Company ('CDC') (a healthcare and consumer products company), a
former affiliate of the Company; from June 1985 through January 1989 she served
as Vice President of Cooper & Company, CDC's mergers and acquisitions
subsidiary. From October 1971 until June 1985 she held a variety of offices at
Cooper Laboratories, Inc. (the Company's former parent).
Audrey A. Murray has served as Vice President of Risk Management and
Employee Benefits since November 1993. She served as Director of Risk Management
from July 1988 until November 1993. From November 1985 until July 1988, she held
the positions of Senior Risk Analyst and then Associate Director of Risk
Management. From October 1984 until November 1985, she served as Employee
Benefits Manager at GTE Sprint (a long distance telephone company). From June
1977 until October
9
<PAGE>
<PAGE>
1984, she served as Risk Manager at The O'Brien Corporation (a manufacturer of
paints and technical coatings).
Nicholas J. Pichotta has served as President and Chief Executive Officer of
CooperSurgical since September 1992. He served as Vice President of the Company
from December 1992 to May 1993 and as Vice President, Corporate
Development -- Healthcare from December 1991 to December 1992 and as President
of CooperVision from November 1990 to June 1991. He has served in a number of
other positions since joining the Company in January 1989. From May to October
1988 he was Managing Director of Heraeus LaserSonics and from December 1986 to
May 1988 he served as President of the Surgical Laser Division of CLS.
Mark R. Russell has served as the President and Chief Executive Officer of
Hospital Group of America, Inc. since June 1993 and served as Executive Vice
President and Chief Operating Officer from January 1987 (through the time of its
acquisition by the Company in May 1992) until June 1993. From May 1986 to
January 1987 he served as Senior Vice President and Chief Operating Officer of
Nu-Med Psychiatric and from February 1981 to May 1986, he served as Senior Vice
President and Chief Operating Officer of the Kennedy Health Care Foundation (the
parent organization for a diversified healthcare services company).
Robert S. Weiss became the Executive Vice President in October 1995. He has
been the Treasurer and Chief Financial Officer of the Company since 1989. From
October 1992 until October 1995, he was also as a Senior Vice President; from
March 1984 to October 1992 he served as a Vice President, and from 1984 through
July 1990 he served as Corporate Controller. He served as Corporate Controller
of Cooper Laboratories, Inc. (the Company's former parent) from 1980 until March
1984 and as Vice President from March 1983 until March 1984.
Stephen C. Whiteford has served as Vice President and Corporate Controller
since July 1992. He served as Assistant Corporate Controller from March 1988 to
July 1992, as International Controller from August 1986 to February 1988 and as
Vice President and Controller of CooperVision Ophthalmic Products from June 1985
to August 1986.
There is no family relationship between any of the above-named officers or
between any such officer and any director of the Company.
10
<PAGE>
<PAGE>
ITEM 2. PROPERTIES.
The following are TCC's principal facilities as of December 31, 1995:
<TABLE>
<CAPTION>
APPROXIMATE APPROXIMATE
FLOOR AREA ANNUAL LEASE
LOCATION OPERATIONS (SQ. FT.) RENT EXPIRATION
- ---------------------------- ----------------------- ----------- ------------ -----------
<S> <C> <C> <C> <C>
United States
Pleasanton, CA......... Executive Offices 14,000 $212,000 Sept. 2000
Fort Lee, NJ........... Offices 11,000(1) $231,000(1) Feb. 2005
Chicago, IL............ Psychiatric Hospital 74,000 Owned in fee N/A(2)
New Castle, DE......... Psychiatric Hospital 45,000 Owned in fee N/A(2)
Mt. Holly, NJ.......... Learning Facility 22,000 $235,000 Sept. 1997
Rancocas, NJ........... Psychiatric Hospital 65,000 Owned in fee N/A(2)
Irvine, CA............. CVI Offices, 17,500 $120,000 Jan. 1998
distribution and
customer service
Huntington Beach, CA... CVI Manufacturing & 21,000 $185,000 April 1999
technical offices
Fairport, NY........... CVI Administrative 15,000 $237,000(3) March 1999
offices & marketing
Scottsville, NY........ CVI Manufacturing, 35,000 Owned in fee N/A
distribution and
warehouse facilities
Shelton, CT............ CSI Manufacturing, 25,000 $250,000 Dec. 2001
research and
development,
marketing,
distribution and
warehouse facilities
Canada
Markham, Ont........... CVI Offices, 21,000 $ 75,000 Feb. 2000
manufacturing
distribution and
warehouse facilities
</TABLE>
- ------------
(1) On December 9, 1994, the Company entered into a sublease pursuant to which
it has subleased to a third party approximately 6,000 square feet of its
Fort Lee, NJ, office space at an annual base rent commencing at $113,924 in
year one and increasing to $125,916 in years two through five, the last year
of the sublease. The subtenant has an option to renew the sublease for an
additional five years. An agreement in principal has been reached to
sublease the remaining 5,000 square feet of this office to the same
subtenant for four years beginning April 1, 1996, with a similar option to
renew for an additional five years.
(2) Outstanding loans, totaling $11,347,000 as of October 31, 1995, were secured
by these properties.
(3) Includes utilities, common area charges and taxes.
------------------------
The Company believes its properties are suitable and adequate for its
businesses.
11
<PAGE>
<PAGE>
ITEM 3. LEGAL PROCEEDINGS.
See the discussion of legal proceedings contained in Note 14.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
The 1995 Annual Meeting of Stockholders was held on September 20, 1995.
Each of the seven individuals nominated to serve as directors of the
Company were re-elected to office. Information with respect to votes cast for or
withheld from such nominee is set forth below:
<TABLE>
<CAPTION>
DIRECTOR VOTES FOR VOTES WITHHELD
- --------------------------------------------------------------- ----------- --------------
<S> <C> <C>
A. Thomas Bender............................................... 30,526,290 1,676,845
Mark A. Filler................................................. 30,420,947 1,782,188
Michael H. Kalkstein........................................... 30,421,005 1,782,130
Moses Marx..................................................... 30,526,563 1,676,572
Donald Press................................................... 30,525,770 1,677,365
Steven Rosenberg............................................... 30,421,723 1,781,412
Allan E. Rubenstein............................................ 30,422,094 1,781,041
</TABLE>
Stockholders were asked to approve proposals to reduce the authorized
capital stock of the Company and to effectuate a one-for-three reverse common
stock split. A total of 29,108,488 and 28,569,024 shares, respectively, voted in
favor of the proposals, 2,772,727 and 3,486,291 shares, respectively, voted
against the two proposals, and a total of 321,720 and 147,190 shares,
respectively, abstained from voting.
Stockholders were also asked to ratify the appointment of KPMG Peat Marwick
LLP as independent certified public accountants for the Company for the fiscal
year which ended October 31, 1995. A total of 30,510,989 shares were voted in
favor of the ratification, 1,617,037 shares were voted against it and 75,809
shares abstained. The numbers contained in this section have not been adjusted
to reflect the one-for-three reverse stock split which was effectuated on the
day following the Annual Meeting.
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
The Company's common stock is traded on The New York Stock Exchange, Inc.
and the Pacific Stock Exchange Incorporated. No cash dividends were paid with
respect to the common stock in fiscal 1995 or 1994.
The Indenture, dated as of March 1, 1985, governing the Company's
Debentures, as amended by the First Supplemental Indenture dated as of June 29,
1989 and the Second Supplemental Indenture dated as of January 6, 1994, and the
Indenture dated as of January 6, 1994 governing the Company's 10% Senior
Subordinated Secured Notes due 2003 (collectively, the 'Indentures'), prohibit
the payment of cash dividends on the Company's common stock unless (i) no
defaults exist or would exist under the Indentures, (ii) the Company's Cash Flow
Coverage Ratio (as defined in the Indentures) for the most recently ended four
full fiscal quarters has been at least 1.5 to 1, and (iii) such cash dividend,
together with the aggregate of all other Restricted Payments (as defined in the
Indentures), is less than the sum of 50% of the Company's cumulative net income
plus the proceeds of certain sales of the Company's or its subsidiaries' capital
stock subsequent to February 1, 1994. The Company does not anticipate, in the
foreseeable future, paying cash dividends on its common stock.
The ability of the Company to declare and pay dividends is also subject to
restrictions set forth in the Delaware General Corporation Law (the 'Delaware
GCL'). As a general rule, a Delaware corporation may pay dividends under the
Delaware GCL either out of its 'surplus,' as defined in the Delaware GCL, or,
subject to certain exceptions, out of its net profits for the fiscal year in
which the dividend is declared and/or the preceding fiscal year. The Company's
ability to pay cash dividends depends upon whether the Company satisfies the
requirements of the Delaware GCL at the time any such proposed dividend is
declared.
Other information called for by this Item is set forth in Note 17.
12
<PAGE>
<PAGE>
ITEM 6. SELECTED FINANCIAL DATA
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
FIVE YEAR FINANCIAL HIGHLIGHTS
CONSOLIDATED OPERATIONS
<TABLE>
<CAPTION>
YEARS ENDED OCTOBER 31,
-------------------------------------------------------
1995 1994 1993 1992 1991
------- -------- -------- -------- --------
(IN THOUSANDS, EXCEPT PER SHARE FIGURES)
<S> <C> <C> <C> <C> <C>
Net sales of products.................................. $55,296 $ 51,034 $ 47,369 $ 43,873 $ 35,524
Net service revenue.................................... 41,794 44,611 45,283 19,406 --
------- -------- -------- -------- --------
Net operating revenue............................. 97,090 95,645 92,652 63,279 35,524
------- -------- -------- -------- --------
Cost of products sold.................................. 17,549 17,906 17,538 18,236 16,979
Cost of services provided.............................. 40,454 41,039 42,754 17,353 --
Research and development expense....................... 2,914 4,407 3,209 3,267 2,268
Selling, general and administrative expense............ 25,826 31,027 49,382 44,600 45,627
Costs associated with restructuring operations......... 1,480 -- 451 -- --
Amortization of intangibles............................ 859 843 772 742 946
------- -------- -------- -------- --------
Income (loss) from operations.......................... 8,008 423 (21,454) (20,919) (30,296)
------- -------- -------- -------- --------
Settlement of disputes, net............................ 3,532 4,950 6,350 4,498 --
Debt restructuring costs............................... -- 340 2,131 -- --
Investment income (loss),net........................... 444 (153) 1,615 14,254 12,268
Gain on sales of assets and businesses, net............ -- 214 620 1,030 --
Other income, net...................................... 51 42 174 772 574
Interest expense....................................... 4,741 4,533 6,129 6,697 7,148
------- -------- -------- -------- --------
Income (loss) from continuing operations before income
taxes................................................ 230 (9,297) (33,655) (16,058) (24,602)
Provision for (benefit of) income taxes................ 115 (4,600) 417 100 201
------- -------- -------- -------- --------
Income (loss) from continuing operations before
extraordinary items.................................. 115 (4,697) (34,072) (16,158) (24,803)
Loss on sale of discontinued operations, net of
taxes................................................ -- -- (13,657) (9,300) --
------- -------- -------- -------- --------
Income (loss) before extraordinary items............... 115 (4,697) (47,729) (25,458) (24,803)
Extraordinary items.................................... -- -- 924 640 5,428
------- -------- -------- -------- --------
Net income (loss)...................................... 115 (4,697) (46,805) (24,818) (19,375)
Less, preferred stock dividends........................ -- 89 320 1,804 2,325
------- -------- -------- -------- --------
Net income (loss) applicable to common stock........... $ 115 $ (4,786) $(47,125) $(26,622) $(21,700)
------- -------- -------- -------- --------
------- -------- -------- -------- --------
Net income (loss) per common share*:
Continuing operations............................. $ .01 $ (.47) $ (3.43) $ (1.96) $ (3.18)
------- -------- -------- -------- --------
Loss on sale of discontinued operations........... -- -- (1.36) (1.01) --
------- -------- -------- -------- --------
Income (loss) before extraordinary items.......... .01 (.47) (4.79) (2.97) (3.18)
Extraordinary items............................... -- -- .09 .07 .64
------- -------- -------- -------- --------
Net income (loss) per common share................ $ .01 $ (.47) $ (4.70) $ (2.90) $ (2.54)
------- -------- -------- -------- --------
------- -------- -------- -------- --------
Average number of common shares outstanding*...... 11,576 10,193 10,035 9,167 8,530
------- -------- -------- -------- --------
------- -------- -------- -------- --------
</TABLE>
- ------------
* Prior periods have been restated to reflect the impact of the one-for-three
reverse stock split effected in September 1995.
13
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
FIVE YEAR FINANCIAL HIGHLIGHTS
CONSOLIDATED FINANCIAL POSITION
<TABLE>
<CAPTION>
OCTOBER 31,
--------------------------------------------------------
1995 1994 1993 1992 1991
-------- -------- -------- -------- --------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
Current assets....................................... $ 41,228 $ 43,505 $ 51,875 $119,282 $173,857
Property, plant and equipment, net................... 34,062 34,787 39,895 39,732 3,593
Intangible assets, net............................... 14,933 15,327 16,285 10,083 8,843
Other assets......................................... 1,769 1,439 1,469 3,910 1,340
-------- -------- -------- -------- --------
Total assets......................................... $ 91,992 $ 95,058 $109,524 $173,007 $187,633
-------- -------- -------- -------- --------
-------- -------- -------- -------- --------
Current liabilities.................................. $ 39,613 $ 42,256 $ 51,995 $ 68,119 $ 67,274
Long-term debt....................................... 43,490 46,184 48,077 58,591 48,657
Other long-term liabilities.......................... 10,638 10,272 9,000 -- --
-------- -------- -------- -------- --------
Total liabilities.................................... 93,741 98,712 109,072 126,710 115,931
-------- -------- -------- -------- --------
Stockholders' equity (deficit)....................... (1,749) (3,654) 452 46,297 71,702
-------- -------- -------- -------- --------
Total liabilities and stockholders' equity
(deficit).......................................... $ 91,992 $ 95,058 $109,524 $173,007 $187,633
-------- -------- -------- -------- --------
-------- -------- -------- -------- --------
</TABLE>
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
References to Note numbers herein are references to the 'Notes to
Consolidated Financial Statements' of the Company located in Item 8 herein.
Reference is also made to Part I, Item 1 'Business' herein.
CAPITAL RESOURCES & LIQUIDITY
The Company's financial condition improved significantly in 1995, driven by
both the successful settlement of various disputes and improved operating
results. Primary contributors include continued strong performance by
CooperVision, Inc. ('CVI'), the Company's contact lens business, and decreased
legal fees. In addition, with a view toward leveraging its net operating loss
carryforwards, the Company adjusted its focus in 1995 to favor acquiring
products ready for market, and/or already in the market, rather than funding
longer-term, higher risk research and development projects.
Cash provided by the Company's operating activities overcame an operating
cash flow deficit of $5.0 million in the first quarter of 1995, generating $8.4
million of cash in the succeeding nine months, including $2.0 million from the
successful settlement of certain disputes. This resulted in positive operating
cash flow of $3.4 million for fiscal 1995 vs. negative operating cash flows of
$2.0 million in 1994 and $44.8 million in 1993. Investing cash flow was $2.4
million negative in 1995, as the Company expended cash primarily to expand its
manufacturing capacity for contact lenses in response to strong market
acceptance of new product offerings, to upgrade certain manufacturing equipment
and to purchase a product line for its gynecology business. The corresponding
figures for 1994 and 1993 were positive investing cash flows of $9.1 million and
$26.6 million, respectively, primarily reflecting cash received from the sale by
the Company of its temporary investments, which sales were necessitated by the
negative operating cash flows in those years.
Management believes that, absent extraordinary events, the Company is now
positioned to generate sufficient operating cash flow to fund its day-to-day
needs, and, based on the expectation of sales growing faster than expenses,
expects that operating cash flow will continue to increase in the future. As
with fiscal 1995, the Company expects that operating cash flow for the first
quarter of 1996 will be negative, due to scheduled payments to Dr. Pottash of
$3.1 million (see Note 14) and Medical Engineering Corporation of $1.5 million
(see Note 4).
The Company is evaluating various acquisition opportunities which, if
consummated, would be funded by a combination of cash then on hand, financing
vehicles now in place (see Note 11 'Loan and Security Agreement') and other
methods of raising additional capital currently being explored.
14
<PAGE>
<PAGE>
RESULTS OF OPERATIONS
Comparison of each of the years in the three-year period ended October 31,
1995:
NET SALES OF PRODUCTS
The following table summarizes the increases and decreases in net sales of
products of the Company's CooperVision, Inc. ('CVI') and CooperSurgical, Inc.
('CSI') business units over the three-year period. Sales generated by the
Company's CooperVision Pharmaceuticals, Inc. ('CVP') unit were $16 thousand in
1995, $394 thousand in 1994 and $570 thousand in 1993.
<TABLE>
<CAPTION>
INCREASE (DECREASE)
----------------------------------------------------------------
1995 VS. 1994 1994 VS. 1993
------------------------------ ------------------------------
(DOLLARS IN THOUSANDS)
<S> <C> <C> <C> <C>
Business Unit
CVI................................................... $ 4,663 12% $ 5,673 18%
-- --
-- --
------------- -------------
------------- -------------
CSI................................................... $ (23) -- % $ (1,832) (12)%
-- --
-- --
------------- -------------
------------- -------------
</TABLE>
1995 VS. 1994
Net sales of CVI increased both domestically and in Canada. The primary
contributors to the growth included increased sales of the Preference'r'
spherical product line and the Hydrasoft'r' Toric and Preference Toric'tm'
product lines (the latter of which was launched in the fourth quarter of fiscal
1994). Sales of toric lenses in the United States grew by approximately 50% in
1995. Toric and other specialty lenses now account for approximately two-thirds
of CooperVision's total sales. The 1995 increases were partially offset by
anticipated decreases in sales of more mature product lines. CVI's sales mix
continues to shift toward daily wear, planned replacement and other specialty
products and away from extended wear products. The Company expects this trend to
continue and considers itself to be well positioned to compete successfully in
specialty niches of the contact lens market, particularly with its Preference'r'
line of planned replacement lenses and its line of custom toric lenses.
Net sales of CSI products were essentially flat in 1995 as compared to
1994. Nearly 75% of CSI's net sales now relate to womens' healthcare products,
as the unit continues to direct its sales efforts towards the gynecology market
to take advantage of the lower cost to service a highly focused market niche.
1994 VS. 1993
The increase in CVI net sales was primarily due to CoastVision, Inc.
('CoastVision'), a manufacturer of custom toric contact lenses for use by
patients with astigmatic vision, being included in fiscal 1993 results for only
seven months, as this company was acquired on April 1, 1993.
Net sales of CSI declined primarily due to slower domestic sales of its
capital equipment, including surgical systems launched in 1992 for use in the
loop electrosurgical excision procedure, used diagnostically and operatively in
the treatment of cervical cancer and other indications in gynecology. This
decline was partially offset by increased sales in the international arena.
Consolidated net sales of products have grown 8% per year over the three
year period.
NET SERVICE REVENUE
Net service revenue consists of the following:
<TABLE>
<CAPTION>
1995 1994 1993
------- ------- -------
(IN THOUSANDS)
<S> <C> <C> <C>
Net patient revenue.......................................... $40,643 $42,611 $43,283
Management fees.............................................. 1,151 2,000 2,000
------- ------- -------
$41,794 $44,611 $45,283
------- ------- -------
------- ------- -------
</TABLE>
15
<PAGE>
<PAGE>
Net patient revenue by major providers was as follows:
<TABLE>
<CAPTION>
1995 1994 1993
------------------ ------------------ ------------------
AMOUNT % TOTAL AMOUNT % TOTAL AMOUNT % TOTAL
------- ------- ------- ------- ------- -------
(DOLLARS IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
Commercial Ins................ $ 5,055 13% $ 9,170 21% $15,081 35%
Medicare...................... 11,767 29 9,225 22 6,654 15
Medicaid...................... 8,566 21 7,254 17 4,353 10
Blue Cross.................... 4,015 10 4,729 11 5,821 13
HMOs.......................... 8,714 21 7,722 18 8,408 20
Other......................... 2,526 6 4,511 11 2,966 7
------- ------- ------- ------- ------- -------
$40,643 100% $42,611 100% $43,283 100%
------- ------- ------- ------- ------- -------
------- ------- ------- ------- ------- -------
</TABLE>
NET PATIENT REVENUE (SEE NOTE 1 'NET SERVICE REVENUE')
Net patient revenue decreased by $2.0 million or 4.6% in 1995. Revenue has
been pressured by the current industry trend towards increased managed care,
which results in decreased daily rates and declines in average lengths of stay.
Management is endeavoring to mitigate those pressures by increasing the number
of admissions to its hospitals, and by providing outpatient and other ancillary
services. In addition, management estimates that the dispute with the Hampton
Medical Group, P.A., which was recently settled (see Note 14), reduced revenue
during 1995 at Hampton Hospital by approximately $2 million compared with 1994.
MANAGEMENT FEES
On May 29, 1992, PSG Management, Inc. ('PSG Management'), a subsidiary of
the Company, entered into a three-year management agreement with three
indirectly owned subsidiaries of Nu-Med, Inc. ('Nu-Med'), under which PSG
Management managed three hospitals owned by those subsidiaries, having a total
of 220 licensed beds. PSG Management received a management fee of $166,667 per
month under the agreement, which expired by its terms in May 1995.
COST OF SERVICES PROVIDED
Cost of services provided represents all normal operating costs incurred by
Hospital Group of America, Inc. ('HGA') in generating net service revenue. The
results of subtracting cost of services provided from net service revenue is an
operating profit of $1.3 million, or 3%, of net service revenue in 1995, $3.6
million, or 8%, of net service revenue in 1994 and $2.5 million, or 6%, of net
service revenue in 1993. The decreased percentage of operating profits in 1995
compared with 1994 is primarily attributable to lower revenue as described
above, partially offset by lower cost of services. The 1994 increased percentage
of operating profit over 1993 is primarily attributable to reduced service
costs. Also, in 1993, HGA incurred nonrecurring charges of approximately $360
thousand associated with severance and approximately $400 thousand to write down
certain receivables.
COST OF PRODUCTS SOLD
Gross profit (net sales of products less cost of products sold) as a
percentage of net sales of products ('margin') was as follows:
<TABLE>
<CAPTION>
MARGIN
--------------------
1995 1994 1993
---- ---- ----
<S> <C> <C> <C>
CVI...................................................................... 73% 71% 69%
CSI...................................................................... 52% 48% 49%
Consolidated............................................................. 68% 65% 63%
</TABLE>
1995 VS. 1994
CVI's margin has increased due to efficiencies associated with higher
production levels, as well as a favorable product mix. CSI's margin increased
due to a favorable product mix in the United States.
16
<PAGE>
<PAGE>
Internationally, the margin increase was primarily due to cost reductions
accomplished within the LEEP product line. Also, 1994 CSI margins were impacted
by a $200 thousand write-down of endoscopy inventory, which reduced margins by
2%.
1994 VS. 1993
Margin for CVI increased due to the inclusion of higher margin CoastVision
products for a full year in 1994 and also reduced unit costs of manufactured
products as a result of higher production levels. The margin decrease at CSI
primarily related to increased sales in the lower margin international division
and the impact of the inventory write-down disclosed above.
RESEARCH AND DEVELOPMENT EXPENSE
Research and development expense was $2.9 million or 5% of net sales of
products in 1995 compared to $4.4 million or 9% in 1994 and $3.2 million or 7%
in 1993.
The decrease in 1995 is primarily attributable to reduced development
activity related to CVP's calcium channel blocker, CalOptic'tm'. Discussions
continue with potential strategic partners to out-license CalOptic'tm'. The
increase in 1994 vs. 1993 is primarily attributable to the increased development
activity related to CalOptic'tm' at that time. CVP accounted for 43%, 63% and
51% of consolidated research and development expense in 1995, 1994 and 1993,
respectively. This percentage, as well as the overall level of R&D expenditures,
is expected to decrease in the future, reflective of the 1995 shift in the
Company's focus to leverage its net operating loss carryforwards by acquiring
products ready for market rather than funding their development in-house.
In 1994, CSI signed an agreement with InnerDyne, Inc. covering the
development and commercialization of InnerDyne's proprietary thermal ablation
technology for gynecological applications. In May 1995, after spending
approximately $214 thousand in 1994 and $381 thousand in 1995, CSI announced
that it had discontinued funding this project.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSE
The Company's selling, general and administrative expense ('SGA') by
business unit and corporate was as follows:
<TABLE>
<CAPTION>
1995 1994 1993
------- ------- -------
(IN THOUSANDS)
<S> <C> <C> <C>
CVI.......................................................... $15,949 $13,621 $13,386
CSI.......................................................... 5,520 6,125 10,305
CVP.......................................................... 76 369 598
Corporate/Other.............................................. 4,281 10,912 25,093
------- ------- -------
$25,826 $31,027 $49,382
------- ------- -------
------- ------- -------
</TABLE>
The 61% decrease in 1995 vs. 1994 in Corporate/Other SGA reflects the
resolution of various legal matters, a reduction in the level of corporate
staffing, a credit of $648 thousand for the recovery of the Company's claim
against the Cooper Laboratories, Inc. Liquidating Trust, representing payment
for previously rendered administrative services, the reversal of a $649 thousand
receivable reserve and certain other accruals no longer required and a
significant reduction in the cost of the Company's Directors and Officers
insurance. The decrease in 1994 vs. 1993 in Corporate/Other SGA reflects the
impact on legal costs of an agreement reached on September 30, 1993 with Medical
Engineering Corporation and its parent, Bristol-Myers Squibb Company (the 'MEC
Agreement'), which limited the Company's liability for breast implant litigation
(see Note 4). This reduction, coupled with reductions in staffing related costs,
legal fees and costs in other areas, resulted in a 57% reduction in
Corporate/Other SGA.
SGA for CVI increased by 17% and 2% in 1995 vs. 1994 and 1994 vs. 1993,
respectively. The increase in 1995 vs. 1994 was due primarily to costs
associated with the successful launch of the Preference Toric'tm' line of
contact lenses and the cost of programs associated with the launch of additional
new products. The inclusion of SGA for CoastVision accounted for the 1994 vs.
1993
17
<PAGE>
<PAGE>
increase. As a percentage of sales, CVI's SGA was 38% in 1995, 36% in 1994 and
42% in 1993. The 1994 vs. 1993 decrease in SGA cost as a percentage of sales
reflected cost synergies effected as a result of merging CoastVision's
operations into CVI.
The 1995 and 1994 decreases at CSI reflect savings generated by the
consolidation of CSI facilities with attendant efficiencies.
COSTS ASSOCIATED WITH RESTRUCTURING OPERATIONS (SEE NOTE 8)
In 1995, the Company recorded $1.5 million of restructuring costs to
provide for costs primarily associated with the closure of facilities in the
Company's CVP, CSI and corporate operations and downsizing HGA headquarters. In
1993, the Company recorded $451 thousand of restructuring costs for
consolidation of CSI facilities and related reorganization and relocation costs.
AMORTIZATION OF INTANGIBLES
Amortization of intangibles was $859 thousand in 1995, $843 thousand in
1994 and $772 thousand in 1993. The changes in each year reflect acquisition and
divestiture activity during the three-year period. (See Note 3.)
INCOME (LOSS) FROM OPERATIONS
As a result of the variances discussed above, income (loss) from operations
has improved by $29.5 million over the three-year period. Income (loss) from
operations by business unit and corporate was as follows:
<TABLE>
<CAPTION>
OCTOBER 31,
--------------------------------
1995 1994 1993
-------- -------- --------
(IN THOUSANDS)
<S> <C> <C> <C>
CVI....................................................... $ 13,959 $ 11,963 $ 7,842
CVP....................................................... (1,425) (3,063) (2,045)
CSI....................................................... (425) (932) (3,407)
HGA....................................................... 878 3,321 2,124
Corporate/Other........................................... (4,979) (10,866) (25,968)
-------- -------- --------
$ 8,008 $ 423 $(21,454)
-------- -------- --------
-------- -------- --------
</TABLE>
SETTLEMENT OF DISPUTES, NET
In 1995, the Company recorded a charge of $5.6 million for the settlement
of the Hampton Medical Group, P.A. dispute. (See Note 14.) This charge was
partially offset by net credits to income of $2.0 million, which primarily
represented cash received by the Company in connection with the settlement of
other litigation matters. (See Note 7.)
In 1994, the Company recorded the following items related to settlement of
disputes:
A credit of $850 thousand following receipt of funds by the Company to
settle certain of the Company's claims associated with a real estate
transaction.
A charge of $5.8 million which represented the Company's estimate of costs
required to settle certain disputes and other litigation matters,
including $3.5 million associated with the Company's criminal conviction
and the related SEC enforcement action against the Company.
The charge of $6.4 million in 1993 was comprised of $4.9 million paid in
connection with the settlement reached between the Company and Cooper Life
Sciences, Inc. ('CLS') (see Note 15), and $1.5 million for certain other
disputes.
DEBT RESTRUCTURING COSTS
The $2.1 million charge for debt restructuring costs in 1993 reflected the
Company's estimate of transaction costs associated with the Exchange Offer and
Solicitation. (See Note 11.) An additional charge of $340 thousand was required
in 1994.
18
<PAGE>
<PAGE>
INVESTMENT INCOME (LOSS), NET
Investment income (loss), net includes interest income of $394 thousand in
1995, $377 thousand in 1994 and $2.4 million in 1993. The decrease in interest
income from 1993 reflects the Company's use of cash for the acquisition of
CoastVision on April 1, 1993 (see Note 3) and the purchase of a portion of its
Debentures, operating cash use, declining interest rates and a shift in
investment strategy towards more conservative instruments with lower risk and
correspondingly lower returns. Also included in investment income, net is a net
gain on marketable securities of $50 thousand in 1995, and losses thereon of
$530 thousand in 1994 and $824 thousand in 1993.
GAIN ON SALES OF ASSETS AND BUSINESSES, NET
In 1994, the Company sold two parcels of land for cash and notes, for a net
gain of $134 thousand, and its EYEscrub'tm' trademark in Canada, for a net gain
of $80 thousand. In 1993, the Company sold its EYEscrub'tm' product line for
$1.4 million, which sale resulted in a $620 thousand gain.
OTHER INCOME, NET
Other income, net was $51 thousand in 1995, $42 thousand in 1994 and $174
thousand in 1993. Other income, net includes foreign exchange gains (losses) of
($130 thousand), $53 thousand and ($550 thousand) in 1995, 1994 and 1993,
respectively, on transactions denominated in currencies other than the local
currency of the subject business units. Other income, net in 1993 included
consent fees, extension fees and collection fees related to the Company's
temporary investment activity and rental income from the Company's real estate
ventures, all of which were partially offset by the foreign exchange loss.
INTEREST EXPENSE
Interest expense was $4.7 million in 1995, $4.5 million in 1994 and $6.1
million in 1993. The increase in interest expense in 1995 was primarily a result
of the increased borrowing related to a line of credit, partially offset by
reduced interest expense due to the Exchange Offer and Consent Solicitation
which occurred in the first quarter of fiscal 1994. (See Note 11.) The decrease
in interest expense in 1994 v. 1993 relates to: 1) reduction of outstanding
debt, 2) reduced interest rate on approximately $22.0 million of outstanding
debt and 3) amortization of deferred premium, all as a result of the Exchange
Offer and Consent Solicitation (see Note 11) and reduced HGA debt.
PROVISION FOR (BENEFIT OF) INCOME TAXES
Details with regard to the Company's provision for income taxes for each of
the years in the three-year period ended October 31, 1995 are set forth in Note
10. The 1995 provision for state income and franchise taxes of $315 thousand was
partially offset by a reversal of $200 thousand of tax accruals no longer
required. The 1994 provision for state income and franchise taxes of $400
thousand was offset by a reversal of $5.0 million of tax accruals no longer
required following the successful resolution of certain tax issues. The 1993
provision of $417 thousand related entirely to state income and franchise taxes.
LOSS ON SALE OF DISCONTINUED OPERATIONS
A charge of $14 million in 1993 represented an increase to the Company's
accrual for contingent liabilities associated with breast implant litigation
involving the plastic and reconstructive surgical division of the Company's
former Cooper Surgical business segment which was sold in fiscal 1989. (See Note
4.) In 1993, the Company also recorded a reversal of $343 thousand of accruals
no longer necessary related to another discontinued business. No tax benefit has
been applied against the above figures, as the Company was not profitable in
1993.
EXTRAORDINARY ITEM
Extraordinary item represents the gain recorded by the Company in 1993
associated with the early retirement of $4.8 million principal amount of its
long-term debt.
19
<PAGE>
<PAGE>
INFLATION AND CHANGING PRICES
Inflation has had little affect on the Company's operations in the last
three years. Revenue resulting from stays at HGA facilities has been decreasing
due to a shift from commercial insurance to lower rate managed care providers.
(See 'Net Service Revenue,' above.)
IMPACT OF STATEMENTS OF FINANCIAL ACCOUNTING STANDARDS ISSUED BUT NOT ADOPTED
In October 1995, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards (SFAS) No. 123, Accounting for Stock-Based
Compensation. SFAS No. 123 applies to all transactions in which an entity
acquires goods or services by issuing equity instruments such as common stock,
except for employee stock ownership plans. SFAS No. 123 establishes a new method
of accounting for stock-based compensation arrangements with employees which is
fair value based. The statement encourages (but does not require) employers to
adopt the new method in place of the provisions of Accounting Principles Board
(APB) Opinion No. 25, 'Accounting for Stock Issued to Employees.' Companies may
continue to apply the accounting provisions of APB No. 25 in determining net
income, however, they must apply the disclosure requirements of SFAS No. 123.
Companies that adopt the fair value based method of SFAS No. 123 would typically
incur a higher compensation cost for fixed stock option plans and a different
compensation cost for contingent or variable stock option plans. The recognition
provisions and disclosure requirements of SFAS No. 123 are effective for fiscal
years beginning after December 15, 1995. The Company will adopt the disclosure
requirements in its 1997 fiscal year. Such adoption will have no impact on
reported results.
20
<PAGE>
<PAGE>
INDEPENDENT AUDITORS' REPORT
The Board of Directors and Stockholders
The COOPER COMPANIES, INC.:
We have audited the accompanying consolidated balance sheets of The Cooper
Companies, Inc. and subsidiaries as of October 31, 1995 and 1994 and the related
consolidated statements of operations, stockholders' equity (deficit) and cash
flows for each of the years in the three-year period ended October 31, 1995. In
connection with our audits of the consolidated financial statements, we also
have audited financial statement schedules I and II. These consolidated
financial statements and financial statement schedules are the responsibility of
the Company's management. Our responsibility is to express an opinion on these
consolidated financial statements and financial statement schedules based on our
audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the financial position of The Cooper
Companies, Inc. and subsidiaries at October 31, 1995 and 1994 and the results of
their operations and their cash flows for each of the years in the three-year
period ended October 31, 1995, in conformity with generally accepted accounting
principles. Also in our opinion, the related financial statement schedules, when
considered in relation to the basic consolidated financial statements taken as a
whole, present fairly, in all material respects, the information set forth
therein.
KPMG PEAT MARWICK LLP
San Francisco, California
December 11, 1995
21
<PAGE>
<PAGE>
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
STATEMENT OF CONSOLIDATED OPERATIONS
<TABLE>
<CAPTION>
YEARS ENDED OCTOBER 31,
----------------------------------
1995 1994 1993
------- ------- --------
(IN THOUSANDS, EXCEPT PER SHARE
FIGURES)
<S> <C> <C> <C>
Net sales of products..................................................... $55,296 $51,034 $ 47,369
Net service revenue....................................................... 41,794 44,611 45,283
------- ------- --------
Net operating revenue................................................ 97,090 95,645 92,652
------- ------- --------
Cost of products sold..................................................... 17,549 17,906 17,538
Cost of services provided................................................. 40,454 41,039 42,754
Research and development expense.......................................... 2,914 4,407 3,209
Selling, general and administrative expense............................... 25,826 31,027 49,382
Costs associated with restructuring operations............................ 1,480 -- 451
Amortization of intangibles............................................... 859 843 772
------- ------- --------
Income (loss) from operations............................................. 8,008 423 (21,454)
------- ------- --------
Settlement of disputes, net............................................... 3,532 4,950 6,350
Debt restructuring costs.................................................. -- 340 2,131
Investment income (loss), net............................................. 444 (153) 1,615
Gain on sales of assets and businesses, net............................... -- 214 620
Other income, net......................................................... 51 42 174
Interest expense.......................................................... 4,741 4,533 6,129
------- ------- --------
Income (loss) from continuing operations before income taxes.............. 230 (9,297) (33,655)
Provision for (benefit of) income taxes................................... 115 (4,600) 417
------- ------- --------
Income (loss) from continuing operations before extraordinary items....... 115 (4,697) (34,072)
Loss on sale of discontinued operations................................... -- -- (13,657)
------- ------- --------
Income (loss) before extraordinary item................................... 115 (4,697) (47,729)
Extraordinary item........................................................ -- -- 924
------- ------- --------
Net income (loss)......................................................... 115 (4,697) (46,805)
Less preferred stock dividends............................................ -- 89 320
------- ------- --------
Net income (loss) applicable to common stock.............................. $ 115 $(4,786) $(47,125)
------- ------- --------
------- ------- --------
Net income (loss) per common share (See Note 2):
Continuing operations................................................ $.01 $(.47) $(3.43)
Discontinued operations.............................................. -- -- (1.36)
------- ------- --------
Income (loss) before extraordinary item.............................. .01 (.47) (4.79)
Extraordinary item................................................... -- -- .09
------- ------- --------
Net income (loss) per common share........................................ $.01 $(.47) $(4.70)
Average number of common shares outstanding (See Note 2).................. 11,576 10,193 10,035
------- ------- --------
------- ------- --------
</TABLE>
See accompanying notes to consolidated financial statements.
22
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
<TABLE>
<CAPTION>
OCTOBER 31,
----------------------
1995 1994
--------- ---------
(IN THOUSANDS)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents.......................................................... $11,207... $ 10,320
Trade and patient accounts receivable, less allowances of $2,241,000 in 1995 and
$2,647,000 in 1994................................................................ 17,717 18,181
Inventories........................................................................ 9,570 11,696
Prepaid expenses and other current assets.......................................... 2,734 3,308
--------- ---------
Total current assets.......................................................... 41,228 43,505
--------- ---------
Property, plant and equipment at cost................................................... 46,597 45,470
Less accumulated depreciation and amortization.......................................... 12,535 10,683
--------- ---------
34,062 34,787
--------- ---------
Goodwill and other intangibles, net..................................................... 14,933 15,327
Other assets............................................................................ 1,769 1,439
--------- ---------
$ 91,992 $ 95,058
--------- ---------
--------- ---------
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Current installments of long-term debt............................................. $ 2,190 $ 1,453
Borrowings under line of credit.................................................... 1,025 --
Accounts payable................................................................... 5,828 6,580
Employee compensation, benefits and severance...................................... 6,978 6,390
Other accrued liabilities.......................................................... 13,596 17,728
Accrued income taxes............................................................... 9,996 10,105
--------- ---------
Total current liabilities..................................................... 39,613 42,256
--------- ---------
Long-term debt.......................................................................... 43,490 46,184
Other noncurrent liabilities............................................................ 10,638 10,272
--------- ---------
Total liabilities............................................................. 93,741 98,712
--------- ---------
Commitments and Contingencies (See Note 14)
Stockholders' equity (deficit):
Preferred stock, $.10 par value, shares authorized: 1,000,000; zero shares issued
or outstanding at October 31, 1995 and 1994....................................... -- --
Common stock, $.10 par value, shares authorized: 20,000,000; issued and
outstanding: 11,576,482 and 11,293,370 at October 31, 1995 and 1994, respectively
(See Note 2)...................................................................... 1,158 1,129
Additional paid-in capital......................................................... 183,840 182,142
Translation adjustments............................................................ (333) (396)
Accumulated deficit................................................................ (186,414) (186,529)
--------- ---------
Total stockholders' equity (deficit).......................................... (1,749) (3,654)
--------- ---------
$ 91,992 $ 95,058
--------- ---------
--------- ---------
</TABLE>
See accompanying notes to consolidated financial statements.
23
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
STATEMENT OF CONSOLIDATED STOCKHOLDERS' EQUITY (DEFICIT)
YEARS ENDED OCTOBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
SENIOR
EXCHANGEABLE
REDEEMABLE
RESTRICTED
VOTING SERIES B
PREFERRED PREFERRED
STOCK STOCK COMMON STOCK
------------- ------------- --------------
PAR PAR PAR PAID-IN TRANSLATION ACCUMULATED
SHARES VALUE SHARES VALUE SHARES VALUE CAPITAL ADJUSTMENTS DEFICIT
------ ----- ------ ----- ------ ------ -------- ----------- -----------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Balance October 31, 1992.................... 151 $ 15 0 $ 0 10,060 $1,006 $182,509 $ (66) $ (134,938)
Net loss............................... -- -- -- -- -- -- -- -- (46,805)
Aggregate translation adjustment....... -- -- -- -- -- -- -- (157) --
Unamortized stock compensation related
to restricted stock grants........... -- -- -- -- 48 5 85 -- --
Restricted stock amortization and share
issuance, forfeiture and lifting of
restrictions......................... -- -- -- -- (65) (7) (791) -- --
Dividend requirements on Senior
Preferred Stock...................... -- -- -- -- -- -- (320) -- --
Issuance of Senior Preferred Stock..... 10 1 -- -- -- -- 320 -- --
CLS Exchange Agreement -- June 14, 1993
(see Note 15)........................ (161) (16) 345 -- -- -- 16 -- --
------ ----- ------ ----- ------ ------ -------- ----------- -----------
Balance October 31, 1993.................... 0 $ 0 345 $ 0 10,043 $1,004 $181,819 $(223) $ (181,743)
------ ----- ------ ----- ------ ------ -------- ----------- -----------
Net loss............................... -- -- -- -- -- -- -- -- (4,697)
Aggregate translation adjustment....... -- -- -- -- -- -- -- (173) --
Restricted stock amortization and share
issuance, forfeiture and lifting of
restrictions......................... -- -- -- -- 99 10 436 -- --
Exercise of stock options.............. -- -- -- -- 1 -- 2 -- --
Dividend requirements on Series B
Preferred Stock...................... -- -- -- -- -- -- -- -- (89)
Conversion of Series B Preferred to
Common (see Note 15)................. -- -- (345) -- 1,150 115 (115) -- --
------ ----- ------ ----- ------ ------ -------- ----------- -----------
Balance October 31, 1994.................... 0 $ 0 0 $ 0 11,293 $1,129 $182,142 $(396) $ (186,529)
------ ----- ------ ----- ------ ------ -------- ----------- -----------
Net income............................. -- -- -- -- -- -- -- -- 115
Aggregate translation adjustment....... -- -- -- -- -- -- -- 63 --
Restricted stock amortization and share
issuance, forfeiture and lifting of
restrictions......................... -- -- -- -- 176 18 1,526 -- --
Exercise of stock options.............. -- -- -- -- 5 1 9 -- --
Exercise of warrants and warrant
valuation............................ -- -- -- -- 102 10 163 -- --
------ ----- ------ ----- ------ ------ -------- ----------- -----------
Balance October 31, 1995............... 0 $ 0 0 $ 0 11,576 $1,158 $183,840 $(333) $ (186,414)
------ ----- ------ ----- ------ ------ -------- ----------- -----------
------ ----- ------ ----- ------ ------ -------- ----------- -----------
<CAPTION>
UNAMORTIZED
RESTRICTED
STOCK
AWARD
COMPENSATION TOTAL
------------ --------
<S> <C> <C>
Balance October 31, 1992.................... $ (2,229) $ 46,297
Net loss............................... -- (46,805)
Aggregate translation adjustment....... -- (157)
Unamortized stock compensation related
to restricted stock grants........... (88) 2
Restricted stock amortization and share
issuance, forfeiture and lifting of
restrictions......................... 1,912 1,114
Dividend requirements on Senior
Preferred Stock...................... -- (320)
Issuance of Senior Preferred Stock..... -- 321
CLS Exchange Agreement -- June 14, 1993
(see Note 15)........................ -- 0
------------ --------
Balance October 31, 1993.................... $ (405) $ 452
------------ --------
Net loss............................... -- (4,697)
Aggregate translation adjustment....... -- (173)
Restricted stock amortization and share
issuance, forfeiture and lifting of
restrictions......................... 405 851
Exercise of stock options.............. -- 2
Dividend requirements on Series B
Preferred Stock...................... -- (89)
Conversion of Series B Preferred to
Common (see Note 15)................. -- 0
------------ --------
Balance October 31, 1994.................... $ 0 $ (3,654)
------------ --------
Net income............................. -- 115
Aggregate translation adjustment....... -- 63
Restricted stock amortization and share
issuance, forfeiture and lifting of
restrictions......................... -- 1,544
Exercise of stock options.............. -- 10
Exercise of warrants and warrant
valuation............................ -- 173
------------ --------
Balance October 31, 1995............... $ 0 $ (1,749)
------------ --------
------------ --------
</TABLE>
See accompanying notes to consolidated financial statements.
24
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS
<TABLE>
<CAPTION>
YEARS ENDED OCTOBER 31,
------------------------------
1995 1994 1993
------- ------- --------
(IN THOUSANDS)
<S> <C> <C> <C>
Cash flows from operating activities:
Net income (loss)........................................................... $ 115 $(4,786) $(46,805)
Adjustments to reconcile net income (loss) to net cash provided (used) by
operating activities:
Current and deferred income taxes........................................... (224) (132) 417
Depreciation expense........................................................ 2,704 2,870 2,624
Provision for doubtful accounts............................................. 2,300 2,431 3,202
Amortization expenses:
Intangible assets...................................................... 992 975 904
Debt discount.......................................................... (443) (499) 201
Restricted stock....................................................... -- 853 1,084
Net (gain) loss from:
Sales of assets and businesses......................................... -- (214) (620)
Investments............................................................ (50) 530 824
Debt restructuring costs............................................... -- 340 --
Extraordinary items.................................................... -- -- (924)
Change in assets and liabilities net of effects from acquisitions and sales
of assets and businesses:
Net (increases) decreases in assets:
Restricted cash................................................... -- (8) 441
Receivables....................................................... (1,918) (5,373) 5,101
Inventories....................................................... 2,126 3,291 1,150
Other current assets.............................................. 668 (423) (383)
Other assets...................................................... (393) 836 282
Net increases (decreases) in liabilities:
Accounts payable............................................. (1,050) 2,311 (10,055)
Accrued liabilities.......................................... (2,000) (925) (10,704)
Income taxes payable......................................... 115 (4,600) (581)
Other long-term liabilities.................................. 429 524 9,000
------- ------- --------
Net cash provided (used) by operating activities............................ 3,371 (1,999) (44,842)
------- ------- --------
Cash flows from investing activities:
Sales of assets and businesses (including releases of cash from escrow), and
cash from Progressions settlement, recorded as a reduction to goodwill.... 594 2,720 9,700
Purchases of assets and businesses, net..................................... (821) -- (9,794)
Purchases of property, plant and equipment.................................. (2,185) (938) (1,749)
Sales of temporary investments, net......................................... 50 7,302 28,399
------- ------- --------
Net cash provided (used) by investing activities............................ (2,362) 9,084 26,556
------- ------- --------
</TABLE>
See accompanying notes to consolidated financial statements.
25
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS -- (CONCLUDED)
<TABLE>
<CAPTION>
YEARS ENDED OCTOBER 31,
------------------------------
1995 1994 1993
------- ------- --------
(IN THOUSANDS)
<S> <C> <C> <C>
Cash flows from financing activities:
Payments associated with the Exchange Offer and Consent Solicitation
including debt restructuring costs....................................... $ -- $(5,416) $ --
Purchase of the Company's 10-5/8% Debentures............................... -- -- (3,861)
Proceeds from line of credit, net.......................................... 1,025 -- --
Net payments of notes payable and current long-term debt................... (1,270) (1,462) (5,818)
Proceeds from exercise of warrants and options............................. 123 -- --
------- ------- --------
Net cash used by financing activities................................. (122) (6,878) (9,679)
------- ------- --------
Net increase (decrease) in cash and cash equivalents............................ 887 207 (27,965)
Cash and cash equivalents at beginning of year.................................. 10,320 10,113 38,078
------- ------- --------
Cash and cash equivalents at end of year........................................ $11,207 $10,320 $ 10,113
------- ------- --------
------- ------- --------
Supplemental disclosures of cash flow information:
Cash paid for:
Interest (net of amounts capitalized)................................. $ 4,755 $ 4,791 $ 6,275
------- ------- --------
------- ------- --------
Dividends on Preferred Stock.......................................... $ -- $ 89 $ --
------- ------- --------
------- ------- --------
Income taxes.......................................................... $ 224 $ 132 $ 90
------- ------- --------
------- ------- --------
Supplemental schedule of noncash investing and financing activities:
Paid-in-kind Senior Preferred Stock dividends.............................. $ -- $ -- $ 320
------- ------- --------
------- ------- --------
</TABLE>
In January 1994, the Company issued $22,000,000 of 10% Senior Subordinated
Secured Notes due 2003 (the 'Notes') and paid approximately $4,350,000 in cash
(exclusive of transaction costs) in exchange for approximately $30,000,000 of
Debentures. (See Note 11.)
During 1993, the Company acquired businesses and entered into certain
licensing and distribution agreements. In connection with these acquisitions and
agreements, the Company assumed liabilities as follows:
<TABLE>
<CAPTION>
YEAR ENDED
OCTOBER 31,
1993
----------------------
(IN THOUSANDS)
<S> <C>
Fair value of assets and businesses acquired including capitalized
costs............................................................... $ 10,517
Cash paid............................................................. (9,794)
----------
Liabilities assumed................................................... $ 723
----------
----------
</TABLE>
See accompanying notes to consolidated financial statements.
26
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
GENERAL
The Cooper Companies, Inc., (together with its subsidiaries, the 'Company')
develops, manufactures and markets healthcare products, including a range of
hard and soft daily, flexible and extended wear contact lenses, and diagnostic
and surgical instruments. The Company also provides healthcare services through
the ownership of psychiatric facilities, and through May 1995, the management of
other such facilities.
PRINCIPLES OF CONSOLIDATION
Intercompany transactions and accounts are eliminated in consolidation.
Certain reclassifications have been applied to prior years' financial statements
to conform such statements to the current year's presentation. None of these
reclassifications had any impact on results of operations, although the
restatement following the September 1995 one-for-three reverse stock split (see
Note 2) impacted previously reported earnings per share amounts and the average
number of shares outstanding.
FOREIGN CURRENCY TRANSLATION
Assets and liabilities of the Company's operations located outside the
United States (primarily Canada) are translated at prevailing year-end rates of
exchange. Related income and expense accounts are translated at weighted average
rates for each year. Gains and losses resulting from the translation of
financial statements in foreign currencies into U. S. dollars are recorded in
the equity section of the consolidated balance sheet. Gains and losses resulting
from the impact of changes in exchange rates on transactions denominated in
foreign currencies are included in the determination of net income or loss for
each period. Foreign exchange gains (losses) included in the Company's
consolidated statement of income for each of the years ended October 31, 1995,
1994 and 1993 were ($130,000), $53,000 and ($550,000), respectively.
NET SALES OF PRODUCTS
Net sales of products consists primarily of sales generated by the
Company's CooperVision, Inc. ('CVI') and CooperSurgical, Inc. ('CSI')
businesses. The Company recognizes revenue when risk of ownership has
transferred to the buyer, with appropriate provisions for sales returns.
With respect to net sales of products, management believes trade
receivables do not include any concentrated groups of credit risk.
NET SERVICE REVENUE
Net service revenue consists primarily of net patient service revenue,
which is based on the Hospital Group of America, Inc. ('HGA') hospitals'
established billing rates less allowances and discounts principally for patients
covered by Medicare, Medicaid, Blue Cross, HMO's and other contractual programs.
Payments under these programs are based on either predetermined rates or the
cost of services. Settlements for retrospectively determined rates are estimated
in the period the related services are rendered and are adjusted in future
periods as final settlements are determined. Management believes that adequate
provision has been made for adjustments that may result from the final
determination of amounts earned under these programs. In 1995, the Company
received and recognized revenue of approximately $2 million associated with
prior year cost report settlements. Approximately 50%, 39% and 25%,
respectively, of 1995, 1994 and 1993 net service revenue is from participation
by hospitals in Medicare and Medicaid programs.
27
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The Company provides care to indigent patients who meet certain criteria
under its charity care policy without charge or at amounts less than its
established rates. Because the Company does not pursue collection of amounts
determined to qualify as charity care, they are not reported as revenue. The
Company maintains records to identify and monitor the level of charity care it
provides. These records include the amount of charges foregone for services and
supplies furnished under its charity care policy. Charges at the Company's
established rates foregone for charity care provided by the Company amounted to
$2,142,000, $2,498,000 and $3,220,000 for 1995, 1994 and 1993, respectively.
Hampton Hospital is required by its Certificate of Need to incur not less than
5% of total patient days as free care.
With respect to net service revenue, receivables from government programs
represent the only concentrated group of potential credit risk to the Company.
Management does not believe that there are any credit risks associated with
these governmental agencies. Negotiated and private receivables consist of
receivables from various payors, including individuals involved in diverse
activities, subject to differing economic conditions, and do not represent any
concentrated credit risks to the Company. Furthermore, management continually
monitors and, where indicated, adjusts the allowances associated with these
receivables.
CASH AND CASH EQUIVALENTS
Cash and cash equivalents includes commercial paper and other short-term
income producing securities with a maturity date at purchase of three months or
less. These investments are readily convertible to cash, and are carried at cost
which approximates market.
INVENTORIES
Inventories are stated at the lower of cost, determined on a first-in,
first-out or average cost basis, or market.
The components of inventories are as follows:
<TABLE>
<CAPTION>
OCTOBER 31,
--------------------------
1995 1994
----------- -----------
(IN THOUSANDS)
<S> <C> <C>
Raw materials................................................................ $2,212 $ 3,197
Work-in-process.............................................................. 1,114 973
Finished goods............................................................... 6,244 7,526
----------- -----------
$9,570 $11,696
----------- -----------
----------- -----------
</TABLE>
PROPERTY, PLANT AND EQUIPMENT AT COST
<TABLE>
<CAPTION>
OCTOBER 31,
--------------------------
1995 1994
----------- -----------
(IN THOUSANDS)
<S> <C> <C>
Land and improvements........................................................ $ 1,360 $ 1,360
Buildings and improvements................................................... 34,005 33,391
Machinery and equipment...................................................... 11,232 10,719
----------- -----------
$46,597 $45,470
----------- -----------
----------- -----------
</TABLE>
Depreciation is computed on the straight-line method in amounts sufficient
to write-off depreciable assets over their estimated useful lives. Leasehold
improvements are amortized over the shorter of their estimated useful lives or
the period of the related lease.
28
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Depreciation expense amounted to $2,704,000, $2,870,000 and $2,624,000 for
the years ended October 31, 1995, 1994 and 1993, respectively.
Expenditures for maintenance and repairs are expensed; major replacements,
renewals and betterments are capitalized. The cost and accumulated depreciation
of depreciable assets retired or otherwise disposed of are eliminated from the
asset and accumulated depreciation accounts, and any gains or losses are
reflected in operations for the period.
AMORTIZATION OF INTANGIBLES
Amortization is provided for on all intangible assets (primarily goodwill,
which represents the excess of purchase price over fair value of net assets
acquired) on a straight-line basis over periods of up to thirty years.
Accumulated amortization at October 31, 1995 and 1994 was $3,909,000 and
$2,916,000, respectively. The Company assesses the recoverability of goodwill
and other long-lived assets by determining whether the amortization of the
related balance over its remaining life can be recovered through reasonably
expected future cash flow.
RESTRICTED STOCK AND COMPENSATION EXPENSE
Under the Company's various stock plans for employees and directors (see
Note 12), certain directors, officers and key employees designated by the Board
of Directors or a committee thereof have purchased, for par value, shares of the
Company's common stock restricted as to resale ('Restricted Shares') unless or
until certain prescribed objectives are met or certain events occur. The
difference between market value and par value of the Restricted Shares on the
date of grant is recorded as unamortized restricted stock award compensation, an
equity account, and charged to operations as earned.
INCOME TAXES (SEE NOTE 10)
Effective with the beginning of fiscal 1994, the Company adopted the
liability method of accounting for income taxes as prescribed by Statement of
Financial Accounting Standards No. 109, 'Accounting for Income Taxes' ('FAS
109'). The liability method under FAS 109 measures the expected tax impact of
future taxable income or deductions resulting from temporary differences in the
tax and financial reporting bases of assets and liabilities reflected in the
consolidated balance sheet. Deferred tax assets and liabilities are determined
using the enacted tax rates in effect for the year in which these differences
are expected to reverse. Under FAS 109, the effect on deferred tax assets and
liabilities of a change in tax rates is recognized in the period that the change
was enacted. In 1993 and prior years, the Company accounted for income taxes
under Accounting Principles Board Opinion No. 11.
EARNINGS PER COMMON SHARE
Net income (loss) per common share is determined by using the weighted
average number of common shares and common share equivalents (stock warrants and
stock options) outstanding during each year (except where antidilutive). Fully
diluted net income (loss) per common share is not materially different from
primary net income (loss) per common share.
NOTE 2. REVERSE COMMON STOCK SPLIT AND AUTHORIZED SHARE REDUCTION
In September 1995, at the Annual Stockholders Meeting, stockholders
approved a 1-for-3 reverse split of the Company's common stock. Also, the
stockholders approved an amendment to the Company's Certificate of Incorporation
to decrease the number of shares of common stock authorized to be issued from
100 million to 20 million and the number of shares of preferred stock authorized
to be issued from 10 million to 1 million.
29
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Except where noted to the contrary, all share and per share data included
in this annual report have been restated to reflect the reverse stock split.
NOTE 3. ACQUISITIONS AND DISPOSITIONS
ACQUISITIONS
In June 1995, CSI acquired from Blairden Precision Instruments the
exclusive worldwide rights to RUMI'tm'uterine manipulator injector and related
products for $1,000,000. Payments of $800,000 have been made through October 31,
1995, and the balance of $200,000 is due at the earlier of June 15, 1996 or the
date certain contractual milestones are met. No goodwill arose from the
recording of this acquisition.
On April 1, 1993, CVI acquired via a purchase transaction the stock of
CoastVision, Inc. ('CoastVision') for approximately $9,800,000 cash. CoastVision
manufactured and marketed a range of contact lens products, primarily custom
soft toric contact lenses, which are designed to correct astigmatism. The
purchase of CoastVision expanded CooperVision's customer base for its existing
product lines. CoastVision had net sales of $9,600,000 in its fiscal year ended
October 31, 1992. Excess cost over net assets acquired recorded on the purchase
was $7,279,000, which is being amortized over 30 years.
DISPOSITIONS
In January 1994, the Company's Canadian subsidiary, CooperVision Inc.
('CooperVision Canada'), sold its EYEscrub'tm' trademark for $110,000 cash,
resulting in an $80,000 gain.
On February 12, 1993, the Company sold its EYEscrub'tm' product line for
$1,400,000 cash, which resulted in a $620,000 gain.
NOTE 4. DISCONTINUED OPERATIONS
In 1993, the Company recorded a charge of $14,000,000 to increase the
Company's accrual (the 'Breast Implant Accrual') for contingent liabilities
associated with breast implant litigation involving the plastic and
reconstructive surgical division of the Company's former Cooper Surgical
business segment ('Surgical') which was sold in fiscal 1989 to Medical
Engineering Corporation ('MEC'), a subsidiary of Bristol-Myers Squibb Company
('Bristol-Myers'). The Breast Implant Accrual will be charged for payments made
and to be made to MEC under the agreement reached in September 1993 with MEC and
Bristol-Myers, which limited the Company's liability for breast implant
litigation (the 'MEC Agreement') (see Note 14 for the schedule of payments), as
well as certain related charges. In October 1993 the Company made the initial
payment of $3,000,000 to MEC. At October 31, 1995, the Company's balance sheet
included $6,250,000 of the Breast Implant Accrual in 'other noncurrent
liabilities' and $1,500,000 in accounts payable (which was paid to MEC on
December 31, 1995) for future payments to MEC. The Company also recorded, in
1993, a reversal of $343,000 of accruals no longer necessary related to another
discontinued business.
No tax benefit was applied against the above figures, as the Company was
not profitable.
NOTE 5. EXTRAORDINARY ITEMS
The extraordinary gain of $924,000, or $.09 per share, in 1993 represented
gains on the Company's purchases of $4,846,000 principal amount of its 10 5/8%
Convertible Subordinated Reset Debentures due 2005 ('Debentures'). The purchases
were privately negotiated and executed at prevailing market prices.
30
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
NOTE 6. STOCKHOLDERS RIGHTS PLAN
On October 29, 1987, the Board of Directors of the Company declared a
dividend distribution of one right for each outstanding share of the Company's
common stock, par value $.10 per share (a 'Right'). Following the effectiveness
of the one-for-three reverse stock split in September 1995, the number of Rights
associated with each share of the Company's common stock increased from one to
three. Each Right entitles the registered holder of an outstanding share of the
Company's common stock to initially purchase from the Company a unit consisting
of one one-hundredth of a share of Series A Junior Participating Preferred Stock
(a 'Unit'), par value $.10 per share, at a purchase price of $60.00 per Unit,
subject to adjustment. The Rights are exercisable only if a person or group
acquires (an 'Acquiring Person'), or generally obtains the right to acquire
beneficial ownership of 20% or more of the Company's common stock, or commences
a tender or exchange offer which would result in such person or group
beneficially owning 30% or more of the Company's common stock.
If, following the acquisition of 20% or more of the Company's common stock,
(i) the Company is the surviving corporation in a merger with an Acquiring
Person and its common stock is not changed, (ii) a person or entity becomes the
beneficial owner of more than 30% of the Company's common stock, except in
certain circumstances such as through a tender or exchange offer for all the
Company's common stock which the Board of Directors determines to be fair and
otherwise in the best interests of the Company and its stockholders, (iii) an
Acquiring Person engages in certain self-dealing transactions or (iv) an event
occurs which results in such Acquiring Person's ownership interest being
increased by more than 1%, each holder of a Right, other than an Acquiring
Person, will thereafter have the right to receive, upon exercise, the Company's
common stock (or, in certain circumstances, cash, property or other securities
of the Company) having a value equal to two times the exercise price of the
Right.
Under certain circumstances, if (i) the Company is acquired in a merger or
other business combination transaction in which the Company is not the surviving
corporation, unless (a) the transaction occurs pursuant to a transaction which
the Board of Directors determines to be fair and in the best interests of the
Company and its stockholders (b) the price per share of common stock offered in
the transaction is not less than the price per share of common stock paid to all
holders pursuant to the tender or exchange offer, and (c) the consideration used
in the transaction is the same as that paid pursuant to the offer, or (ii) 50%
or more of the Company's assets or earning power is sold or transferred, each
holder of a Right, other than an Acquiring Person, shall thereafter have the
right to receive, upon exercise, common stock of the acquiring company having a
value equal to two times the exercise price of the Right.
At any time until the close of business on the tenth day following a public
announcement that an Acquiring Person has acquired, or generally obtained the
right to acquire, beneficial ownership of 20% or more of the Company's common
stock, the Company will generally be entitled to redeem the Rights in whole, but
not in part, at a price of $.05 per Right. After the redemption period has
expired, the Company's right of redemption may be reinstated if an Acquiring
Person reduces his beneficial ownership to 10% or less of the outstanding shares
of common stock in a transaction or series of transactions not involving the
Company.
Until a Right is exercised, the holder thereof, as such, will have no
rights as a stockholder of the Company, including, without limitation, the right
to vote or to receive dividends. The Rights expire on October 29, 1997.
In June 1993, the Board of Directors amended the Rights Agreement dated as
of October 29, 1987, between the Company and The First National Bank of Boston,
as Rights Agent, so that Cooper Life Sciences, Inc. ('CLS') and its affiliates
and associates as of the amendment date would not be Acquiring Persons
thereunder as a result of CLS's beneficial ownership of more than 20% of the
outstanding common stock of the Company by reason of its ownership of Series B
Preferred Stock or common stock issued upon conversion thereof. In January 1995,
the Rights Agreement was further amended to provide that any person who becomes
the beneficial owner of 10% or more, but not more
31
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
than 30%, of the outstanding common stock of CLS, and is, therefore, deemed to
be the beneficial owner of the shares of common stock of the Company held by CLS
would not be an Acquiring Person, provided that such person is not otherwise,
and does not thereafter become, the beneficial owner of more than 1% of the
Company's outstanding common stock. (See 'Agreements With CLS' in Note 15.)
NOTE 7. SETTLEMENT OF DISPUTES, NET
In 1995, the Company recorded a charge of $5,551,000 for the settlement of
a dispute with the Hampton Medical Group, P.A. The charge was partially offset
by the favorable impact of settlements regarding a refund of $915,000 for
directors and officers insurance premiums and disgorgement of $648,000 from a
former officer of the Company. In addition, in April 1995, HGA and Progressions
Health Systems, Inc. entered into the purchase price agreement which settled
cross claims between the parties related to purchase price adjustments (which
were credited to goodwill) and other disputes and provided for a series of
payments to be made to HGA. Pursuant to this agreement, HGA received
approximately $853,000 in 1995, $421,000 of which has been credited to
Settlement of Disputes, Net.
In 1994, the Company recorded the following items related to settlement of
disputes:
A credit of $850,000 following receipt of funds by the Company to
settle certain claims made by the Company associated with a real
estate transaction.
A charge of $5,800,000, which represents the Company's estimate of
costs required to settle certain disputes and other litigation
matters including $3,450,000 associated with the criminal conviction
and related SEC enforcement action. (See Note 14.)
The Company and CLS entered into a settlement agreement, dated June 14,
1993, pursuant to which CLS delivered a general release of claims against the
Company, subject to exceptions for specified ongoing contractual obligations,
and agreed to certain restrictions on its acquisitions, voting and transfer of
securities of the Company, in exchange for the Company's payment of $4,000,000
in cash and delivery of 200,000 shares of common stock of CLS owned by the
Company and a general release of claims against CLS, subject to similar
exceptions. See Note 15 for a discussion of the settlement terms. The cash paid
and fair value of CLS shares returned to CLS were charged to the Company's
statement of operations for 1993 as settlement of disputes. In addition, the
Company charged another $1,500,000 for certain other disputes.
NOTE 8. COSTS ASSOCIATED WITH RESTRUCTURING OPERATIONS
In 1995, the Company recorded $1,480,000 of restructuring costs to provide
for costs primarily associated with the closure of facilities, with attendant
reductions in personnel, in the Company's CVP, CSI and corporate operations and
downsizing HGA headquarters. Approximately 85% of the $1,480,000 provision
related to severance benefits accrued for 16 employees. The balance primarily
reflected provisions for unproductive assets. In 1993, the Company recorded
$451,000 of restructuring costs for consolidation of CSI facilities and related
reorganization and relocation costs.
NOTE 9. PREFERRED STOCK
On June 14, 1993, the Company acquired from CLS all of the remaining
outstanding shares of the Company's Senior Exchangeable Redeemable Restricted
Voting Preferred Stock ('SERPS'), having an aggregate liquidation preference of
$16,060,000, together with all rights to any dividends or distributions thereon,
in exchange for shares of Series B Preferred Stock having an aggregate
liquidation preference of $3,450,000 and a par value of $.10 per share. The 345
shares of the Series B Preferred Stock, and any shares of the Series B Preferred
Stock issued as dividends, were convertible into one share of common stock of
the Company for each $3.00 of liquidation preference, subject to customary
antidilution adjustments. The Company also had the right to compel conversion of
the Series B Preferred Stock at any time after the market price of the common
stock on its principal trading market averaged at least
32
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
$4.125 for 90 consecutive calendar days and closed at not less than $4.125 on at
least 80% of the trading days during such period.
On September 26, 1994, the Company's common stock met the above
requirements, and the Series B Preferred Stock was converted into 1,150,000
shares (see Note 2) of the Company's common stock.
During 1994 the Company paid $89,000 or $258.90 per share in dividends on
the Series B Preferred Stock.
NOTE 10. INCOME TAXES
The income tax provision (benefit) in the statement of consolidated
operations is related solely to current state provisions (benefits).
A reconciliation of the provision for (benefit of) income taxes included in
the Company's statement of consolidated operations and the amount computed by
applying the federal income tax rate to income (loss) from continuing operations
before extraordinary items and income taxes follows:
<TABLE>
<CAPTION>
YEAR ENDED OCTOBER 31,
------------------------------
1995 1994 1993
----- ------- --------
(IN THOUSANDS)
<S> <C> <C> <C>
Computed expected provision for (benefit of) taxes.................. $ 78 $(3,161) $(11,443)
Increase (decrease) in taxes resulting from:
Income outside the United States operations, subject to
different tax rates.......................................... 132 (65) (186)
Amortization of intangibles.................................... 185 185 148
State taxes, net of federal income tax benefit................. 76 264 275
Reversal of prior years' estimated tax liabilities no longer
required..................................................... (200) (5,000) --
Amortization of restricted stock compensation.................. -- (31) 335
Net operating losses for which no tax benefit was recognized... -- 3,293 11,546
Interest expense related to original issue discount............ (100) (100) --
Other, net..................................................... (56) 15 (258)
----- ------- --------
Actual provision for (benefit of) income taxes...................... $ 115 $(4,600) $ 417
----- ------- --------
----- ------- --------
</TABLE>
33
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets and deferred tax liabilities are as follows:
<TABLE>
<CAPTION>
OCTOBER 31,
--------------------
1995 1994
------- --------
(IN THOUSANDS)
<S> <C> <C>
Deferred Tax Assets:
Accounts receivable, principally due to allowances for doubtful accounts... $ 1,138 $ 886
Inventories, principally due to obsolescence reserves...................... 871 675
Investments, principally due to unrealized losses and other reserves....... 73 112
Accrued liabilities, principally due to litigation reserves and
compensation accruals.................................................... 4,868 4,571
Deferred income, principally due to the debenture exchange................. 1,258 1,199
Net operating loss carryforwards........................................... 81,871 83,417
Capital loss carryforwards................................................. 2,428 --
Tax credit carryforwards................................................... 2,560 2,455
Other...................................................................... 490 259
------- --------
Total gross deferred tax assets....................................... 95,557 93,574
Less valuation allowance.............................................. (88,755) (87,175)
------- --------
Net deferred tax assets............................................... 6,802 6,399
------- --------
Deferred Tax Liabilities:
Plant and equipment, principally due to purchase accounting requirements... (6,507) (6,037)
Other, principally due to differences in accounting methods for financial
and tax purposes......................................................... (295) (362)
------- --------
Total gross deferred tax liabilities.................................. (6,802) (6,399)
------- --------
Net deferred tax assets............................................... $ -- $ --
------- --------
------- --------
</TABLE>
The net change in the total valuation allowance for the years ended October
31, 1995 and 1994 was an increase of $1,580,000 and $2,327,000, respectively.
Subsequently recognized tax benefits relating to the valuation allowance
for deferred tax assets as of October 31, 1995 will be allocated as follows:
<TABLE>
<CAPTION>
(IN
THOUSANDS)
<S> <C>
Income tax benefit that would be reported in the consolidated
statement of income................................................ $87,264
Goodwill and other noncurrent intangible assets...................... 1,491
-------------
$88,755
-------------
-------------
</TABLE>
34
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
At October 31, 1995 the Company had capital loss, net operating loss, and
tax credit carryforwards for federal tax purposes expiring as follows:
<TABLE>
<CAPTION>
YEAR OF CAPITAL OPERATING TAX
EXPIRATION LOSSES LOSSES CREDITS
- ---------- ------- --------- -------
(IN THOUSANDS)
<S> <C> <C> <C>
1998 ............................................. $ 5,925 $ -- $ --
1999 ............................................. 1,216 6,745 867
2000 ............................................. -- 725 1,132
2001 ............................................. -- 70,473 202
2002 ............................................. -- 27,326 29
2003 ............................................. -- 1,378 330
2004 ............................................. -- 22,241 --
2005 ............................................. -- 11,006 --
2006 ............................................. -- 22,265 --
2007 ............................................. -- 22,155 --
2008 ............................................. -- 49,535 --
2009 ............................................. -- 6,553 --
2010 ............................................. -- 396 --
------- --------- -------
$ 7,141 $ 240,798 $ 2,560
------- --------- -------
------- --------- -------
</TABLE>
NOTE 11. LONG-TERM DEBT
Long-term debt consists of the following:
<TABLE>
<CAPTION>
OCTOBER 31,
-------------------
1995 1994
------- -------
(IN THOUSANDS)
<S> <C> <C>
10% Senior Subordinated Secured Notes due 2003 ('Notes')..... $24,816 $25,410
10 5/8% Convertible Subordinated Reset Debentures due 2005
('Debentures')............................................. 9,215 9,210
Bank term loan ('HGA Term Loan')............................. 9,889 10,556
Industrial Revenue Bonds ('HGA IRB')......................... 1,458 2,000
Capitalized leases, interest rates from 11.5% to 13.0%
maturing 1997.............................................. 302 461
------- -------
45,680 47,637
Less current installments.................................... 2,190 1,453
------- -------
$43,490 $46,184
------- -------
------- -------
</TABLE>
Aggregate annual maturities, including current installments, for each of
the five years subsequent to October 31, 1995 are as follows:
<TABLE>
<CAPTION>
(IN THOUSANDS)
<S> <C>
1996............................................ $2,190
1997............................................ $9,323
1998............................................ 127
1999............................................ 9
2000............................................ --
</TABLE>
In January 1994, the Company completed an Exchange Offer and Consent
Solicitation, pursuant to which the Company issued approximately $22,000,000
aggregate principal amount of Notes and paid approximately $4,350,000 in cash
($725 principal amount of Notes and $145 in cash for each $1,000 principal
amount of Debentures) in exchange for approximately $30,000,000 aggregate
principal amount
35
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
of its Debentures (out of $39,384,000 aggregate principal amount then
outstanding). $9,290,000 aggregate principal amount of Debentures remains
outstanding.
In connection with the Exchange Offer and Consent Solicitation, the Company
amended the indenture governing the Debentures (the 'Indenture') to, among other
things, eliminate a covenant, with which the Company was not in compliance,
requiring the Company to repurchase Debentures. The amendment also reduced the
conversion price at which holders may convert Debentures into shares of the
Company's common stock from $82.35 to $15.00 per share, subject to adjustment
under certain conditions to prevent dilution to the holders. The Company also
obtained a waiver (the 'Waiver') of any and all Defaults and Events of Default
(as such terms are defined in the Indenture) that occurred or may have occurred
prior to the expiration of the Exchange Offer and Consent Solicitation.
The Exchange Offer and Consent Solicitation was accounted for in accordance
with Statement of Financial Accounting Standards No. 15 'Accounting by Debtors
and Creditors for Troubled Debt Restructurings.' Consequently, the difference
between the carrying value of the Debentures exchanged less the face value of
the Notes issued and the aggregate cash payment for the Debentures was recorded
as a deferred premium aggregating approximately $4,000,000 as of the date of the
Exchange. The Company is recognizing the benefit of the deferred premium as a
reduction to the effective interest rate on the Notes over the life of the
issue. In addition, the Company recorded a charge of $2,131,000 in the fourth
quarter of fiscal 1993 and an additional charge of $340,000 in fiscal 1994 for
costs related to the Exchange Offer and Consent Solicitation. The Debentures
mature on March 1, 2005, with interest payments due semi-annually each March 1
and September 1.
The Notes mature on June 1, 2003. Interest at 10% per annum is payable
quarterly on each March 1, June 1, September 1 and December 1. The Notes are
redeemable solely at the option of the Company, in whole or in part, at any
time, at a redemption price equal to 100% of their principal amount, together
with accrued and unpaid interest thereon to the redemption date. The Company is
not required to effect any mandatory redemptions or make any sinking fund
payments with respect to the Notes, except in connection with certain sales or
other dispositions of, or certain financings secured by, the collateral securing
the Notes. Pursuant to a pledge agreement dated as of January 6, 1994, between
the Company and the trustee for the holders of the Notes, the Company has
pledged a first priority security interest in all of its right, title and
interest in stock of its subsidiaries HGA and CSI, all additional shares of
stock of, or other equity interests in HGA and CSI from time to time acquired by
the Company, all intercompany indebtedness of HGA and CSI from time to time held
by the Company, except as set forth in the indenture governing the Notes, and
the proceeds received from the sale or disposition of any or all of the
foregoing.
The Debentures and the Notes each contain various covenants, including
limitations on incurrence and ranking of indebtedness, payment of cash
dividends, acquisition of the Company's common stock and transactions with
affiliates.
HGA DEBT
Substantially all of the property and equipment and accounts receivable of
HGA collateralize its outstanding debt. The HGA Term Loan carries interest at 4
percentage points over the prime interest rate, with a floor of 12% per annum.
The rate in effect at October 31, 1995 was 12.75%. Interest and principal
payments on the HGA Term Loan are due monthly through August 1997. The HGA IRB
carries interest at 85% of prime, or approximately 7.44% per annum at October
31, 1995. Interest and principal payments on the HGA IRB are due monthly and
holders have elected their right to accelerate all payments of outstanding
principal at December 31, 1995. The HGA IRB of $1,336,000 was paid and the
amount was rolled into the HGA Term Loan due August 1997. The HGA Term Loan
contains and the HGA IRB contained covenants including the maintenance by HGA of
certain ratios and levels of net worth (as defined), capital expenditures,
interest and debt payments, as well as restrictions on payment of cash
dividends.
36
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
LOAN AND SECURITY AGREEMENT
In September 1994, CVI entered into a Loan and Security Agreement ('Line of
Credit') with a commercial lender providing for revolving advances of up to
$8,000,000. On October 31, 1995 the balance outstanding on the line of credit
was $1,025,000. Advances under the Line of Credit bear interest at 2 1/2
percentage points above the highest most recently announced prime rate of the
three financial institutions of national repute named in the agreement, with a
floor of 8.5% per annum. The rate in effect at October 31, 1995 was 11.25% per
annum. CVI agreed to the payment of various fees and minimum annual interest of
$150,000. The aggregate amount of advances under the agreement is capped at the
lesser of $8,000,000, or a percentage of CVI's levels of eligible receivables
and inventory as defined in the agreement (approximately $5,900,000 in total
line availability at October 31, 1995) and is collateralized by virtually all of
the assets of CVI.
The Line of Credit provides that CVI (provided that no Event of Default, as
defined, has occurred and is continuing) may make loans, advances, investments,
capital contributions and distributions to the Company, and pay management fees
to the Company, so long as the total amount of all such amounts does not exceed
an amount equal to the sum of (i) 75% of CVI's Tangible Net Worth, as defined,
on the closing date, plus (ii) all amounts in excess of required increases in
CVI's Tangible Net Worth for each fiscal year ending after October 31, 1994. On
the closing date, CVI's Tangible Net Worth was $11,480,000. At October 31, 1995,
CVI had Tangible Net Worth of $9,492,000, of which $6,142,000 was unrestricted
under the terms of the Loan and Security Agreement.
The Line of Credit contains various covenants, including the maintenance of
certain ratios and levels of net worth (as defined), limitations on capital
expenditures and incurrence of indebtedness as well as limitations regarding
change in control and transactions with affiliates.
In connection with the Line of Credit, the Company guaranteed all of the
obligations under the HGA Term Loan and CVI's obligations under the Line of
Credit and the Company pledged all of the outstanding stock of CVI as collateral
for the HGA Term Loan guaranty.
UNAMORTIZED BOND DISCOUNT AND DEFERRED PREMIUM
The difference between the carrying amount and the principal amount of the
Company's Debentures represents unamortized discount which is being charged to
expense over the life of the issue. As of October 31, 1995, the amount of
unamortized discount was approximately $75,000.
The carrying value of the Debentures exchanged less the face value of the
Notes issued and the aggregate cash payment for the Debentures was recorded as a
deferred premium. The Company is recognizing the benefit of the deferred premium
as a reduction to the effective interest rate on the Notes over the life of the
issue. As of October 31, 1995, the amount of the unamortized deferred premium
was $2,873,000.
NOTE 12. EMPLOYEE STOCK PLANS
1988 LONG-TERM INCENTIVE PLAN ('LTIP')
The LTIP is a vehicle for the Company to attract, retain and motivate key
employees and consultants to the Company and its subsidiaries and affiliates,
who are directly linked to the profitability of the Company and to increasing
stockholder value.
The LTIP authorizes a committee consisting of three or more individuals not
eligible to participate in the LTIP or, if no committee is appointed, the
Company's Board of Directors, to grant to eligible individuals during a period
of ten years from September 15, 1988, stock options, stock appreciation rights,
restricted stock, deferred stock, stock purchase rights, phantom stock units and
long-term performance awards for up to 2,125,570 shares of common stock, subject
to adjustment for future stock
37
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
splits, stock dividends, expirations, forfeitures and similar events. As of
October 31, 1995, 903,868 shares remained available under the LTIP for future
grants.
As of August 1, 1993, there were outstanding options to purchase an
aggregate of 367,500 shares of common stock granted to, and not subsequently
forfeited by, optionholders at exercise prices ranging from $2.07 to $12.75. The
Company offered each employee who held options granted under the LTIP an
opportunity to exchange those options for a smaller number of substitute
options. Each new option is exercisable at $1.68 per share. The number of shares
each employee was entitled to purchase pursuant to such option was computed by
an independent nationally recognized compensation consulting firm using an
option exchange ratio derived under the Black-Scholes option pricing model. Each
person who elected to participate in the option exchange program received an
option to purchase an individually calculated percentage ranging from 21% to 70%
of the shares such person was originally entitled to purchase. A percentage of
the new option, equal to the percentage of the outstanding option that was
already exercisable, was immediately exercisable, and the remainder became
exercisable in 1994 in 25% tranches when the trading price of the Company's
common stock over 30 days averaged, $3.00, $4.50, $6.00 and $7.50 per share,
respectively. The option exchange program provided optionholders the opportunity
to exchange options with exercise prices well in excess of the then current
market price of the Company's common stock with a lesser number of options
exercisable at a price that, while still above the then price, was lower than
the exercise price on the surrendered options. Under the terms of the option
exchange offer, each person who elected to participate waived the vesting of
options that otherwise would have resulted from the Change in Control (as such
term is defined in the LTIP) that occurred when stockholders approved the
conversion rights of the Series B Preferred Stock on September 14, 1993. (See
Note 9.)
1990 NON-EMPLOYEE DIRECTORS RESTRICTED STOCK PLAN ('NEDRSP')
Under the terms of the NEDRSP, upon joining the Board of Directors, each
director of the Company who is not also an employee of or a consultant to the
Company or any subsidiary of the Company ('Non-Employee Director') is granted
the right to purchase, for $.10 per share, 1,666 shares of the Company's common
stock, subject to restrictions, which can be lifted either upon the fair market
value of the Company's common stock achieving stated targets, or upon the
passage of a stated period of time, typically 9 1/2 years after the date of
grant. A total of 33,333 shares of such common stock were authorized and
reserved for issuance under the NEDRSP. Shares which are forfeited become
available for new awards under such plan. At October 31, 1995, there were 15,000
shares of the Company's common stock available for future grants under the
NEDRSP. Upon approval by the Company's stockholders of the 1996 Long Term
Incentive Plan for Non-Employee Directors, which is described below, the NEDRSP
will terminate.
Transactions involving the grant of options or restricted shares of the
Company's common stock in connection with the LTIP and NEDRSP during each of the
years in the three year period ended October 31, 1995 are summarized below.
Options issued and outstanding have option prices ranging from $1.68 to
$11.25 per share.
38
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
<TABLE>
<CAPTION>
NUMBER OF SHARES
-------------------
LTIP NEDRSP
--------- ------
<S> <C> <C>
1995
Balance at beginning of year.......................................... 977,078 18,333
Options granted....................................................... 131,111 --
Options forfeited..................................................... (62,683) --
Restricted shares granted............................................. 176,196 --
--------- ------
Balance at end of year................................................ 1,221,702 18,333
--------- ------
--------- ------
Consisting of:
Options issued but not exercisable............................... 250,191 --
Options issued and exercisable................................... 78,650 --
Options exercised at $1.68 to $2.07 per share.................... 6,226 --
Restricted shares issued with restrictions in force.............. 91,659 --
Restricted shares issued with restrictions removed............... 794,976 18,333
--------- ------
1,221,702 18,333
--------- ------
--------- ------
</TABLE>
<TABLE>
<CAPTION>
NUMBER OF SHARES
-----------------
LTIP NEDRSP
------- ------
<S> <C> <C>
1994
Balance at beginning of year............................................ 789,265 18,333
Options granted......................................................... 136,667 --
Options forfeited....................................................... (48,113) --
Restricted shares granted............................................... 99,259 --
------- ------
Balance at end of year.................................................. 977,078 18,333
------- ------
------- ------
Consisting of:
Options issued but not exercisable................................. 195,552 --
Options issued and exercisable..................................... 70,004 --
Options exercised at $1.68 per share............................... 1,073 --
Restricted shares issued with restrictions in force................ 54,444 --
Restricted shares issued with restrictions removed................. 656,005 18,333
------- ------
977,078 18,333
------- ------
------- ------
</TABLE>
39
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
<TABLE>
<CAPTION>
NUMBER OF SHARES
-------------------
LTIP NEDRSP
--------- ------
<S> <C> <C>
1993
Balance at beginning of year.......................................... 935,173 11,666
Options granted....................................................... 206,666 --
Options forfeited..................................................... (320,696) --
Restricted shares granted............................................. 41,666 6,667
Restricted shares purchased by the Company............................ (65,544) --
Restricted shares forfeited........................................... (8,000) --
--------- ------
Balance at end of year................................................ 789,265 18,333
--------- ------
--------- ------
Consisting of:
Options issued but not exercisable............................... 173,090 --
Options issued and exercisable................................... 4,986 --
Restricted shares issued with restrictions in force.............. 60,870 1,666
Restricted shares issued with restrictions removed............... 550,319 16,667
--------- ------
789,265 18,333
--------- ------
--------- ------
</TABLE>
The excess of market value over $.10 per share of LTIP and NEDRSP
restricted shares on respective dates of grant is initially recorded as
unamortized restricted stock award compensation, a separate component of
stockholders' equity and charged to operations as earned. Restricted shares and
other stock compensation charged against income from operations for the years
ended October 31, 1995, 1994 and 1993 was none, $55,000 and $1,084,000,
respectively.
1996 LONG-TERM INCENTIVE PLAN FOR NON-EMPLOYEE DIRECTORS
On December 12, 1995 the Board of Directors of the Company adopted a
proposal to reduce the annual cash stipend paid to Non-Employee Directors and to
award grants of restricted stock and options annually at the start of each
fiscal year. Specifically, each Non-Employee Director will be awarded the right
to purchase stock worth $7,500 each year (or $9,375 in the case of the Chairman
of the Board who is a Non-Employee Director) and be granted an option to
purchase 5,000 shares of the Company's common stock in fiscal 1996 and 3,333
shares in each subsequent fiscal year (or, in the case of a Chairman of the
Board who is a Non-Employee Director, 6,250 shares in fiscal 1996 and 4,167
shares in each subsequent fiscal year) through fiscal 2000. A total of 215,000
shares of the Company's authorized but unissued common stock have been reserved
for issuance under the plan. Final adoption of the plan requires stockholder
approval, which will be sought at the 1996 Annual Meeting of Stockholders
scheduled to be held in March 1996.
PRIOR STOCK OPTION PLANS
Prior to the September 15, 1988 implementation of the LTIP, the Company had
two stock option plans (the 'Stock Option Plans'). With the adoption of the
LTIP, all authorized but unallocated shares of stock reserved under the Stock
Option Plans (options for approximately 143,500 shares of the Company's common
stock) were transferred to the LTIP. No further grants are allowed from the
Stock Option Plans, although previously existing grants remain in effect. On
October 31, 1995, there were 7,483 outstanding shares with option prices per
share ranging from $48.39 - $59.25.
40
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
NOTE 13. EMPLOYEE BENEFITS
THE COMPANY'S RETIREMENT INCOME PLAN
The Company sponsors a defined benefit Retirement Income Plan which covers
substantially all full-time United States employees of CVI, CVP and the
Company's Corporate Headquarters. The Company's contributions are designed to
fund normal cost on a current basis and to fund over thirty years the estimated
prior service cost of benefit improvements (fifteen years for annual gains and
losses). The unit credit actuarial cost method is used to determine the annual
cost. The Company pays the entire cost of the Retirement Plan and funds such
costs as they accrue. Virtually all of the assets of the Plan are comprised of
participations in equity and fixed income funds.
Net periodic pension cost of the Plan was as follows:
<TABLE>
<CAPTION>
YEARS ENDED OCTOBER 31,
-----------------------------------------------------------------------------
1995 1994 1993
----------------------- ----------------------- -----------------------
(IN THOUSANDS)
<S> <C> <C> <C>
Service cost................................ $ 188 $ 173 $ 180
Interest cost............................... 521 479 453
Actual return on assets..................... (982) (531) (628)
Net amortization and deferral............... 491 2 176
------ ------ ------
Net periodic pension cost............ $ 218 $ 123 $ 181
------ ------ ------
------ ------ ------
</TABLE>
The actuarial present value of benefit obligations and funded status for
the Plan was as follows:
<TABLE>
<CAPTION>
OCTOBER 31,
----------------
1995 1994
------ ------
(IN THOUSANDS)
<S> <C> <C>
Vested benefit obligation.................................................. $7,250 $5,861
Non-vested benefit obligation.............................................. 77 84
------ ------
Accumulated benefit obligation........................................ 7,327 5,945
Projected compensation increases........................................... 825 546
------ ------
Projected benefit obligation.......................................... 8,152 6,491
Fair value of plan assets.................................................. 6,545 5,828
------ ------
Projected benefit obligation in excess of assets........................... 1,607 663
Add (Deduct):
Unrecognized net gain (loss).......................................... (386) 379
Prior service cost remaining to be amortized, including unrecognized
net asset........................................................... (439) (465)
------ ------
Pension liability recognized............................................... $ 782 $ 577
------ ------
------ ------
</TABLE>
Assumptions used in developing the projected benefit obligation as of
October 31 were:
<TABLE>
<CAPTION>
1995 1994
---- ----
<S> <C> <C>
Assumptions:
Discount rate on plan liabilities........................................ 7.5% 8.0%
Long-range rate of return on plan assets................................. 9.0% 9.0%
Salary increase rate..................................................... 6.0% 6.0%
</TABLE>
THE COMPANY'S 401(K) SAVINGS PLAN
The Company's 401(k) Savings Plan provides for the deferral of compensation
as described in the Internal Revenue Code, and is available to substantially all
full-time United States employees of the Company. United States resident
employees of the Company who participate in the 401(k) Plan may
41
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
elect to have from 2% to 10% of their pre-tax salary or wages, (but not more
than $5,000 for highly compensated employees) for the calendar year ended
December 31, 1995, deferred and contributed to the trust established under the
401(k) Plan. The Company's contribution to the 401(k) Plan on account of the
Company's participating employees, net of forfeiture credits, was $95,000,
$80,000 and $90,000 for the years ended October 31, 1995, 1994 and 1993,
respectively.
THE COMPANY'S INCENTIVE PAYMENT PLAN
The Company's Incentive Payment Plan is available to officers and other key
executives. Participants may, in certain years, receive bonuses based on Company
and subsidiary performance. Total payments earned for the years ended October
31, 1995, 1994 and 1993, were approximately $1,504,000, $1,296,000 and $439,000,
respectively.
THE COMPANY'S TURN-AROUND INCENTIVE PLAN
The Company's Turn-Around Incentive Plan ('TIP') was adopted by the Board
of Directors in May 1993. The TIP was adopted, upon the recommendation of the
Company's independent compensation consultants, to recognize the special efforts
of certain individuals in guiding the Company through a resolution of its
difficulties arising from its then current capital structure and its former
ownership of companies that manufactured and distributed breast implants.
The TIP provided for awards in varying amounts to be made to designated
participants. Before any awards could become payable, however, the Company had
to significantly reduce its liabilities relating to the former breast implant
business to levels approved by the Board of Directors, which condition was
satisfied when the MEC Agreement became final on January 6, 1994 (see Note 4).
Upon satisfaction of such condition, one-third of the award was payable when the
average per share price of the Company's common stock over a period of thirty
days equaled or exceeded $4.50 per share. That occurred in May 1994, and
participants in the TIP were, therefore, awarded one-third of the total award
for which they were eligible under the TIP. The payments were made in cash
($246,667) and by means of the issuance of 99,259 shares of restricted stock
under the Company's 1988 LTIP. That stock generally will remain restricted and
nontransferable until May 1996. The remaining two-thirds of the allocated TIP
awards were paid August 30, 1995, the date that the 30-day average of the price
of the Company's common stock equaled $9.00 per share. Payments were made in
cash ($475,833) and by means of the issuance of 97,316 shares of restricted
stock under the LTIP. One-half of that stock generally will remain restricted
and nontransferable for a period of one year from the date of grant. The
remaining shares will generally remain restricted and nontransferable for a
period of two years from the date of grant.
NOTE 14. COMMITMENTS, CONTINGENCIES AND LITIGATION
Total minimum annual rental obligations (net of sublease revenue of
approximately $125,000 per year, through 2000) under noncancelable operating
leases (substantially all real property and equipment) in force at October 31,
1995 are payable in subsequent years as follows:
<TABLE>
<CAPTION>
(IN THOUSANDS)
<S> <C>
1996............................................ $2,194
1997............................................ 1,638
1998............................................ 1,042
1999............................................ 836
2000............................................ 727
2001 and thereafter............................. 1,428
-------
$7,865
-------
-------
</TABLE>
42
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Aggregate rental expense for both cancelable and noncancelable contracts
amounted to $2,354,000, $2,438,000 and $2,105,000 in 1995, 1994 and 1993,
respectively.
The remaining liability recorded for payments to be made to MEC under the
MEC Agreement (see Note 4) become due as follows:
<TABLE>
<CAPTION>
DECEMBER 31, (IN THOUSANDS)
- ------------
<S> <C>
1995 ....................................... $1,500
1996 ....................................... 1,750
1997 ....................................... 2,000
1998 ....................................... 2,500
-------
$7,750
-------
-------
</TABLE>
Additional payments to be made to MEC beginning December 31, 1999 are
contingent upon the Company's earning net income before taxes in each fiscal
year subsequent to the fiscal year ending October 31, 1999, and are, therefore,
not recorded in the Company's financial statements. Such payments are limited to
the smaller of 50% of the Company's net income before taxes in each such fiscal
year on a noncumulative basis or the amounts shown below:
<TABLE>
<CAPTION>
DECEMBER 31, (IN THOUSANDS)
- ------------
<S> <C>
1999 ....................................... $3,000
2000 ....................................... $3,500
2001 ....................................... $4,000
2002 ....................................... $4,500
2003 ....................................... $3,000
</TABLE>
Under the terms of a supply agreement most recently modified in 1993, the
Company agreed to purchase by December 31, 1997, certain contact lenses from
Pilkington plc, with an aggregate cost of approximately 'L'4,063,000. Lenses
with an aggregate value of approximately 'L'477,000, 'L'400,000 and 'L'213,000
were purchased under the terms of the supply agreement in fiscal years 1995,
1994 and 1993, respectively. As of December 31, 1995, there remained a
commitment of approximately 'L'2,747,000.
Payments amounting to $3,100,000 were made related to a settlement with
Hampton Medical Group, P.A. ('HMG') and Dr. Pottash (see Litigation below) in
December 1995. Two additional payments are scheduled to be made to HMG in May
1997 and 1998, each in the amount of $1,537,500. These amounts were charged
against net income in fiscal 1995.
WARRANTS
In connection with agreements to extend the due date on certain of the
Company's outstanding debt in 1988, the Company issued warrants to a group of
its lenders, which after a series of adjustments had an exercise price of $1.11
per share. Warrants to purchase 219,650 shares of the Company's common stock
vested in December 1988 and had an expiration date of December 29, 1995.
Warrants to purchase 167,227 shares of common stock were exercised by the
expiration date.
The Company issued a warrant to Foothill Capital Corporation ('Foothill')
to purchase 26,666 shares of the Company's common stock at $5.625 per share in
connection with the loan and security agreement among Foothill, CVI, and
CooperVision Canada. (See Note 11 'Loan and Security Agreement.') The warrant
becomes exercisable on September 21, 1997 and expires on May 26, 1999. Both the
number of shares under the warrant and the exercise price per share are
adjustable under certain circumstances to avoid dilution.
43
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
LITIGATION
The Company is a defendant in a number of legal actions relating to its
past or present businesses in which plaintiffs are seeking damages. In the
opinion of Management, after consultation with counsel, the ultimate disposition
of those actions will not materially affect the Company's financial position.
In January 1994, the Company was found guilty on six counts of mail fraud
and one count of wire fraud based upon the conduct of a former Co-Chairman
relating to a 'trading scheme' to 'frontrun' high yield bond purchases, but was
acquitted of charges of conspiracy and aiding and abetting violations of the
Investment Advisers Act of 1940. The Company was sentenced on July 15, 1994, at
which time it was ordered to make restitution to Keystone Custodian Funds, Inc.
of $1,310,166, which was paid August 15, 1994. In addition, the Company was
ordered to pay a noninterest bearing fine over the next three years in the
amount of $1,831,568. A total of $350,000 was paid on July 14, 1995, with the
additional payments of $350,000 and $1,131,568 payable on July 15, 1996 and
1997, respectively. These amounts were charged against net income in previous
fiscal years. Also the Company settled in December 1994 a related SEC action
under which the Company agreed to the disgorgement of $1,621,474 and the payment
of a civil penalty of $1,150,000. The Company had already disgorged $1,310,166
in connection with the sentence imposed in a related criminal action involving
the 'frontrunning' arrangement; the balance of the disgorgement was paid in
January 1995. The civil penalty imposed by the SEC is offset by the larger fine
to which the Company was sentenced in the criminal action. In the SEC
settlement, the Company also consented to being permanently enjoined from
violating certain provisions of the Securities Exchange Act of 1934, from aiding
and abetting violations of certain provisions of the Investment Advisers Act and
from further employing certain former employees and/or any of their relatives.
The Company was named as a nominal defendant in a shareholder derivative
action entitled Harry Lewis and Gary Goldberg v. Gary A. Singer, Steven G.
Singer, Arthur C. Bass, Joseph C. Feghali, Warren J. Keegan, Robert S. Holcombe
and Robert S. Weiss, which was filed on May 27, 1992 in the Court of Chancery,
State of Delaware, New Castle County. Lewis and Goldberg subsequently amended
their complaint, and the Delaware Chancery Court consolidated the amended
complaint with a similar complaint filed by another plaintiff as In re The
Cooper Companies, Inc. Litigation, Consolidated C.A. 12584. The Lewis and
Goldberg amended complaint was designated as the operative complaint (the
'Derivative Complaint').
The Derivative Complaint alleges that certain directors of the Company and
Gary A. Singer, as Co-Chairman of the Board of Directors, caused or allowed the
Company to be a party to a 'trading scheme' to 'frontrun' high yield bond
purchases by the Keystone Custodian Fund, Inc., a group of mutual funds. The
Derivative Complaint also alleges that the defendants violated their fiduciary
duties to the Company by not vigorously investigating certain allegations of
securities fraud. The Derivative Complaint requests that the Court order the
defendants (other than the Company) to pay damages and expenses to the Company
and certain of the defendants to disgorge their profits to the Company. The
parties have been engaged in negotiations and have agreed upon the terms of a
settlement, which will have no material impact on the Company. Upon completion
of the settlement documentation, the proposed settlement will be submitted to
the Court for approval following notice to the Company's shareholders and a
hearing. Accordingly, there can be no assurance that the proposed settlement
will ultimately end the litigation. The individual defendants have advised the
Company that they believe they have meritorious defenses to the lawsuit and
that, in the event the case proceeds to trial, they intend to defend vigorously
against the allegations in the Derivative Complaint.
The Company was also named as a nominal defendant in a shareholder
derivative action entitled Bruce D. Sturman v. Gary A. Singer, Steven G. Singer,
Brad C. Singer, Dorothy Singer as the Executrix of the Estate of Martin Singer,
Karen Sue Singer, Norma Singer Brandes, Normel Construction Corp., Brandes &
Singer, and Romulus Holdings, Inc., which was filed on June 6, 1995 in the Court
of Chancery of the State of Delaware, New Castle County. The complaint is
similar to a derivative
44
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
complaint filed by Mr. Sturman in the Supreme Court of the State of New York on
May 26, 1992, which was dismissed under New York Civil Practice Rule 327(a) on
August 17, 1993. The dismissal of the New York case was affirmed by the
Appellate Division on March 28, 1995. The allegations in the Delaware complaint
relate to substantially the same facts and events at issue in In re The Cooper
Companies, Inc. Litigation described above, and similar relief is sought. The
parties have tentatively agreed that plaintiff's action will be consolidated
into and settled with In re The Cooper Companies, Inc. Litigation (see above).
In two virtually identical actions, Frank H. Cobb, Inc. v. The Cooper
Companies, Inc., et al., and Arthur J. Korf v. The Cooper Companies, Inc., et
al., class action complaints were filed in the United States District Court for
the Southern District of New York in August 1989, against the Company and
certain individuals who served as officers and/or directors of the Company after
June 1987. The complaints, as amended, alleged that the defendants knew or
recklessly disregarded and failed to disclose to the investing public material
adverse information about the Company. The amended complaints also alleged that
the defendants are liable for having violated Section 10(b) of the Securities
Exchange Act and Rule 10(b)-5 thereunder and having engaged in common law fraud.
The Company reached a settlement with counsel for the class plaintiffs, which
had no material impact on the Company's financial condition. On May 5, 1995, the
settlement was approved by the court.
Under an agreement dated July 11, 1985, as amended (the 'HMG Agreement'),
Hampton Medical Group, P.A. ('HMG'), which is not affiliated with the Company,
contracted to provide clinical and clinical administrative services at Hampton
Psychiatric Institute ('Hampton Hospital'), the primary facility operated by
Hospital Group of New Jersey, Inc. ('HGNJ'), a subsidiary of the Company's
psychiatric hospital holding company, Hospital Group of America, Inc. ('HGA').
In late 1993 and early 1994, HGNJ delivered notices to HMG asserting that HMG
had defaulted under the HMG Agreement based upon billing practices by HMG that
HGNJ believed to be fraudulent. At the request of HMG, a New York state court
enjoined HGNJ from terminating the HMG Agreement based upon the initial notice
and ordered the parties to arbitrate whether HMG had defaulted.
On February 2, 1994, HMG commenced an arbitration in New York, New York
(the 'Arbitration'), entitled Hampton Medical Group, P.A. and Hospital Group of
New Jersey, P.A. (American Arbitration Association), in which it contested the
alleged default. In addition, HMG made a claim against HGNJ for unspecified
damages based on allegedly foregone fees on the contention that HMG had the
right to provide services at all HGNJ-owned facilities in New Jersey, including
certain outpatient clinics and the Hampton Academy, at which non-HMG physicians
have been employed.
On December 30, 1994, Blue Cross and Blue Shield of New Jersey, Inc.
commenced a lawsuit in the Superior Court of New Jersey entitled Blue Cross and
Blue Shield of New Jersey, Inc. v. Hampton Medical Group, et al. against HMG and
certain related entities and individuals unrelated to HGNJ or its affiliates
alleging, among other things, fraudulent billing practices (the 'Blue Cross
Action').
On or about April 12, 1995, an individual defendant in the Blue Cross
Action who was formerly employed by HMG, Dr. Charles Dackis, commenced a third
party claim in the Blue Cross Action against HGNJ, HGA and the Company, alleging
a right under the HMG Agreement to indemnity in an unspecified amount for fees,
expenses and damages that he might incur in that action. In a letter brief filed
on or about April 17, 1995, HMG indicated an intention to bring a similar claim
at a later date. On or about May 16, 1995, HGNJ, HGA and the Company filed an
answer to the complaint, and HGNJ and HGA brought counterclaims against Dr.
Dackis and cross-claims against HMG and Dr. A.L.C. Pottash, another individual
defendant and the owner of HMG, in an amount to be determined, based on
allegations of fraudulent and improper billing practices.
On October 27, 1995, the Court dismissed with prejudice all claims asserted
by Dr. Dackis against HGA, HGNJ and the Company in the Blue Cross Action. On
December 11, 1995, the Company announced a settlement of all disputes with HMG
and Dr. Pottash. Pursuant to the settlement, (i) the parties released each other
from, among other things, the claims underlying the Arbitration, (ii) HGA
45
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
purchased HMG's interest in the HMG Agreement on December 31, 1995, and (iii)
HGNJ agreed to make certain payments to Dr. Pottash in respect of claims he had
asserted. While only HMG and Dr. Pottash are parties to the settlement with HGA,
HGNJ and the Company, the Company has not been notified of any claims by other
third party payors or others relating to the billing or other practices at
Hampton Hospital, although it continues to respond voluntarily to requests for
information from the State of New Jersey Department of Insurance and other
government agencies with respect to these matters. The settlement with HMG and
Dr. Pottash resulted in a one-time charge with a present value of $5,551,000 to
fourth quarter fiscal 1995 earnings. That charge reflects amounts paid to Dr.
Pottash in December 1995 of $3,100,000 included in other current liabilities at
October 31, 1995, as well as two payments scheduled to be made to HMG in May
1997 and 1998, each in the amount of $1,537,500.
NOTE 15. RELATIONSHIPS AND TRANSACTIONS BETWEEN THE COMPANY, CLS, COOPER
DEVELOPMENT COMPANY ('CDC') AND THE COOPER LABORATORIES, INC. STOCKHOLDERS'
LIQUIDATING TRUST (THE 'TRUST')
ADMINISTRATIVE SERVICES
Pursuant to separate agreements between the Company and CDC, CLS and the
Trust, which was formed in connection with the liquidation of the Company's
former parent, Cooper Laboratories, Inc., the Company provided certain
administrative services to CDC, CLS and the Trust, including the services of the
Company's treasury, legal, tax, data processing, corporate development, investor
relations and accounting staff. Expenses were charged on the basis of specific
utilization or allocated based on personnel, space, percent of assets used or
other appropriate bases. The agreements relating to the provision of
administrative services to CDC and CLS terminated on September 17, 1988. The
Company has not performed any services for CDC and CLS since September 17, 1988,
other than historic tax services. Combined corporate administrative expenses
charged to the Trust by the Company were $213,000 in 1992 and $560,000 in 1991.
On July 9, 1992, the Trust filed a petition in Bankruptcy under Chapter 7 of the
Bankruptcy Code; and, effective July 31, 1992, the Company ceased providing
services to the Trust. The Company has asserted a claim for approximately
$750,000 in the Trust's bankruptcy proceedings, primarily representing unpaid
administrative service fees and expenses and legal fees advanced by the Company
on behalf of the Trust. In October 1995, in connection with a final distribution
of assets from the Trust, the Company received a payment of $648,000 in partial
satisfaction of its outstanding claim, which was recorded as a reduction of
general and administrative expenses.
AGREEMENTS WITH CLS
On June 12, 1992, the Company consummated a transaction (the '1992 CLS
Transaction') with CLS, which eliminated approximately 80% of the Company's then
outstanding SERPS. (See Note 8.) Pursuant to an Exchange Agreement between the
Company and CLS dated as of June 12, 1992 (the '1992 Exchange Agreement'), the
Company acquired from CLS, among other things, 488,004 shares of the SERPS owned
by CLS, and all of CLS's right to receive, by way of dividends pursuant to the
terms of the SERPS, an additional 11,996 shares of SERPS (such 11,996 shares
together with the 488,004 shares being referred to collectively as the SERPS) in
exchange for 1,616,667 newly issued shares of the Company common stock (the
'Company Shares'). In addition, the Company entered into a settlement agreement
with CLS dated as of June 12, 1992 (the '1992 Settlement Agreement'), with
respect to certain litigation and administrative proceedings in which the
Company and CLS were involved. Pursuant to the 1992 Settlement Agreement, the
Company agreed, among other things, that, if requested by CLS, it would use its
reasonable best efforts to cause the election to the Company's Board of
Directors of one or two designees of CLS, reasonably acceptable to the Company
(the number of designees depending, respectively, on whether CLS owns more than
333,333 but less than 800,000 shares, or more than 800,000 shares of the
Company's common stock).
46
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
On June 14, 1993, the Company acquired from CLS all of the remaining
outstanding SERPS of the Company, having an aggregate liquidation preference of
$16,060,000, together with all rights to any dividends or distributions thereon,
in exchange for shares of Series B Preferred Stock having an aggregate
liquidation preference of $3,450,000 and a par value of $.10 per share (the
'1993 Exchange Agreement'). Such shares, and any shares of Series B Preferred
Stock issued as dividends, were convertible into one share of common stock of
the Company for each $3.00 of liquidation preference, subject to customary
antidilution adjustments.
The Company also had the right to compel conversion of Series B Preferred
Stock at any time after the market price of the common stock on its principal
trading market averaged at least $4.125 for 90 consecutive calendar days and
closed at not less than $4.125 on at least 80% of the trading days during such
period. On September 26, 1994, the Company's common stock met the above
requirements, and the Series B Preferred Stock was converted into 1,150,000
shares of the Company's common stock.
No dividends accrued on the Series B Preferred Stock through June 14, 1994.
Subsequently, dividends accrued and were paid in cash, at the rate of 9% (of
liquidation preference) per annum, through the date of conversion.
The Company and CLS also entered into a Registration Rights Agreement,
dated June 14, 1993, providing for the registration under the Securities Act of
the shares of common stock issued upon such conversion of any of the Series B
Preferred Stock and any of the 1,616,667 shares of common stock currently owned
by CLS which have not been sold prior thereto.
On June 14, 1993, the Board of Directors amended the Rights Agreement dated
as of October 29, 1987, between the Company and The First National Bank of
Boston, as Rights Agent, so that CLS and its affiliates and associates as of the
amendment date would not be Acquiring Persons thereunder as a result of CLS's
beneficial ownership of more than 20% of the outstanding common stock of the
Company by reason of its ownership of Series B Preferred Stock or common stock
issued upon conversion thereof. (See Note 9.)
CLS obtained 1,616,667 shares of the Company's common stock pursuant to the
1992 Exchange Agreement described above. In Amendment No. 1 to its Schedule 13D,
filed with the SEC on November 12, 1992, CLS disclosed that 'in light of the
recent public disclosures relating to the Company and the recent significant
decline in the public trading price of the common stock, CLS is presently
considering various courses of action which it may determine to be necessary or
appropriate in order to maintain and restore the value of the common stock.
Included among the actions which CLS is considering pursuing are the initiation
of litigation against the Company and the replacement of management and at least
a majority of the members of the Board of Directors of the Company.
On June 14, 1993, in order to resolve all disputes with CLS, the Company
and CLS entered into a Settlement Agreement (the '1993 Settlement Agreement'),
pursuant to which CLS delivered a general release of claims against the Company,
subject to exceptions for specified ongoing contractual obligations, and agreed
to certain restrictions on its voting and transfer of securities of the Company,
in exchange for the Company's payment of $4,000,000 in cash and delivery of
200,000 shares of common stock of CLS owned by the Company and a general release
of claims against CLS, subject to similar exceptions.
Pursuant to the 1993 Settlement Agreement, the Company agreed to nominate,
and to vote all of its shares of common stock of the Company in favor of the
election of, a Board of Directors of the Company consisting of eight members, up
to three of whom will, at CLS's request, be designated by CLS (such designees to
be officers or more than 5% stockholders of CLS as of June 14, 1993 or otherwise
be reasonably acceptable to the Company). The number of CLS designees will
decline as CLS's ownership of common stock declines. A majority of the Board
members (other than CLS designees) are to be individuals who are not officers or
employees of the Company. Pursuant to the Settlement Agreement, CLS designated,
and on August 10, 1993 the Board of Directors elected, one person to serve as a
director of the Company until the 1993 Annual Meeting. CLS also designated that
47
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
individual along with two other people as its three designees to the
eight-member Board of Directors that was elected at the 1993 Annual Meeting.
Three CLS designees were elected or reelected to the Board at the 1994 and 1995
Annual Meetings.
CLS also agreed in the 1993 Settlement Agreement not to acquire any
additional securities of the Company and to certain limitations on its transfer
of securities of the Company. In addition, CLS agreed, among other things, not
to seek control of the Company or the Board or otherwise take any action
contrary to the 1993 CLS Settlement Agreement. CLS is free, however, to vote all
voting securities owned by it as it deems appropriate on any matter before the
Company's stockholders.
The agreements with respect to Board representation and voting, and the
restrictions on CLS's acquisition and transfer of securities of the Company,
were to terminate on June 14, 1995, or earlier if CLS beneficially owned less
than 333,333 shares of common stock (including as owned the common stock into
which shares of Series B Preferred Stock owned by CLS were converted). The
agreements were to be extended if the market price of the common stock increased
to specified levels prior to each of June 12, 1995, and June 12, 1996, or if the
Company agreed to nominate one CLS designee, who was independent of CLS and
reasonably acceptable to the Company, in addition to that number of designees to
which CLS was then entitled on each such date, which would have resulted in such
agreements continuing through October 31, 1996, and CLS having up to five
designees on the Board (which would then have a total of ten members, or eleven
members if a new chairman or chief executive officer was then serving on the
Board). In January 1995, in connection with the further amendment to the Rights
Agreement (see Note 6), the Company and CLS amended the 1993 Settlement
Agreement to provide that the provisions relating to CLS representation on the
Company's Board, CLS's obligations with respect to voting its securities of the
Company and the restrictions on CLS's acquisition and transfer of securities of
the Company, will now end on the earlier of (i) the first date on which CLS
beneficially owns fewer than 333,333 shares of the Company's outstanding common
stock or (ii) October 31, 1996, or if any person (other than two specified
individuals) becomes the beneficial owner of 20% or more of the outstanding
shares of common stock of CLS, April 30, 1997.
Following termination of the 1993 Settlement Agreement and through June 12,
2002, CLS will continue to have the contractual right that it had pursuant to
the 1992 CLS Settlement Agreement to designate two directors of the Company, so
long as CLS continues to own at least 800,000 shares of common stock, or one
director, so long as it continues to own at least 333,333 shares of common
stock.
OTHER
CLS was formerly an 89.5% owned subsidiary of the Company's former parent,
Cooper Laboratories, Inc.
As of December 31, 1995, CLS owned 2,322,533 shares (or approximately 20%)
of common stock of the Company.
Two members of the Company's Board of Directors are also directors and/or
officers of CLS. Moses Marx is a Director of CLS. Steven Rosenberg is serving as
Acting President, Vice President and Chief Financial Officer of CLS and he is
also a Director of CLS. In addition to shares purchased on the open market, Mr.
Marx owns 1,333 shares and Mr. Rosenberg owns 1,666 shares of the Company's
common stock, obtained through the NEDRSP. (See Note 12.)
NOTE 16. BUSINESS AND GEOGRAPHIC SEGMENT INFORMATION
The Company's operations are attributable to four business segments:
HGA, which provides healthcare services for inpatient and outpatient
treatment and partial hospitalization programs through the ownership
and operation of certain psychiatric facilities, and through May 1995
also managed other such facilities,
48
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
CVI, which develops, manufactures and markets a range of contact
lenses,
CVP, a development stage business, which develops proprietary
ophthalmic pharmaceuticals, and
CSI, which develops, manufactures and distributes diagnostic and
surgical equipment, instruments and disposables, primarily for
gynecology.
Total net revenue by business segment represents service and sales revenue
as reported in the Company's statement of consolidated operations. Total net
revenue by geographic area includes intercompany sales which are generally
priced at terms that allow for a reasonable profit for the seller. Operating
income (loss) is total net revenue less cost of products sold (or services
provided, in the case of HGA revenue), research and development expenses,
selling, general and administrative expenses, costs of restructuring and
amortization of intangible assets. Corporate operating loss is principally
corporate headquarters expense. Investment income, net, settlement of disputes,
net, debt restructuring costs, gain on sales of assets and businesses, net,
other income (expense), net, and interest expense were not allocated to
individual business or geographic segments.
Identifiable assets are those assets used in continuing operations
(exclusive of cash and cash equivalents) or which are allocated thereto when
used jointly. Corporate assets include cash and cash equivalents and temporary
investments.
49
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Information by business segment for each of the years in the three-year
period ended October 31, follows:
<TABLE>
<CAPTION>
CORPORATE &
1995 HGA(1) CVI CVP CSI ELIMINATIONS CONSOLIDATED
- -------------------------------------- ------- ------- ------- ------- ----------- ------------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
Net revenue from non-affiliates....... $41,794 $42,456 $ 16 $12,824 $-- $ 97,090
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
Operating income (loss)............... $ 878 $13,959 $(1,425) $ (425) $(4,979) $ 8,008
------- ------- ------- ------- -----------
------- ------- ------- ------- -----------
Investment income, net................ 444
Settlement of disputes, net........... (3,532)
Other income (expense), net........... 51
Interest expense...................... (4,741)
------------
Income from continuing operations
before income taxes................. $ 230
------------
------------
Identifiable assets................... $48,086 $21,965 $ 285 $ 8,953 $12,703 $ 91,992
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
Depreciation Expense.................. $ 1,443 $ 863 $ 27 $ 288 $ 83 $ 2,704
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
Amortization Expense.................. $ 205 $ 448 $ 22 $ 317 $-- $ 992
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
Capital Expenditures.................. $ 335 $ 1,449 $ 1 $ 267 $ 133 $ 2,185
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
</TABLE>
- ------------
(1) Results include Management fee revenue through May 1995.
------------------------
<TABLE>
<CAPTION>
CORPORATE &
1994 HGA CVI CVP CSI ELIMINATIONS CONSOLIDATED
- -------------------------------------- ------- ------- ------- ------- ----------- ------------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
Net revenue from non-affiliates....... $44,611 $37,793 $ 394 $12,847 $ -- $ 95,645
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
Operating income (loss)............... $ 3,321 $11,963 $(3,063) $ (932) $ (10,866) $ 423
------- ------- ------- ------- -----------
------- ------- ------- ------- -----------
Investment income (loss), net......... (153)
Settlement of disputes, net........... (4,950)
Debt restructuring costs.............. (340)
Gain on sale of assets and businesses,
net................................. 214
Other income (expense), net........... 42
Interest expense...................... (4,533)
------------
Loss from continuing operations before
income taxes........................ $ (9,297)
------------
------------
Identifiable assets................... $50,522 $22,814 $ 442 $ 9,289 $ 11,991 $ 95,058
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
Depreciation expense.................. $ 1,387 $ 1,025 $ 36 $ 339 $ 83 $ 2,870
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
Amortization expense.................. $ 205 $ 448 $ 22 $ 302 $ -- $ 977
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
Capital expenditures.................. $ 338 $ 524 $ 12 $ 58 $ 6 $ 938
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
</TABLE>
50
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
<TABLE>
<CAPTION>
CORPORATE &
1993 HGA CVI CVP CSI ELIMINATIONS CONSOLIDATED
- -------------------------------------- ------- ------- ------- ------- ----------- ------------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
Net revenue from non-affiliates....... $45,283 $32,120 $ 570 $14,679 $ -- $ 92,652
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
Operating income (loss)............... $ 2,124 $ 7,842 $(2,045) $(3,407) $ (25,968) $(21,454)
------- ------- ------- ------- -----------
------- ------- ------- ------- -----------
Investment income, net................ 1,615
Settlement of disputes, net........... (6,350)
Debt restructuring costs.............. (2,131)
Gain on sales of assets and
businesses, net..................... 620
Other income (expense), net........... 174
Interest expense...................... (6,129)
------------
Loss from continuing operations before
income taxes and extraordinary
items............................... $(33,655)
------------
------------
Identifiable assets................... $48,434 $24,339 $ 833 $12,133 $ 23,785 $109,524
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
Depreciation Expense.................. $ 1,324 $ 807 $ 46 $ 343 $ 104 $ 2,624
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
Amortization Expense.................. $ 205 $ 187 $ 90 $ 290 $ -- $ 772
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
Capital Expenditures.................. $ 774 $ 398 $ 91 $ 305 $ 181 $ 1,749
------- ------- ------- ------- ----------- ------------
------- ------- ------- ------- ----------- ------------
</TABLE>
Information by geographic area for each of the years in the three year
period ended October 31, 1995 follows:
<TABLE>
<CAPTION>
UNITED ELIMINATIONS
1995 STATES EUROPE CANADA OTHER AND CORPORATE CONSOLIDATED
- ---------------------------------------- ------- ------ ------ ------ ------------- ------------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
Revenue from non-affiliates............. $85,730 $1,063 $8,054 $2,243 $ -- $ 97,090
Sales between geographic areas.......... 5,192 867 -- -- (6,059) --
------- ------ ------ ------ ------------- ------------
Net operating revenue................... $90,922 $1,930 $8,054 $2,243 $ (6,059) $ 97,090
------- ------ ------ ------ ------------- ------------
------- ------ ------ ------ ------------- ------------
Operating income(loss).................. $12,595 $ (81) $ (126) $ 599 $ (4,979) $ 8,008
------- ------ ------ ------ ------------- ------------
------- ------ ------ ------ ------------- ------------
Identifiable assets..................... $76,490 $ 267 $2,532 $ -- $ 12,703 $ 91,992
------- ------ ------ ------ ------------- ------------
------- ------ ------ ------ ------------- ------------
<CAPTION>
1994
- ----------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Revenue from non-affiliates............. $84,871 $ 946 $7,406 $2,422 $ -- $ 95,645
Sales between geographic areas.......... 3,859 -- -- -- (3,859) --
------- ------ ------ ------ ------------- ------------
Net operating revenue................... $88,730 $ 946 $7,406 $2,422 $ (3,859) $ 95,645
------- ------ ------ ------ ------------- ------------
------- ------ ------ ------ ------------- ------------
Operating income (loss)................. $10,939 $ 12 $ 168 $ 170 $ (10,866) $ 423
------- ------ ------ ------ ------------- ------------
------- ------ ------ ------ ------------- ------------
Identifiable assets..................... $80,084 $ 603 $3,560 $ -- $ 10,811 $ 95,058
------- ------ ------ ------ ------------- ------------
------- ------ ------ ------ ------------- ------------
<CAPTION>
1993
- ----------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Revenue from non-affiliates............. $83,189 $ 795 $7,131 $1,537 $ -- $ 92,652
Sales between geographic areas.......... 4,593 -- -- -- (4,593) --
------- ------ ------ ------ ------------- ------------
Net operating revenue................... $87,782 $ 795 $7,131 $1,537 $ (4,593) $ 92,652
------- ------ ------ ------ ------------- ------------
------- ------ ------ ------ ------------- ------------
Operating income (loss)................. $ 4,161 $ (72) $ 561 $ (136) $ (25,968) $(21,454)
------- ------ ------ ------ ------------- ------------
------- ------ ------ ------ ------------- ------------
Identifiable assets..................... $85,962 $ 832 $3,059 $ -- $ 19,671 $109,524
------- ------ ------ ------ ------------- ------------
------- ------ ------ ------ ------------- ------------
</TABLE>
51
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
NOTE 17. QUARTERLY FINANCIAL DATA (UNAUDITED)
<TABLE>
<CAPTION>
FIRST SECOND THIRD FOURTH
QUARTER QUARTER QUARTER QUARTER
------- ------- ------- -------
(IN THOUSANDS, EXCEPT PER SHARE FIGURES)
<S> <C> <C> <C> <C>
1995
Net operating revenue................................................. $23,210 $23,794 $25,249 $24,837
Income (loss) applicable to common stock from continuing operations... 275 605 2,820 (3,585)
------- ------- ------- -------
Income (loss) applicable to common stock.............................. $ 275 $ 605 $ 2,820 $(3,585)
------- ------- ------- -------
------- ------- ------- -------
Net income (loss) per common share*:
Continuing operations............................................ $ .02 $ .05 $ .24 $ (.31)
------- ------- ------- -------
Net loss per common share*............................................ $ .02 $ .05 $ .24 $ (.31)
------- ------- ------- -------
------- ------- ------- -------
Common Stock price range:
High............................................................. $ 8.625 $ 8.250 $ 9.000 $10.500
Low.............................................................. $ 6.375 $ 5.625 $ 5.250 $ 5.875
1994
Net operating revenue................................................. $22,907 $24,455 $23,901 $24,382
Income (loss) applicable to common stock from continuing operations... (5,150) (3,850) 3,000 1,214
------- ------- ------- -------
Net income (loss) applicable to common stock.......................... $(5,150) $(3,850) $ 3,000 $ 1,214
------- ------- ------- -------
------- ------- ------- -------
Net income (loss) per common share*:
Continuing operations............................................ $ (.51) $ (.38) $ .26 $ .11
------- ------- ------- -------
Net income (loss) per common share.................................... $ (.51) $ (.38) $ .26 $ .11
------- ------- ------- -------
------- ------- ------- -------
Common Stock price range:
High............................................................. $ 2.250 $ 3.750 $ 5.625 $10.500
Low.............................................................. $ 1.500 $ 1.406 $ 3.000 $ 4.875
</TABLE>
- ------------
* The sum of income (loss) per common share for the four quarters is different
from the full year net income (loss) per common share as a result of
computing the quarterly and full year amounts on the weighted average number
of common shares outstanding in the respective periods.
52
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONCLUDED)
<TABLE>
<CAPTION>
FIRST SECOND THIRD FOURTH
QUARTER QUARTER QUARTER QUARTER
------- ------- ------- -------
<S> <C> <C> <C> <C>
Included in the 1995 quarters are the following items:
Investment income (loss), net.................................... $ 124 $ 76 $ 93 $ 151
Interest expense................................................. (1,090) (1,190) (1,192) (1,269)
Settlement of disputes, net...................................... 328 140 1,031 (5,031)
Cost of restructuring operations................................. -- -- -- (1,480)
Adjustment to tax and receivable provisions...................... -- -- -- 849
CLI Trust Collection............................................. -- -- -- 648
All other components of net income (loss)........................ 913 1,579 2,888 2,547
------- ------- ------- -------
Income (loss) applicable to common stock......................... $ 275 $ 605 $ 2,820 $(3,585)
------- ------- ------- -------
------- ------- ------- -------
Included in the 1994 quarters are the following items:
Investment income (loss), net.................................... $ (351) $ (129) $ 209 $ 118
Interest expense................................................. (1,402) (1,024) (1,042) (1,065)
Settlement of disputes, net...................................... (1,950) (2,000) (1,000) --
Gain on sales of assets and businesses, net...................... 214 -- -- --
Discontinued operations.......................................... -- -- -- --
Dividend requirements on Preferred Stock......................... -- -- (54) (35)
Tax Reserve Adjustment........................................... -- -- 4,000 1,000
All other components of net income (loss)........................ (1,661) (697) 887 1,196
------- ------- ------- -------
Net income (loss) applicable to common stock..................... $(5,150) $(3,850) $ 3,000 $ 1,214
------- ------- ------- -------
------- ------- ------- -------
</TABLE>
- ------------
At December 31, 1995 and 1994 there were 3,067 and 4,495 common
stockholders of record, respectively.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
During fiscal years 1995 and 1994, TCC neither changed its accountants nor
reported a disagreement on Form 8-K on any matter of accounting principles or
practices of financial statement disclosure.
53
<PAGE>
<PAGE>
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.
The information contained under the heading 'Election of Directors' in the
Company's Proxy Statement for the Annual Meeting of Stockholders scheduled to be
held in March 1996 is incorporated herein by reference with respect to each of
the Company's directors. For information relating to executive officers who are
not also directors of the Company, see, 'Executive Officers of the Company,'
located in Part I.
ITEM 11. EXECUTIVE COMPENSATION.
The information contained under the sub-heading 'Executive Compensation' of
the 'Election of Directors' section of the Company's Proxy Statement for the
Annual Meeting of Stockholders scheduled to be held in March 1996 is
incorporated herein by reference with respect to the Company's chief executive
officer, the most highly compensated executive officers of the Company and the
directors.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
The information contained under the sub-heading 'Securities Held by
Management' of the 'Election of Directors' section of the Company's Proxy
Statement for the Annual Meeting of Stockholders scheduled to be held in March
1996 is incorporated herein by reference with respect to certain beneficial
owners, the directors and management.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
The information contained under the sub-heading 'Certain Relationships and
Related Transactions' of the 'Election of Directors' section of the Company's
Proxy Statement for the Annual Meeting of Stockholders scheduled to be held in
March 1996 is incorporated herein by reference with respect to each of the
Company's executive officers and directors.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.
(a) Documents filed as part of this report:
1. FINANCIAL STATEMENTS OF THE COMPANY.
The Consolidated Financial Statements and the Notes thereto, the Financial
Statement Schedules identified in (2) below and the Accountants' Report on the
foregoing are included in Part II, Item 8 of this report.
2. FINANCIAL STATEMENT SCHEDULES OF THE COMPANY.
<TABLE>
<CAPTION>
SCHEDULE
NUMBER DESCRIPTION
- -------- -----------
<S> <C>
I. Condensed Financial Information of Registrant
II. Valuation and Qualifying Accounts
</TABLE>
All other schedules for which provision is made in the applicable
accounting regulations of the Securities and Exchange Commission are not
required under the related instructions or are not applicable and, therefore,
have been omitted.
Also included herein are separate company Financial Statements and the
Notes thereto, the Accountants' Report thereon and required Financial Statement
Schedules of:
Hospital Group of America, Inc. and Subsidiaries and CooperSurgical,
Inc.
54
<PAGE>
<PAGE>
SCHEDULE I
THE COOPER COMPANIES, INC.
CONDENSED STATEMENT OF OPERATIONS
<TABLE>
<CAPTION>
YEAR ENDED OCTOBER 31,
-------------------------------
1995 1994 1993
------- -------- --------
(IN THOUSANDS,
EXCEPT PER SHARE FIGURES)
<S> <C> <C> <C>
General and administrative expense............................................. $(4,274) $(10,781) $(24,134)
Costs associated with restructuring operations................................. (705) -- --
(Charge) credit for settlement of disputes, net................................ 1,681 (4,292) (6,350)
Debt restructuring costs....................................................... -- (340) (2,131)
Equity in earnings of subsidiaries............................................. 5,809 9,390 1,894
Investment income (loss), net.................................................. 299 (307) 1,415
Other income (expense), net.................................................... 111 (54) (113)
Interest expense............................................................... (2,691) (2,913) (4,236)
------- -------- --------
Income (loss) from continuing operations before income taxes................... 230 (9,297) (33,655)
Provision for (benefit of) income taxes........................................ 115 (4,600) 417
------- -------- --------
Income (loss) from continuing operations before extraordinary items............ 115 (4,697) (34,072)
Loss on sale of discontinued operations, net of taxes.......................... -- -- (13,657)
------- -------- --------
Income (loss) before extraordinary items....................................... 115 (4,697) (47,729)
Extraordinary items............................................................ -- -- 924
------- -------- --------
Net income (loss).............................................................. 115 (4,697) (46,805)
------- -------- --------
Less, preferred stock dividends................................................ -- 89 320
------- -------- --------
Net income (loss) applicable to common stock................................... $ 115 $ (4,786) $(47,125)
------- -------- --------
------- -------- --------
Net income (loss) per common share:*
Continuing operations..................................................... $ .01 $ (.47) $ (3.43)
Discontinued operations................................................... -- -- (1.36)
------- -------- --------
Income (loss) before extraordinary items....................................... .01 (.47) (4.79)
Extraordinary items............................................................ -- -- .09
------- -------- --------
Net income (loss) per common share............................................. $.01 $(.47) $(4.70)
Average number of common shares outstanding*................................... 11,576 10,193 10,035
------- -------- --------
------- -------- --------
</TABLE>
The condensed financial statements presented in this Schedule I are the
parent company only condensed financial statements of The Cooper Companies, Inc.
(the 'Registrant'). The Registrant accounts for its investments in its
consolidated subsidiaries, all of which are virtually wholly owned, under the
equity method. Accordingly, net income (loss) applicable to common stock and
shareholders' equity (deficit) reported in this Schedule I are equal to the
figures reported in the consolidated financial statements of The Cooper
Companies, Inc. and Subsidiaries ('Consolidated Financial Statements') located
herein. See Note 14 of Notes to Consolidated Financial Statements for
disclosures concerning the material contingencies and long-term obligations of
the Registrant.
- ------------
See Note 2 of Notes to Consolidated Financial Statements.
55
<PAGE>
<PAGE>
SCHEDULE I (CONTINUED)
THE COOPER COMPANIES, INC.
CONDENSED BALANCE SHEET
<TABLE>
<CAPTION>
OCTOBER 31,
----------------------
1995 1994
--------- ---------
(IN THOUSANDS)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents.......................................................... $ 8,484 $ 5,270
Other current assets............................................................... 492 1,189
--------- ---------
Total current assets.......................................................... 8,976 6,459
--------- ---------
Property, plant and equipment, at cost.................................................. 1,199 1,141
Less, accumulated depreciation and amortization......................................... 891 880
--------- ---------
308 261
--------- ---------
Investments in and advances to subsidiaries............................................. 49,951 59,180
Other assets............................................................................ 164 221
--------- ---------
$ 59,399 $ 66,121
--------- ---------
--------- ---------
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable................................................................... $ 2,946 $ 3,634
Accrued income taxes payable....................................................... 9,996 10,105
Other accrued liabilities.......................................................... 6,538 11,844
--------- ---------
Total current liabilities..................................................... 19,480 25,583
--------- ---------
Long-term debt:
10% Senior Subordinated Secured Notes due 2003..................................... 24,816 25,410
10 5/8% Convertible Subordinated Reset Debentures due 2005......................... 9,215 9,210
--------- ---------
34,031 34,620
--------- ---------
Other noncurrent liabilities............................................................ 7,637 9,572
--------- ---------
Total liabilities.................................................................. 61,148 69,775
--------- ---------
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $.10 par value.................................................... -- --
Common stock, $.10 par value....................................................... 1,158 1,129
Additional paid-in capital......................................................... 183,840 182,142
Translation adjustments............................................................ (333) (396)
Accumulated deficit................................................................ (186,414) (186,529)
--------- ---------
Total stockholders' equity (deficit).................................................... (1,749) (3,654)
--------- ---------
$ 59,399 $ 66,121
--------- ---------
--------- ---------
</TABLE>
56
<PAGE>
<PAGE>
SCHEDULE I (CONCLUDED)
THE COOPER COMPANIES, INC.
CONDENSED STATEMENT OF CASH FLOWS
<TABLE>
<CAPTION>
YEAR ENDED OCTOBER 31,
-----------------------------
1995 1994 1993
------ ------- --------
(IN THOUSANDS)
<S> <C> <C> <C>
Net cash provided (used) by operating activities................................. $3,001 $(5,172) $(54,620)
Cash flows from investing activities:
Sales of assets and businesses (including releases of cash from escrow)..... 173 2,610 8,300
Purchases of property, plant and equipment.................................. (133) -- --
Sales of temporary investments.............................................. 50 7,302 32,088
Purchases of temporary investment........................................... -- -- (3,689)
------ ------- --------
Net cash provided (used) by investing activities................................. 90 9,912 36,699
------ ------- --------
Cash flows from financing activities:
Cash from warrants exercised................................................ 123 -- --
Payments associated with the Exchange Offer and Consent Solicitation
including debt restructuring costs........................................ -- (5,416) --
Purchase of the Company's 10 5/8% Debentures................................ -- -- (3,861)
------ ------- --------
Net cash used by financing activities............................................ 123 (5,416) (3,861)
------ ------- --------
Net increase (decrease) in cash and cash equivalents............................. 3,214 (676) (21,782)
Cash and cash equivalents at beginning of year................................... 5,270 5,946 27,728
------ ------- --------
Cash and cash equivalents at end of year......................................... $8,484 $ 5,270 $ 5,946
------ ------- --------
------ ------- --------
Supplemental disclosures of cash flow information:
Cash paid for:
Interest (net of amounts capitalized).................................. $3,001 $ 3,063 $ 4,339
------ ------- --------
------ ------- --------
Dividends on preferred stock........................................... $ -- $ 89 $ --
------ ------- --------
------ ------- --------
Income taxes........................................................... $ 224 $ 132 $ 90
------ ------- --------
------ ------- --------
</TABLE>
For other supplemental disclosures, all of which relate to the Cooper
Companies, Inc., see 'The Cooper Companies, Inc. and Subsidiaries Consolidated
Statement of Cash Flows' herein.
57
<PAGE>
<PAGE>
SCHEDULE II
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
VALUATION AND QUALIFYING ACCOUNTS
THREE YEARS ENDED OCTOBER 31,1995
<TABLE>
<CAPTION>
ADDITIONS
BALANCE AT CHARGED TO ADDITIONS DEDUCTIONS/ BALANCE
BEGINNING COSTS AND CHARGED TO RECOVERIES/ AT END
OF YEAR EXPENSES OTHER ACCOUNTS OTHER OF YEAR
---------- ---------- -------------- ----------- -------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
Allowance for doubtful accounts :
Year ended October 31, 1995.......... $2,647 $2,300 $-- $(2,706)(2) $2,241
---------- ---------- ------- ----------- -------
Year ended October 31, 1994.......... $3,240 $2,431 $-- $(3,024)(2) $2,647
---------- ---------- ------- ----------- -------
Year ended October 31, 1993.......... $3,031 $3,202 $-- $(2,993)(1)(2) $3,240
---------- ---------- ------- ----------- -------
---------- ---------- ------- ----------- -------
</TABLE>
- ------------
(1) Represents acquired reserve of CoastVision, Inc.
(2) Uncollectible accounts written off, recovered accounts receivable previously
written off and other items.
58
<PAGE>
<PAGE>
INDEPENDENT AUDITORS' REPORT
Board of Directors
HOSPITAL GROUP OF AMERICA, INC.:
We have audited the accompanying consolidated balance sheets of Hospital
Group of America, Inc. (a wholly owned subsidiary of The Cooper Companies, Inc.)
and subsidiaries as of October 31, 1995 and 1994, and the related consolidated
statements of operations, stockholder's equity (deficiency) and cash flows for
each of the years in the three-year period ended October 31, 1995. In connection
with our audits of the consolidated financial statements, we also audited
financial statement Schedule II. These consolidated financial statements and
financial statement schedule are the responsibility of HGA's management. Our
responsibility is to express an opinion on these consolidated financial
statements and financial statement schedule based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the financial position of Hospital
Group of America, Inc. and subsidiaries at October 31, 1995 and 1994, and the
results of their operations, and their cash flows for each of the years in the
three-year period ended October 31, 1995, in conformity with generally accepted
accounting principles. Also in our opinion, the related financial statement
schedule, when considered in relation to the basic consolidated financial
statements taken as a whole, presents fairly, in all material respects, the
information set forth therein.
KPMG PEAT MARWICK LLP
Philadelphia, Pennsylvania
December 11, 1995
59
<PAGE>
<PAGE>
HOSPITAL GROUP OF AMERICA, INC. AND SUBSIDIARIES
(A WHOLLY OWNED SUBSIDIARY OF THE COOPER COMPANIES, INC.)
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
OCTOBER 31,
-------------------
1995 1994
-------- -------
(IN THOUSANDS)
<S> <C> <C>
ASSETS
Current Assets:
Cash and cash equivalents............................................................. $ 2,314 $ 3,593
Accounts receivable, net of estimated uncollectibles of $1,693 in 1995 and $1,834 in
1994................................................................................. 10,996 10,341
Other receivables..................................................................... 64 893
Supplies.............................................................................. 238 258
Prepaid expenses and other current assets............................................. 1,135 1,006
-------- -------
Total current assets............................................................. 14,747 16,091
-------- -------
Property and equipment:
Land.................................................................................. 1,305 1,305
Buildings and improvements............................................................ 31,521 31,496
Equipment, furniture and fixtures..................................................... 1,988 1,680
-------- -------
34,814 34,481
Less accumulated depreciation......................................................... (4,726) (3,285)
-------- -------
Total property and equipment, net................................................ 30,088 31,196
-------- -------
Goodwill, net of accumulated amortization of $701 in 1995 and $497 in 1994................. 5,032 5,658
Other assets............................................................................... 353 502
-------- -------
$ 50,220 $53,447
-------- -------
-------- -------
LIABILITIES AND STOCKHOLDER'S EQUITY (DEFICIENCY)
Current Liabilities:
Accounts payable...................................................................... $ 577 $ 891
Accrued liabilities................................................................... 4,751 2,208
Accrued salaries and related expenses................................................. 2,565 2,257
Accrued interest payable.............................................................. 177 142
Net estimated third-party payor settlements........................................... 1,918 2,511
Current portion of long-term debt..................................................... 2,124 1,187
Current portion of due to parent...................................................... 17,340 12,559
-------- -------
Total current liabilities........................................................ 29,452 21,755
-------- -------
Long-term debt, less current portion....................................................... 9,222 11,369
Other noncurrent liabilities............................................................... 3,001 700
Due to parent.............................................................................. 16,000 16,000
Stockholder's equity (deficiency):
Common stock, $.01 par value, 1,000 shares authorized, issued and outstanding......... 0 0
Additional paid-in capital............................................................ 12,324 12,324
Accumulated deficit................................................................... (19,779) (8,701)
-------- -------
Total stockholder's equity (deficiency).......................................... (7,455) 3,623
-------- -------
$ 50,220 $53,447
-------- -------
-------- -------
</TABLE>
See accompanying notes to consolidated financial statements.
60
<PAGE>
<PAGE>
HOSPITAL GROUP OF AMERICA, INC. AND SUBSIDIARIES
(A WHOLLY OWNED SUBSIDIARY OF THE COOPER COMPANIES, INC.)
CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
OCTOBER 31,
------------------------------
1995 1994 1993
-------- ------- -------
(IN THOUSANDS)
<S> <C> <C> <C>
Net patient service revenue..................................................... $ 38,392 $40,365 $41,330
Other operating revenue......................................................... 2,520 2,675 2,644
-------- ------- -------
Net operating revenue........................................................... 40,912 43,040 43,974
-------- ------- -------
Costs and expenses:
Salaries and benefits...................................................... 23,654 23,348 23,737
Purchased services......................................................... 1,865 2,044 2,202
Professional fees.......................................................... 3,312 3,177 2,681
Supplies expense........................................................... 1,938 1,929 2,026
Other operating expenses................................................... 7,832 8,620 8,612
Settlement of disputes, net................................................ 5,213 1,508 --
Bad debt expense........................................................... 1,551 1,753 2,792
Depreciation and amortization.............................................. 1,790 1,735 1,674
Interest on long-term debt................................................. 1,377 1,365 1,599
Interest on due to parent note............................................. 3,458 2,795 1,821
-------- ------- -------
Total costs and expenses.............................................. 51,990 48,274 47,144
-------- ------- -------
Net loss........................................................................ $(11,078) $(5,234) $(3,170)
-------- ------- -------
-------- ------- -------
</TABLE>
See accompanying notes to consolidated financial statements.
61
<PAGE>
<PAGE>
HOSPITAL GROUP OF AMERICA, INC. AND SUBSIDIARIES
(A WHOLLY OWNED SUBSIDIARY OF THE COOPER COMPANIES, INC.)
CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY (DEFICIENCY)
YEARS ENDED OCTOBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
TOTAL
ADDITIONAL STOCKHOLDER'S
COMMON PAID-IN ACCUMULATED EQUITY
STOCK CAPITAL DEFICIT (DEFICIENCY)
------ ---------- ----------- -------------
(IN THOUSANDS OF DOLLARS)
<S> <C> <C> <C> <C>
Balance
November 1, 1992......................................... $ 0 $ 12,324 $ (297) $ 12,027
Net Loss................................................. -- -- (3,170) (3,170)
------ ---------- ----------- -------------
Balance
October 31, 1993......................................... $ 0 $ 12,324 $ (3,467) $ 8,857
------ ---------- ----------- -------------
------ ---------- ----------- -------------
Balance
November 1, 1993......................................... $ 0 12,324 (3,467) 8,857
Net Loss................................................. -- -- (5,234) (5,234)
------ ---------- ----------- -------------
Balance
October 31, 1994......................................... $ 0 $ 12,324 $ (8,701) 3,623
------ ---------- ----------- -------------
------ ---------- ----------- -------------
Balance
November 1, 1994......................................... $ 0 12,324 (8,701) 3,623
Net Loss................................................. -- -- (11,078) (11,078)
------ ---------- ----------- -------------
Balance
October 31, 1995......................................... $ 0 $ 12,324 $ (19,779) $ (7,455)
------ ---------- ----------- -------------
------ ---------- ----------- -------------
</TABLE>
See accompanying notes to consolidated financial statements.
62
<PAGE>
<PAGE>
HOSPITAL GROUP OF AMERICA, INC. AND SUBSIDIARIES
(A WHOLLY OWNED SUBSIDIARY OF THE COOPER COMPANIES, INC.)
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
OCTOBER 31,
------------------------------
1995 1994 1993
-------- ------- -------
(IN THOUSANDS OF DOLLARS)
<S> <C> <C> <C>
Cash flows from operating activities:
Net loss.................................................................... $(11,078) $(5,234) $(3,170)
Adjustments to reconcile net loss to net cash provided by operating
activities:
Depreciation and amortization of goodwill and loan fees................ 1,790 1,735 1,674
Accrued interest, management fees and net expenses due to Parent....... 4,328 5,477 1,658
Change in operating assets and liabilities:
(Increase) decrease in accounts receivable............................. (174) (1,698) 1,114
(Increase) decrease in supplies, other current assets and other
noncurrent assets.................................................... 312 (570) 60
Increase (decrease) in accounts payable, accrued expenses, estimated
third party payor settlements, and other noncurrent liabilities...... 5,060 3,785 (2,649)
-------- ------- -------
Net cash provided by (used in) operating activities.............................. 238 3,495 (1,313)
Cash flows from investing activities:
Proceeds from the sale of property.......................................... 0 121 0
Capital expenditures........................................................ (333) (375) (781)
Proceeds from progressions settlement....................................... 421 0 0
Other....................................................................... 5 58 62
-------- ------- -------
Net cash from investing activities............................................... 93 (196) (719)
Cash flows from financing activities:
Principal payments on long-term debt........................................ (1,210) (1,162) (5,168)
Cash advance (to) from parent............................................... (400) 1,000 2,321
-------- ------- -------
Net cash used by financing activities............................................ (1,610) (162) (2,847)
Net (decrease) increase in cash and cash equivalents............................. (1,279) 3,137 (4,879)
Cash and cash equivalents, beginning of period................................... 3,593 456 5,335
Cash and cash equivalents, end of period......................................... $ 2,314 $ 3,593 $ 456
-------- ------- -------
-------- ------- -------
Supplemental disclosure of cash flow information:
Interest paid during the period............................................. $ 1,452 $ 1,452 $ 1,520
-------- ------- -------
-------- ------- -------
</TABLE>
See accompanying notes to consolidated financial statements.
63
<PAGE>
<PAGE>
HOSPITAL GROUP OF AMERICA, INC. AND SUBSIDIARIES
(A WHOLLY OWNED SUBSIDIARY OF THE COOPER COMPANIES, INC.)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED OCTOBER 31, 1995, 1994 AND 1993
A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Accounting -- On May 29, 1992, The Cooper Companies, Inc.
('Cooper' or 'Parent') acquired all of the common stock of Hospital Group of
America, Inc. (HGA) from its ultimate parent, Nu-Med, Inc. (Nu-Med). The
acquisition of HGA was accounted for as a purchase and the purchase adjustments
were 'pushed-down' to the separate financial statements of HGA resulting in a
new basis of accounting as of May 30, 1992. The Parent's cost of the acquisition
was approximately $50 million, including the assumption of approximately $22
million of third-party debt of HGA. The purchase price was allocated to assets
and liabilities based on their estimated fair values as of the acquisition date.
The purchase price exceeded the estimated fair value of the identifiable net
assets acquired resulting in goodwill. The estimated goodwill amount of
$6,155,000 was recorded as of May 30, 1992 and is being amortized over 30 years
on a straight-line basis.
Business -- The accompanying consolidated financial statements include the
accounts of HGA and its wholly owned subsidiaries (the 'Company'). All
intercompany balances and transactions have been eliminated. The Company owns
and operates the following psychiatric facilities:
<TABLE>
<CAPTION>
NAME OF FACILITY LOCATION
- -------------------- --------------------
<S> <C>
Hartgrove Hospital Chicago, Illinois
Hampton Hospital Rancocas, New Jersey
Meadow Wood Hospital New Castle, Delaware
</TABLE>
Effective May 30, 1992, PSG Management, Inc. (PSG), a sister company to HGA
and a wholly-owned subsidiary of Cooper, entered into a three year agreement to
manage two psychiatric hospitals and the substance abuse treatment center owned
by the subsidiaries of Nu-Med, Inc. HGA was not a party to this agreement and
therefore the management fee earned by PSG from the subsidiaries of Nu-Med, Inc.
is not recognized in the accompanying financial statements. However, in
connection with this agreement, HGA performed services on behalf of PSG for
which it earns a fee of 25% of certain of its corporate headquarters' cost plus
a 20% mark-up. Such fees earned by HGA from PSG amounted to $269,000, $428,000
and $691,000 for 1995, 1994 and 1993, respectively. The agreement expired by its
terms in May 1995.
Net Patient Service Revenue -- Net patient service revenue is recorded at
the estimated net realizable amounts from patients, third-party payors, and
others for services rendered, including estimated retroactive adjustments under
reimbursement agreements with third-party payors. Retroactive adjustments are
accrued on an estimated basis in the period the related services are rendered
and adjusted in the period as final settlements are determined. In 1995, HGA
received and recognized approximately $2,000,000 associated with prior year cost
report settlements.
Charity Care -- The Company provides care to indigent patients who meet
certain criteria under its charity care policy without charge or at amounts less
than its established rates. Because the Company does not pursue collection of
amounts determined to qualify as charity care, they are not reported as revenue.
The Company maintains records to identify and monitor the level of charity care
it provides. These records include the amount of charges foregone for services
and supplies furnished under its charity care policy. Charges at the Company's
established rates foregone for charity care provided by the Company amounted to
$2,142,000, $2,498,000 and $3,220,000 for 1995, 1994 and 1993 respectively.
Hampton Hospital is required by its Certificate of Need to incur not less than
5% of total patient days as free care.
Health Insurance Coverage -- The Company is self-insured for the health
insurance coverage offered to its employees. The provision for estimated
self-insured health insurance costs includes management's estimates of the
ultimate costs for both reported claims and claims incurred but not reported.
64
<PAGE>
<PAGE>
HOSPITAL GROUP OF AMERICA, INC. AND SUBSIDIARIES
(A WHOLLY OWNED SUBSIDIARY OF THE COOPER COMPANIES, INC.)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
YEARS ENDED OCTOBER 31, 1995, 1994 AND 1993
Supplies -- Supplies consist principally of medical supplies and are stated
at the lower of cost (first-in, first-out method) or market.
Property and Equipment -- Property and equipment are stated at fair value
as of May 29, 1992, the date of the acquisition of HGA by Cooper. Depreciation
is computed on the straight-line method over the estimated useful lives of the
respective assets, which range from 20 to 40 years for buildings and
improvements, and 5 to 10 years for equipment, furniture and fixtures.
Goodwill -- Goodwill is amortized on a straight-line basis over thirty
years. Goodwill is reviewed for impairment whenever events or circumstances
provide evidence that suggest that the carrying amount of goodwill may not be
recoverable. The Company assesses the recoverability of goodwill by determining
whether the amortization of the goodwill balance over its remaining life can be
recovered through reasonably expected future results.
Other Assets -- Loan fees incurred in obtaining long-term financing are
deferred and recorded as other assets. Loan fees are amortized over the terms of
the related loans. The balance of unamortized loan fees amounted to $258,000,
$399,000 and $540,000 respectively, for 1995, 1994 and 1993.
Income Taxes -- The Company is included in the consolidated income tax
returns of the Parent. The consolidated federal, state and local taxes are
subject to a tax sharing agreement under which the Company's liability is
computed on a non-consolidated basis using a combined rate of 40%.
Effective November 1, 1993, the Company adopted the liability method of
accounting for income taxes as prescribed by Statement of Financial Accounting
Standards No. 109, 'Accounting for Income Taxes' (FAS 109). The liability method
under FAS 109 measures the expected tax impact of future taxable income or
deductions resulting from temporary differences in the tax and financial
reporting bases of assets and liabilities reflected in the consolidated balance
sheet. Deferred tax assets and liabilities are determined using the enacted tax
rates in effect for the year in which these differences are expected to reverse.
Under FAS 109, the effect on deferred tax assets and liabilities of a change in
tax rates is recognized in the period that the change was enacted. In 1993, the
Company accounted for income taxes under APB Opinion II.
Cash and Cash Equivalents -- Cash and cash equivalents include investments
in highly liquid debt instruments with a maturity of three months or less.
B. NET PATIENT SERVICE REVENUE
The Company has agreements with third-party payors that provide for
payments to the Company at amounts different from its established rates. A
summary of the payment arrangements with major third-party payors follows:
Commercial Insurance -- Most commercial insurance carriers reimburse
the Company on the basis of the hospitals' charges, subject to the
rates and limits specified in their policies. Patients covered by
commercial insurance generally remain responsible for any differences
between insurance proceeds and total charges.
Blue Cross -- Reimbursement under Blue Cross plans varies depending
on the areas in which the Company presently operates facilities.
Benefits paid to the Company can be charge-based, cost-based,
negotiated per diem rates or approved through a state rate setting
process.
Medicare -- Services rendered to Medicare program beneficiaries are
reimbursed under a retrospectively determined reasonable cost system
with final settlement determined after submission of annual cost
reports by the Company and audits thereof by the Medicare fiscal
intermediary.
65
<PAGE>
<PAGE>
HOSPITAL GROUP OF AMERICA, INC. AND SUBSIDIARIES
(A WHOLLY OWNED SUBSIDIARY OF THE COOPER COMPANIES, INC.)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
YEARS ENDED OCTOBER 31, 1995, 1994 AND 1993
Managed Care -- Services rendered to subscribers of health
maintenance organizations, preferred provider organizations and
similar organizations are reimbursed based on prospective negotiated
rates.
Medicaid -- Services rendered to State Medicaid program beneficiaries
are reimbursed based on rates established by each individual State
program.
The Company's business activities are primarily with large insurance
companies and federal and state agencies or their intermediaries. Other than
adjustments arising from audits by certain of these agencies, the risk of loss
arising from the failure of these entities to perform according to the terms of
their respective contracts is considered remote.
C. RELATED PARTY TRANSACTIONS
The current portion of Due to Parent at October 31, 1995 consists of costs
of amounts due under a Demand Note (Demand Note) for costs incurred or paid by
the Parent in connection with the acquisition, cash advances from the Parent,
interest payable on the subordinated note in the amount of $1,920,000, and an
allocation of Cooper corporate services amounting to $892,000, net of payments
to the Parent.
All current and future borrowings under the terms of the Demand Note bear
interest, payable monthly, commencing on December 1, 1993 at the rate of 15% per
annum (17% in the event principal and interest is not paid when due), and all
principal and all accrued and unpaid interest under the Demand Note shall be
completely due and payable on demand. Prior to December 1, 1993, the Parent did
not charge the Company for amounts due to it except for amounts due under the
Subordinated Promissory Note. The Parent has indicated that a demand for payment
will not be made prior to November 1, 1996.
The non-current portion of Due to Parent consists of a $16,000,000
subordinated note. The annual interest rate on the note is 12%. The principal
amount of this Note shall be due and payable on May 29, 2002 unless payable
sooner pursuant to the terms of the Note.
HGA allocates interest expense to PSG primarily to reflect an estimate of
the interest cost on debt incurred by HGA in connection with the May 29, 1992
acquisition which relates to the PSG management agreement with Nu-Med. Such
allocations amounted to $163,000, $254,000 and $194,000 for 1995, 1994 and 1993,
respectively and are recorded as reductions of interest on long-term debt and
interest on due to Parent note.
D. EMPLOYEE BENEFITS
The Company participates in Cooper's 401(k) plan (the 'Plan'), which covers
substantially all full-time employees with more than 60 days of service. The
Company matches employee contributions up to certain limits. These costs were
$58,000, $61,000 and $40,000 for 1995, 1994 and 1993, respectively.
66
<PAGE>
<PAGE>
HOSPITAL GROUP OF AMERICA, INC. AND SUBSIDIARIES
(A WHOLLY OWNED SUBSIDIARY OF THE COOPER COMPANIES, INC.)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
YEARS ENDED OCTOBER 31, 1995, 1994 AND 1993
E. LONG TERM DEBT
Long-term debt at October 31, 1995 and 1994 consists of the following:
<TABLE>
<CAPTION>
1995 1994
------- -------
(IN THOUSANDS)
<S> <C> <C>
Bank term loan, interest at 4% above the bank's prime rate (8.75% at October 31,
1995), subject to a minimum rate of 12%, payable monthly, principal payable in
installments from September 1992 through August 1997........................... $ 9,889 $10,556
Industrial Revenue Bonds, interest at 85% of prime rate (8.75% at October 31,
1995), payable quarterly, principal payable in installments through December
31, 1995....................................................................... 1,457 2,000
------- -------
11,346 12,556
Less current portion............................................................. (2,124) (1,187)
------- -------
$ 9,222 $11,369
------- -------
------- -------
</TABLE>
Annual maturities of long-term debt are as follows:
<TABLE>
<CAPTION>
YEAR ENDING
OCTOBER 31 (IN THOUSANDS)
- --------------------------------------------------------------------
<S> <C>
1996............................................................. $ 2,124
1997............................................................. 9,222
--------------
$ 11,346
--------------
--------------
</TABLE>
The long-term debt agreements contain several covenants, including the
maintenance of certain ratios and levels of net worth (as defined), restrictions
with respect to the payments of cash dividends on common stock and on the levels
of capital expenditures, interest and debt payments. The Industrial Revenue
Bonds ('IRB') carries interest at 85% of prime, or approximately 7.44% per annum
at October 31, 1995. The holders of the IRB have exercised their right to
accelerate all payments of outstanding principal to December 31, 1995.
Substantially all of the property and equipment and accounts receivable of
the Company collateralize the debt outstanding.
F. COMMITMENTS AND CONTINGENCIES
In the normal course of business, the Company is involved in various
litigation cases. In the opinion of management, the disposition of such
litigation will not have a material adverse effect on the Company's consolidated
financial position.
The Company leases certain space and equipment under operating lease
agreements. The following is a schedule of estimated minimum payments due under
such leases with an initial term of more than one year as of October 31, 1995:
<TABLE>
<CAPTION>
YEAR ENDING OCTOBER 31 BUILDINGS EQUIPMENT TOTAL
- ------------------------------------------------------------- --------- --------- ------
(IN THOUSANDS)
<S> <C> <C> <C>
1996................................................. $ 452 $ 155 $ 607
1997................................................. 238 118 356
1998................................................. 127 51 178
1999 - 2000.......................................... 26 19 45
--------- --------- ------
$ 843 $ 343 $1,186
--------- --------- ------
--------- --------- ------
</TABLE>
67
<PAGE>
<PAGE>
HOSPITAL GROUP OF AMERICA, INC. AND SUBSIDIARIES
(A WHOLLY OWNED SUBSIDIARY OF THE COOPER COMPANIES, INC.)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
YEARS ENDED OCTOBER 31, 1995, 1994 AND 1993
Some of the operating leases contain provisions for renewal or increased
rental (based upon increases in the Consumer Price Index), none of which are
taken into account in the above table. Rental expense under all operating leases
amounted to $840,000, $706,000, and $736,000 for 1995, 1994 and 1993,
respectively.
G. INCOME TAXES
A reconciliation of the provision for (benefit of) income taxes included in
the Company's statement of consolidated operations and the amount computed by
applying the federal income tax rate to loss from continuing operations follows:
<TABLE>
<CAPTION>
YEAR ENDED OCTOBER 31,
-------------------------------
1995 1994 1993
------- ------- -------
(IN THOUSANDS)
<S> <C> <C> <C>
Computed expected (benefit of) taxes............................... $(3,766) $(1,780) $(1,078)
Decrease in benefit resulting from:
Amortization of intangibles................................... 70 70 70
Net operating losses for which no tax benefit was
recognized.................................................. 3,680 1,704 1,002
Other......................................................... 16 6 6
------- ------- -------
Actual provision for income taxes............................. $ 0 $ 0 $ 0
------- ------- -------
------- ------- -------
</TABLE>
The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets and deferred tax liabilities are as follows:
<TABLE>
<CAPTION>
YEAR ENDED OCTOBER 31,
-----------------------
1995 1994
------- -------
(IN THOUSANDS)
<S> <C> <C>
Deferred tax assets:
Accounts receivable, principally due to allowance for doubtful
accounts............................................................ $ 677 $ 668
Accrued liabilities, principally due to litigation reserves........... 2,830 1,008
Net operating loss carryforwards...................................... 6,341 4,806
------- -------
Total gross deferred tax assets.................................. 9,848 6,482
(Valuation allowance)/offset to consolidated valuation
allowance...................................................... (3,250) 678
------- -------
Net deferred tax assets.......................................... 6,598 7,160
------- -------
Deferred tax liabilities:
Plant and equipment, principally due to purchase accounting
requirements........................................................ (6,303) (6,734)
Other, principally due to differences in accounting methods for
financial and tax purposes.......................................... (295) (426)
------- -------
Total gross deferred tax liabilities....................................... (6,598) (7,160)
------- -------
Net deferred tax liability................................................. $ 0 $ 0
------- -------
------- -------
</TABLE>
The Company's net deferred tax liability was offset against the Parent's
consolidated valuation allowance. The net change in the total valuation
allowance for the year ended October 31, 1995 was an increase of $3,928,000. At
October 31, 1994, the net change in the offset against the Parent's consolidated
valuation allowance was a decrease of $3,272,000.
68
<PAGE>
<PAGE>
HOSPITAL GROUP OF AMERICA, INC. AND SUBSIDIARIES
(A WHOLLY OWNED SUBSIDIARY OF THE COOPER COMPANIES, INC.)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
YEARS ENDED OCTOBER 31, 1995, 1994 AND 1993
At October 31, 1995 the Parent had consolidated net operating loss
carryforwards, of which approximately $10,000,000 related to the Company. The
tax benefit of an additional $5,000,000 of the Company's net operating loss
carryforwards which have been utilized in the Parent's consolidated return are
available in the future should the Company have sufficient taxable income during
the carryforward period. The net operating loss carryforwards expire commencing
in 2001.
H. PLEDGE AGREEMENT
Pursuant to a pledge agreement dated as of January 6, 1994, between the
Parent and the Trustee for the holders of a new class of debt issued by the
Parent (the 'Notes') the Parent has pledged a first priority security interest
in all of its right, title and interest of its investment in the Company, all
additional shares of stock of, or other equity interest in the Company from time
to time acquired by the Parent, all additional intercompany indebtedness of the
Company from time to time held by the Parent and except as set forth in the
indenture to the Notes, the proceeds received from the sale or disposition of
any or all of the foregoing.
I. SETTLEMENTS
Under an agreement dated July 11, 1985, as amended (the 'HMG Agreement'),
Hampton Medical Group, P.A. ('HMG'), which is not affiliated with HGA,
contracted to provide clinical and clinical administrative services at Hampton
Psychiatric Institute ('Hampton Hospital'), the primary facility operated by
Hospital Group of New Jersey, Inc. ('HGNJ'), a subsidiary of HGA. In late 1993
and early 1994, HGNJ delivered notices to HMG asserting that HMG had defaulted
under the HMG Agreement based upon billing practices by HMG that HGNJ believed
to be fraudulent. At the request of HMG, a New York state court enjoined HGNJ
from terminating the HMG Agreement based upon the initial notice and ordered the
parties to arbitrate whether HMG had defaulted.
On February 2, 1994, HMG commenced an arbitration in New York, New York
(the 'Arbitration'), entitled Hampton Medical Group, P.A. and Hospital Group of
New Jersey, P.A. (American Arbitration Association), in which it contested the
alleged default. In addition, HMG made a claim against HGNJ for unspecified
damages based on allegedly foregone fees on the contention that HMG had the
right to provide services at all HGNJ-owned facilities in New Jersey, including
certain outpatient clinics and the Hampton Academy, at which non-HMG physicians
have been employed.
On December 30, 1994, Blue Cross and Blue Shield of New Jersey, Inc.
commenced a lawsuit in the Superior Court of New Jersey entitled Blue Cross and
Blue Shield of New Jersey, Inc. v. Hampton Medical Group, et al. against HMG and
certain related entities and individuals unrelated to HGNJ or its affiliates
alleging, among other things, fraudulent billing practices (the 'Blue Cross
Action').
On or about April 12, 1995, an individual defendant in the Blue Cross
Action who was formerly employed by HMG, Dr. Charles Dackis, commenced a third
party claim in the Blue Cross Action against HGNJ, HGA and the Parent, alleging
a right under the HMG Agreement to indemnify in an unspecified amount for fees,
expenses and damages that he might incur in that action. In a letter brief filed
on or about April 17, 1995, HMG indicated an intention to bring a similar claim
at a later date. On or about May 16, 1995, HGNJ, HGA and the Parent filed an
answer to the complaint, and HGNJ and HGA brought counterclaims against Dr.
Dackis and cross-claims against HMG and Dr. A.L.C. Pottash, another individual
defendant and the owner of HMG, in an amount to be determined, based on
allegations of fraudulent and improper billing practices.
On October 27, 1995, the Court dismissed with prejudice all claims asserted
by Dr. Dackis against HGA, HGNJ and the Parent in the Blue Cross Action. On
December 11, 1995, the Parent announced a settlement of all disputes with HMG
and Dr. Pottash. Pursuant to the settlement, (i) the parties released
69
<PAGE>
<PAGE>
HOSPITAL GROUP OF AMERICA, INC. AND SUBSIDIARIES
(A WHOLLY OWNED SUBSIDIARY OF THE COOPER COMPANIES, INC.)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONCLUDED)
YEARS ENDED OCTOBER 31, 1995, 1994 AND 1993
each other from, among other things, the claims underlying the Arbitration, (ii)
HGA purchased HMG's interest in the HMG Agreement on December 31, 1995, and
(iii) HGNJ agreed to make certain payments to Dr. Pottash in respect of claims
he had asserted. While only HMG and Dr. Pottash are parties to the settlement
with HGA, HGNJ and the Parent, HGA has not been notified of any claims by other
third party payors or others relating to the billing or other practices at
Hampton Hospital, although it continues to respond voluntarily to requests for
information from the State of New Jersey Department of Insurance and other
government agencies with respect to these matters. The settlement with HMG and
Dr. Pottash resulted in a one-time charge with a present value of $5,551,000 to
fourth quarter fiscal 1995 earnings. That charge reflects amounts paid to Dr.
Pottash in December 1995 of $3,100,000 included in other current liabilities at
October 31, 1995 as well as two payments scheduled to be made to HMG in May 1997
and 1998, each in the amount of $1,537,500.
HGA and Progressions Health Systems, Inc. entered into the purchase price
agreement which settled cross claims between the parties related to purchase
price adjustments (which were credited to goodwill) and other disputes and
provided for a series of payments to be made to HGA. Pursuant to this agreement,
HGA received approximately $853,000 in 1995, $421,000 of which has been credited
to Settlement of Disputes, Net.
70
<PAGE>
<PAGE>
SCHEDULE II
HOSPITAL GROUP OF AMERICA, INC. AND SUBSIDIARIES
VALUATION AND QUALIFYING ACCOUNTS
YEAR ENDED OCTOBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
ADDITIONS ADDITIONS DEDUCTIONS/ BALANCE
BALANCE AT CHARGED TO CHARGED TO WRITE OFFS/ AT END
BEGINNING COSTS AND OTHER RECOVERIES/ OF
OF PERIOD EXPENSES ACCOUNTS OTHER PERIOD
---------- ---------- ---------- ----------- ------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
Allowance for doubtful accounts:
October 31, 1995............................... $1,834 $1,551 $0 $(1,692) $1,693
October 31, 1994............................... $2,067 $1,753 $0 $(1,986) $1,834
October 31, 1993............................... $2,556 $2,792 $0 $(3,281) $2,067
</TABLE>
71
<PAGE>
<PAGE>
INDEPENDENT AUDITORS' REPORT
The Board of Directors and Stockholders
COOPERSURGICAL, INC.:
We have audited the accompanying balance sheets of CooperSurgical, Inc. as
of October 31, 1995 and 1994, and the related statements of operations,
stockholders' equity (deficit), and cash flows for each of the years in the
three-year period ended October 31, 1995. In connection with our audits of the
financial statements, we also have audited financial statement schedule II.
These financial statements and the financial statement schedule are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements and the financial statement schedule based
on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of CooperSurgical, Inc. as of
October 31, 1995 and 1994, and the results of its operations and its cash flows
for each of the years in the three-year period ended October 31, 1995, in
conformity with generally accepted accounting principles. Also in our opinion,
the related financial statement schedule, when considered in relation to the
basic financial statements taken as a whole, presents fairly, in all material
respects, the information set forth therein.
KPMG PEAT MARWICK LLP
Stamford, Connecticut
December 4, 1995
72
<PAGE>
<PAGE>
COOPERSURGICAL, INC.
BALANCE SHEETS
<TABLE>
<CAPTION>
OCTOBER 31,
---------------------
1995 1994
------- --------
(IN THOUSANDS OF
DOLLARS)
<S> <C> <C>
ASSETS
Current assets:
Cash................................................................................ $ 197 $ 247
Receivables
Trade, less allowance for doubtful accounts of $574 in 1995 and $542 in 1994... 1,598 1,649
Other receivables.............................................................. 13 53
------- --------
1,611 1,702
------- --------
Inventories
Raw materials.................................................................. 2,068 2,544
Work-in-process................................................................ 260 283
Finished goods................................................................. 1,121 1,535
------- --------
3,449 4,362
------- --------
Prepaid expenses.................................................................... 246 253
------- --------
Total current assets........................................................... 5,503 6,564
------- --------
Furniture and equipment............................................................. 1,725 1,499
Less accumulated depreciation....................................................... (1,242) (989)
------- --------
483 510
------- --------
Intangibles, net of accumulated amortization
Patents........................................................................ 1,005 --
Goodwill....................................................................... 1,486 1,584
Non-compete agreements......................................................... 45 224
Distribution rights............................................................ 132 157
------- --------
2,668 1,965
------- --------
Other assets........................................................................ 496 496
------- --------
$ 9,150 $ 9,535
------- --------
------- --------
LIABILITIES & STOCKHOLDERS' EQUITY
Current liabilities:
Current installments of long-term debt.............................................. $ -- $ 15
Accounts payable.................................................................... 940 941
Accrued liabilities................................................................. 1,617 1,531
------- --------
Total current liabilities...................................................... 2,557 2,487
------- --------
Long-term debt........................................................................... 153 105
Due to Parent............................................................................ 3,967 3,147
------- --------
Total liabilities.............................................................. 6,677 5,739
------- --------
Commitments and contingencies (see note 8)
Stockholders' equity:
Series A Convertible Preferred stock:
10,633,572 shares authorized, 10,436,660 issued and outstanding at October 31,
1995 and 1994, par value per share $.0001, aggregate liquidation preference of
$20,253 at October 31, 1995 and 1994 plus cumulative dividend of $4,299 at October
31, 1995 ($2,274 in 1994).......................................................... 1 1
Common stock: 12,000,000 shares authorized, 23,212 issued and outstanding, par value
per share $.0001 at October 31, 1995 and 1994...................................... -- --
Additional paid-in capital.......................................................... 20,252 20,252
Translation adjustments............................................................. -- (67)
Accumulated deficit................................................................. (17,780) (16,390)
------- --------
Total stockholders' equity..................................................... 2,473 3,796
------- --------
$ 9,150 $ 9,535
------- --------
------- --------
</TABLE>
See accompanying notes to financial statements.
73
<PAGE>
<PAGE>
COOPERSURGICAL, INC.
STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
YEAR ENDED OCTOBER 31,
-------------------------------
1995 1994 1993
------- ------- -------
(IN THOUSANDS OF DOLLARS)
<S> <C> <C> <C>
Net sales.................................................................... $12,824 $12,847 $14,679
Cost of goods sold...................................................... 6,182 6,680 7,429
------- ------- -------
Gross profit............................................................ 6,642 6,167 7,250
------- ------- -------
Costs and expenses
Research and development expense........................................ 804 673 778
Selling, general and administrative expense............................. 5,909 6,513 10,507
Costs associated with restructuring operations.......................... 425 -- --
Other expense........................................................... 140 9 460
Amortization of intangibles............................................. 318 303 290
Interest:
Parent promissory notes................................................. 429 1,062 2,240
Other................................................................... 7 11 18
------- ------- -------
8,032 8,571 14,293
------- ------- -------
Net loss................................................................ $(1,390) $(2,404) $(7,043)
------- ------- -------
------- ------- -------
</TABLE>
See accompanying notes to financial statements.
74
<PAGE>
<PAGE>
COOPERSURGICAL, INC.
STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
YEARS ENDED OCTOBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
RETAINED TOTAL
SERIES A ADDITIONAL EARNINGS STOCKHOLDERS
PREFERRED COMMON PAID-IN TRANSLATION (ACCUMULATED EQUITY
STOCK STOCK CAPITAL ADJUSTMENT DEFICIT) (DEFICIT)
--------- ------ ---------- ----------- ------------ ------------
(IN THOUSANDS OF DOLLARS)
<S> <C> <C> <C> <C> <C> <C>
Balance at October 31, 1992.......... $ -- $ -- $ 1,242 $-- $ (6,943) $ (5,701)
Net Loss............................. -- -- -- -- (7,043) (7,043)
Aggregate translation adjustment..... -- -- -- 33 -- 33
--------- ------ ---------- ----------- ------------ ------------
Balance at October 31, 1993.......... -- -- 1,242 33 (13,986) (12,711)
Issuance of 9,796,660 shares of
Series A convertible preferred
stock (see note 5)................. 1 -- 19,010 -- -- 19,011
Net Loss............................. -- -- -- -- (2,404) (2,404)
Aggregate translation adjustment..... -- -- -- (100) -- (100)
--------- ------ ---------- ----------- ------------ ------------
Balance at October 31, 1994.......... 1 -- 20,252 (67) (16,390) 3,796
Net Loss............................. -- -- -- -- (1,390) (1,390)
Aggregate translation adjustment..... -- -- -- 67 -- 67
--------- ------ ---------- ----------- ------------ ------------
Balance at October 31, 1995.......... $ 1 $-- $ 20,252 $-- $(17,780) $ 2,473
--------- ------ ---------- ----------- ------------ ------------
--------- ------ ---------- ----------- ------------ ------------
</TABLE>
See accompanying notes to financial statements.
75
<PAGE>
<PAGE>
COOPERSURGICAL, INC.
STATEMENTS OF CASH FLOWS
YEARS ENDED OCTOBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
1995 1994 1993
------- ------- -------
(IN THOUSANDS OF DOLLARS)
<S> <C> <C> <C>
Cash flows provided (used) by operating activities:
Net loss................................................................ $(1,390) $(2,404) $(7,043)
Adjustments to reconcile net loss to cash provided (used) by operating
activities:
Depreciation and amortization........................................... 585 629 540
Bad debt expense........................................................ 18 70 191
Interest on Parent advances............................................. -- -- 2,240
Management fees to Parent............................................... -- -- 1,312
Change in assets and liabilities:
(Increase) decrease in receivables................................. 73 487 (463)
(Increase) decrease in inventories................................. 913 1,579 (1,286)
(Increase) decrease in other current assets........................ 7 113 288
(Increase) in other assets......................................... -- (3) (330)
Increase (decrease) in accounts payable............................ (201) (109) (724)
Increase (decrease) in accrued liabilities and other............... 138 (187) 517
------- ------- -------
Net cash provided (used) by operating activities............................. 143 175 (4,758)
------- ------- -------
Cash flows used in investing activities:
Capital expenditures.................................................... (168) (30) (302)
Purchase of patent...................................................... (821) -- --
------- ------- -------
Net cash (used) by investing activities...................................... (989) (30) (302)
------- ------- -------
Cash flows provided (used) by financing activities:
Proceeds from (repayment of) Parent advances............................ 820 (167) 5,554
Repayment of long-term debt............................................. (24) (28) (404)
------- ------- -------
Net cash provided (used) by financing activities............................. 796 (195) 5,150
------- ------- -------
Net increase (decrease) in cash and cash equivalents......................... (50) (50) 90
------- ------- -------
Cash and cash equivalents, beginning of period............................... 247 297 207
------- ------- -------
Cash and cash equivalents, end of period..................................... $ 197 $ 247 $ 297
------- ------- -------
------- ------- -------
Cash paid for:
Interest................................................................ $ 429 $ 1,062 $ --
------- ------- -------
------- ------- -------
Income taxes............................................................ $ -- $ -- $ --
------- ------- -------
------- ------- -------
Non-cash investing and financing activities:
During fiscal 1994, CooperSurgical's Parent converted $19,011,000 of
Parent advances into 9,796,660 shares of CooperSurgical Series A
convertible preferred stock.
</TABLE>
See accompanying notes to financial statements.
76
<PAGE>
<PAGE>
COOPERSURGICAL, INC.
NOTES TO FINANCIAL STATEMENTS
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
GENERAL
CooperSurgical, Inc. ('CooperSurgical'), a Delaware corporation, develops,
manufactures and distributes electrosurgical, cryosurgical and general
application diagnostic surgical instruments and equipment. The Cooper Companies,
Inc. ('Parent'), a Delaware corporation, owns 100% of CooperSurgical's Series A
convertible preferred stock. CooperSurgical's outstanding common stock is 100%
owned by individuals on the CooperSurgical Advisory Board which provides counsel
and management of clinical trials in the area of minimally invasive surgery. The
accompanying financial statements have been prepared from the separate records
of CooperSurgical and may not be indicative of conditions which would have
existed or the results of its operations if CooperSurgical operated autonomously
(see Note 5). Foreign exchange translation and transactions are immaterial.
DEPENDENCE UPON PARENT
CooperSurgical believes that the acquisition of certain patented products
in fiscal 1995, the continued consolidation of administrative, selling and
marketing functions to its Shelton facility, and continued inventory reductions
will permit it to meet its cash obligations until its liability to its Parent
matures.
CooperSurgical's liability to Parent matures on May 1, 1997, and the Parent
is committed to funding the Company's cash requirements, as necessary, until
that date.
CooperSurgical does not expect to be able to repay its liability to Parent
at maturity without a significant improvement in operating results from present
levels. There can be no assurance that such an improvement will be achieved or
that the Parent will extend further the maturity date of CooperSurgical's
liability.
REVENUE RECOGNITION
CooperSurgical recognizes product revenue when risk of ownership has
transferred to the buyer, net of appropriate provisions for sales returns and
bad debts.
INCOME TAXES
CooperSurgical is included in the consolidated income tax returns of the
Parent. The consolidated federal, state and local taxes are subject to a tax
sharing agreement under which CooperSurgical's liability is computed on a
non-consolidated basis using a combined rate of 40%.
Effective November 1, 1993, CooperSurgical adopted the liability method of
accounting for income taxes as prescribed by Statement of Financial Accounting
Standards No. 109, 'Accounting for Income Taxes' (FAS 109). The liability method
under FAS 109 measures the expected tax impact of future taxable income or
deductions resulting from temporary differences in the tax and financial
reporting bases of assets and liabilities reflected in the consolidated balance
sheet. Deferred tax assets and liabilities are determined using the enacted tax
rates in effect for the year in which these differences are expected to reverse.
Under FAS 109, the effect on deferred tax assets and liabilities of a change in
tax rates is recognized in the period that the change is enacted. In 1993 and
prior years, the Company accounted for income taxes under APB Opinion 11.
POSTEMPLOYMENT BENEFITS
Effective November 1, 1994, CooperSurgical, Inc. adopted Statement of
Financial Accounting Standards No. 112, 'Employer's Accounting for
Postemployment Benefits' ('FAS 112'). FAS 112 establishes accounting standards
for employers who provide benefits to former or inactive employees
77
<PAGE>
<PAGE>
COOPERSURGICAL, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
after employment but before retirement ('postemployment benefit').
Postemployment benefits are all types of benefits provided to former or inactive
employees, their beneficiaries, and covered dependents. Those benefits include,
but are not limited to, salary continuation, supplemental unemployment benefits,
severance benefits, disability-related benefits (including workers'
compensation), job training and counseling, and continuation of benefits such as
healthcare benefits and life insurance coverage.
The termination benefits portion of the restructuring charge, discussed in
note 2, has been accounted for in accordance with the provisions of FAS 112.
INVENTORIES
Inventories are carried at the lower of cost, determined on an average cost
basis, or market.
ADVERTISING
CooperSurgical expenses the production costs of advertising the first time
the advertising takes place, except for direct-response advertising, which is
capitalized and amortized over its expected period of future benefits.
Direct Response advertising consists primarily of catalog mailings that
include order forms for CooperSurgical's products. The capitalized costs of the
advertising are amortized over a three to four month period or until the next
catalog mailing is made.
At October 31, 1995 and 1994, direct response advertising costs of $136,000
and $45,000, respectively, were included in prepaid expenses. Advertising
expense was $839,000, $1,033,000 and $1,300,000 in fiscal 1995, 1994, and 1993,
respectively.
FURNITURE AND EQUIPMENT
Furniture and equipment are carried at cost. Depreciation is computed on
the straight-line method over the estimated useful lives of depreciable assets.
AMORTIZATION OF INTANGIBLES
Amortization is currently provided on all intangible assets on a
straight-line basis over periods up to 20 years. Accumulated amortization at
October 31, 1995 and 1994 was $1,454,000 and $1,136,000, respectively. The
Company assesses the recoverability of goodwill and other long-lived assets by
determining whether the amortization of these assets over their remaining life
can be recovered through reasonably expected future cash flow.
STOCK BASED COMPENSATION
In October, 1995, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards 123, 'Accounting for Stock-Based Compensation
(FAS 123).' FAS 123 applies to all transactions in which an entity acquires
goods or services by issuing equity instruments such as common stock, except for
employee stock ownership plans. FAS 123 establishes a new method of accounting
for stock-based compensation arrangements with employees which is fair value
based. The statement encourages (but does not require) employers to adopt the
new method in place of the provisions of Accounting Principles Board Opinion
(APB) No. 25, Accounting for Stock Issued to Employees. Companies may continue
to apply the accounting provisions of APB No. 25 in determining net income,
however, they must apply the disclosure requirements of FAS 123. If the Company
adopts the fair value based method of FAS 123, a higher compensation cost would
result for fixed stock option plans and a different compensation cost will
result for the Company's contingent or variable stock option plans. The
recognition provisions and disclosure requirements of FAS 123 are effective for
fiscal
78
<PAGE>
<PAGE>
COOPERSURGICAL, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
years beginning after December 15, 1995. The Company will adopt the disclosure
requirements but not the recognition requirements in its 1997 fiscal year. Such
adoption will have no impact on reported results.
(2) SIGNIFICANT EVENTS
RESTRUCTURING
During fiscal 1995, CooperSurgical closed their Redmond, Washington and
Belgium field offices whereby all employees at these locations and certain
support personnel at CooperSurgical's Shelton, Connecticut headquarters were
terminated, resulting in a $425,000 restructuring charge. The restructuring
charge includes termination benefits of $314,000 which covers eight employees.
As of October 31, 1995, $262,000 of these termination benefits had been paid and
five employees had been officially terminated.
PATENT ACQUISITION
During fiscal 1995, CooperSurgical acquired the rights to certain patented
products for $1,000,000. As of October 31, 1995, $800,000 had been paid, the
final $200,000 installment (reported in accounts payable at October 31, 1995) is
due at the earlier of June 15, 1996 or the date certain contractual milestones
are met.
(3) EXPORT SALES
CooperSurgical had export sales of $2,118,000, $2,441,000, and $2,200,000
for the years ended October 31, 1995, 1994 and 1993, respectively.
(4) ACCOUNTS PAYABLE
CooperSurgical utilized a cash concentration account with the Parent
whereby approximately $180,000 and $193,000 of checks issued and outstanding at
October 31, 1995 and 1994, respectively, in excess of related bank cash balances
were reclassified to accounts payable. Sufficient funds were available from the
Parent to cover these checks.
(5) RELATED PARTY TRANSACTIONS
Included in CooperSurgical's selling, general and administrative expense
are Parent allocations for technical service fees of $389,000, $514,000, and
$1,312,000 for the years ended October 31, 1995, 1994 and 1993, respectively.
Technical service fees for the year ended October 31, 1993 include $134,000
relating to redetermination of the appropriate amount for the year ended October
31, 1992. These costs are charges from the Parent for accounting, legal, tax and
other services provided to CooperSurgical and are added to the balance Due to
Parent.
On January 24, 1994, CooperSurgical's Parent converted $19,011,000 of
Parent advances into 9,796,660 shares of CooperSurgical Series A convertible
preferred stock and converted the remaining $3,313,000 balance of Parent
advances into a Term Note, with principal and interest due January 24, 1996,
bearing interest at 12%, compounded monthly (Parent advances in excess of
$4,000,000 bear interest at 15%, compounded monthly). On January 10, 1995, the
maturity date of this Term Note for principal plus any accrued unpaid interest
was extended to May 1, 1997.
79
<PAGE>
<PAGE>
COOPERSURGICAL, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
(6) INCOME TAXES
A reconciliation of the provision for (benefit of) income taxes included in
CooperSurgical's statement of operations and the amount computed by applying the
federal income tax rate to income (loss) from continuing operations before
extraordinary items and income taxes follows:
<TABLE>
<CAPTION>
YEARS ENDED OCTOBER 31,
-------------------------
1995 1994 1993
----- ----- -------
(IN THOUSANDS OF DOLLARS)
<S> <C> <C> <C>
Computed expected provision for (benefit of) taxes......................... $(473) $(817) $(2,395)
Increase (decrease) in taxes resulting from:
Amortization of intangibles........................................... 33 33 29
Net operating losses for which no tax benefit was recognized.......... 432 781 2,364
Other................................................................. 8 3 2
----- ----- -------
Actual provision for income taxes.......................................... $-- $-- $ --
----- ----- -------
----- ----- -------
</TABLE>
The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets and deferred liabilities are as follows:
<TABLE>
<CAPTION>
OCTOBER 31,
------------------
1995 1994
------- -------
(IN THOUSANDS
OF DOLLARS)
<S> <C> <C>
Deferred tax assets:
Accounts receivable, principally due to allowance for doubtful accounts...... $ 230 $ 152
Inventories, principally due to obsolescence reserves........................ 697 594
Accrued liabilities, principally due to compensation accruals................ 327 148
Net operating loss carryforwards............................................. 5,731 5,675
Other........................................................................ 98 11
------- -------
Total gross deferred tax assets.............................................. 7,083 6,580
Less valuation allowance..................................................... (7,083) (6,580)
------- -------
Net deferred tax asset....................................................... $ -- $ --
------- -------
------- -------
</TABLE>
The valuation allowance increased $503,000 and $1,250,000 for the years
ended October 31, 1995 and 1994, respectively.
At October 31, 1995, the Parent had consolidated net operating loss
carryforwards of which approximately $11,400,000 related to CooperSurgical. The
tax benefit of an additional $3,000,000 of CooperSurgical net operating loss
carryforwards which have been utilized in the Parent's consolidated return are
available in the future should CooperSurgical have sufficient taxable income
during the carryforward period. The net operating loss carryforwards expire
commencing in 2006.
80
<PAGE>
<PAGE>
COOPERSURGICAL, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
(7) LONG-TERM DEBT
Long-term debt consists of the following:
<TABLE>
<CAPTION>
OCTOBER 31,
------------
1995 1994
---- ----
(IN THOUSANDS
OF DOLLARS)
<S> <C> <C>
Note payable; interest at 9%, maturing 1998....................................................... $105 $120
Capitalized lease; interest at 8%, maturing 1999.................................................. 48 --
---- ----
153 120
Less current portion.............................................................................. -- (15)
---- ----
$153 $105
---- ----
---- ----
</TABLE>
During fiscal 1995, CooperSurgical acquired a new telephone system under
the terms of a capital lease for $72,000 whereby CooperSurgical can purchase the
system for $1 at the end of the 48 month lease term. As of October 31, 1995,
accumulated depreciation associated with the telephone system totaled $5,000.
Annual maturities of long-term debt, including current installments
thereof, are as follows:
<TABLE>
<CAPTION>
YEAR ENDING OCTOBER 31, (IN THOUSANDS OF DOLLARS)
- ------------------------------------------------- -------------------------
<S> <C>
1996............................................. $ --
1997............................................. 35
1998............................................. 109
1999............................................. 9
</TABLE>
(8) COMMITMENTS AND CONTINGENCIES
In the normal course of its business, CooperSurgical is involved in various
litigation cases. In the opinion of management, the disposition of such
litigation will not have a materially adverse effect on CooperSurgical's
financial condition.
CooperSurgical leases certain property and equipment under noncancelable
operating lease agreements. The following is a schedule of the estimated minimum
payment due under such leases with an initial term of more than one year as of
October 31, 1995:
<TABLE>
<CAPTION>
YEAR ENDING OCTOBER 31, (IN THOUSANDS OF DOLLARS)
- ------------------------------------------------- -------------------------
<S> <C>
1996............................................. $ 263
1997............................................. 256
1998............................................. 262
1999............................................. 263
2000............................................. 263
2001 and thereafter.............................. 262
</TABLE>
Rental expense for all leases amounted to approximately $317,000, $311,000,
and $340,000 for the years ended October 31, 1995, 1994 and 1993, respectively.
(9) EMPLOYEE BENEFITS
CooperSurgical employees are eligible to participate in the Parent's 401(k)
Savings Plan, a defined contribution plan and the Parent's Retirement Income
Plan, a defined benefit plan. As of October 31, 1995, CooperSurgical has not
elected to participate in the Parent's Retirement Income Plan. Employer
contributions to the Parent's 401(k) Savings Plan, as well as costs and expenses
of administering the
81
<PAGE>
<PAGE>
COOPERSURGICAL, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONCLUDED)
Plan, are allocated to CooperSurgical as appropriate. These amounts were not
significant for the years ended October 31, 1995, 1994 and 1993.
(10) SERIES A CONVERTIBLE PREFERRED STOCK
The Series A Convertible Preferred Stock is convertible into Common Stock
on a one-to-one basis, subject to adjustment for stock splits, dividends and
certain other distributions of Common Stock and has voting rights equal to the
number of shares of Common Stock into which it is convertible. CooperSurgical is
required to reserve for issuance, shares of Common Stock equal to the shares of
Preferred Stock issued and outstanding at any given date. The Preferred Stock
has a liquidation preference of $1.940625 per share and accrues cumulative
dividends of $0.1940625 per share per annum. The aggregate liquidation
preference of the Preferred Stock at October 31, 1995 is $20,253,000, plus
cumulative dividends of $4,299,000. The Preferred Stock participates ratably
with the Common Stock in any additional dividends declared beyond the cumulative
dividends and in any remaining assets beyond the liquidation preference. The
Series A Convertible Preferred Stock represents 99.8% of the total voting rights
of all outstanding CooperSurgical stock.
82
<PAGE>
<PAGE>
SCHEDULE II
COOPERSURGICAL, INC.
VALUATION AND QUALIFYING ACCOUNTS
THREE YEARS ENDED OCTOBER 31, 1995
<TABLE>
<CAPTION>
ADDITIONS
BALANCE AT CHARGED TO CHARGED TO BALANCE
BEGINNING COSTS AND OTHER END OF
CLASSIFICATION OF YEAR EXPENSES ACCOUNTS DEDUCTIONS YEAR
- ----------------------------------------------------- ---------- ---------- ---------- ---------- -------
(AMOUNTS IN THOUSANDS OF DOLLARS)
<S> <C> <C> <C> <C> <C>
Allowance for doubtful accounts:
Year ended October 31, 1995..................... $542 $ 18 $ 38 $ 24 $ 574
---------- ---------- --- --- -------
---------- ---------- --- --- -------
Year ended October 31, 1994..................... $472 $ 70 $ -- $ -- $ 542
---------- ---------- --- --- -------
---------- ---------- --- --- -------
Year ended October 31, 1993..................... $281 $197 $ -- $ 6 $ 472
---------- ---------- --- --- -------
---------- ---------- --- --- -------
</TABLE>
83
<PAGE>
<PAGE>
3. EXHIBITS.
<TABLE>
<CAPTION>
EXHIBIT
NUMBER PAGE
- ------- ----
<C> <S> <C>
3.1 -- Restated Certificate of Incorporation, as partially amended, incorporated by reference to Exhibit
4(a) to the Company's Registration Statement on Form S-3 (No. 33-17330) and Exhibits 19(a) and
19(c) to the Company's Quarterly Report on Form 10-Q for the Fiscal Quarter ended April 30, 1988.
3.2 -- Certificate of Amendment of Restated Certificate of Incorporation dated September 21, 1995.
3.3 -- Amended and Restated By-Laws, incorporated by reference to Exhibit 3.2 to the Company's Report on
Form 8-A dated January 18, 1994.
4.1 -- Second Supplemental Indenture, dated as of January 6, 1994, between the Company and Bankers Trust
Company, as successor trustee, with respect to the 10 5/8% Convertible Subordinated Reset
Debentures due 2005, incorporated by reference to Exhibit 4.3 to the Company's Report on Form 8-A
dated January 18, 1994.
4.2 -- Indenture, dated as of January 6, 1994, between the Company and IBJ Schroder Bank & Trust
Company, as trustee, with respect to the 10% Senior Subordinated Secured Notes due 2003,
incorporated by reference to Exhibit 4.8 to the Company's Report on Form 8-A dated January 18,
1994.
4.3 -- Pledge Agreement, dated January 6, 1994, by the Company in favor of IBJ Schroder Bank & Trust
Company, as Trustee, incorporated by reference to Exhibit 4.9 to the Company's Report on Form 8-A
dated January 18, 1994.
4.4 -- Rights Agreement, dated as of October 29, 1987, between the Company and The First National Bank
of Boston, incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K
dated October 29, 1987.
4.5 -- Amendment No. 1 to Rights Agreement, dated as of June 14, 1993, between the Company and The First
National Bank of Boston, incorporated by reference to Exhibit 10.4 to the Company's Quarterly
Report on Form 10-Q for the fiscal quarter ended April 30, 1993.
4.6 -- Amendment No. 2 to Rights Agreement, dated as of January 16, 1995, between the Company and The
First National Bank of Boston, incorporated by reference to Exhibit 4.6 to the Company's Annual
Report on Form 10-K for the fiscal year ended October 31, 1994.
4.7 -- Certificate of Designation, Preferences and Rights of Series A Junior Participating Preferred
Stock of The Cooper Companies, Inc., incorporated by reference to Exhibit 4.10 of the Company's
Annual Report on Form 10-K for the fiscal year ended October 31, 1989.
10.1 -- 1988 Long Term Incentive Plan, Amended and Restated as of January 16, 1995, incorporated by
reference to Exhibit 10.1 to the Company's Annual Report on Form 10-K for the fiscal year ended
October 31, 1994.
10.2 -- Turn-Around Incentive Plan, incorporated by reference to Exhibit 10.2 to the Company's Annual
Report on Form 10-K for the fiscal year ended October 31, 1994.
10.3 -- Severance Agreement entered into as of June 10, 1991, by and between CooperVision, Inc. and A.
Thomas Bender, incorporated by reference to Exhibit 10.26 to Amendment No. 1 to the Company's
Annual Report on Form 10-K for the fiscal year ended October 31, 1992.
10.4 -- Letter dated March 25, 1994, to A. Thomas Bender from the Chairman of the Compensation Committee
of the Company's Board of Directors, incorporated by reference to Exhibit 10.4 to the Company's
Annual Report on Form 10-K for the fiscal year ended October 31, 1994.
</TABLE>
84
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
EXHIBIT
NUMBER PAGE
- ------- ----
<C> <S> <C>
10.5 -- Employment Agreement dated as of December 1, 1991, by and between Robert S. Holcombe and the
Company, incorporated by reference to Exhibit 10.27 to Amendment No. 1 to the Company's Annual
Report on Form 10-K for the fiscal year ended October 31, 1992.
10.6 -- Letter Agreement dated November 16, 1994, by and between Robert S. Holcombe and the Company,
incorporated by reference to Exhibit 10.6 to the Company's Annual Report on Form 10-K for the
fiscal year ended October 31, 1994.
10.7 -- Letter Agreement dated October 3, 1995, by and between Robert S. Holcombe and the Company.
10.8 -- Severance Agreement entered into as of April 26, 1990, by and between Nicholas J. Pichotta and
the Company.
10.9 -- Letter Agreement dated November 1, 1992, by and between Nicholas J. Pichotta and the Company.
10.10 -- Employment Agreement entered into as of May 27, 1992, by and between Mark R. Russell and Hospital
Group of America, Inc., incorporated by reference to Exhibit 10.20 to Form 10-K-A dated February
27, 1995.
10.11 -- Letter Agreement dated June 18, 1993, by and between Mark R. Russell and Hospital Group of
America, Inc., incorporated by reference to Exhibit 10.21 to Form 10-K-A dated February 27, 1995.
10.12 -- Letter Agreement dated January 11, 1995, by and between Mark R. Russell and Hospital Group of
America, Inc., incorporated by reference to Exhibit 10.22 to Form 10-K-A dated February 27, 1995.
10.13 -- Severance Agreement entered into as of August 21, 1989, by and between Robert S. Weiss and the
Company, incorporated by reference to Exhibit 10.28 to Amendment No. 1 to the Company's Annual
Report on Form 10-K for the fiscal year ended October 31, 1992.
10.14 -- 1990 Restricted Stock Plan for Non-Employee Directors of The Cooper Companies, Inc., incorporated
by reference to the Company's Proxy Statement dated June 15, 1990.
10.15 -- 1996 Long Term Incentive Plan for Non-Employee Directors of The Cooper Companies, Inc.,
incorporated by reference to the Company's proxy statement for its 1996 Annual Meeting of
Stockholders.
10.16 -- Exchange Agreement, dated June 12, 1992 by and between the Company and Cooper Life Sciences,
Inc., incorporated by reference to Exhibit 28(d) to the Company's Current Report on Form 8-K dated
June 12, 1992.
10.17 -- Settlement Agreement, dated June 12, 1992, by and between the Company and Cooper Life Sciences,
Inc., incorporated by reference to Exhibit 28(e) to the Company's Current Report on Form 8-K dated
June 12, 1992.
10.18 -- Exchange Agreement, dated June 14, 1993, between the Company and Cooper Life Sciences, Inc.,
incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the
fiscal quarter ended April 30, 1993.
10.19 -- Registration Rights Agreement, dated June 14, 1993, between the Company and Cooper Life Sciences,
Inc., incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q for
the fiscal quarter ended April 30, 1993.
10.20 -- Settlement Agreement, dated June 14, 1993, between the Company and Cooper Life Sciences, Inc.,
incorporated by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q for the
fiscal quarter ended April 30, 1993.
</TABLE>
85
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
EXHIBIT
NUMBER PAGE
- ------- ----
<C> <S> <C>
10.21 -- Amendment No. 1 to Settlement Agreement of June 14, 1993, dated as of January 16, 1995, between
the Company and Cooper Life Sciences, Inc., incorporated by reference to exhibit 10.14 to the
Company's Annual Report on Form 10-K for the fiscal year ended October 31, 1994.
10.22 -- Agreement dated as of September 28, 1993, among Medical Engineering Corporation, Bristol-Myers
Squibb Company and the Company, incorporated by reference to Exhibit 10.1 to the Company's Current
Report on Form 8-K dated October 1, 1993.
11 -- Calculation of Net Income per Common Share.
21 -- Subsidiaries.
23 -- Consent of KPMG Peat Marwick LLP.
27 -- Financial Data Schedule.
(b) Reports on Form 8-K.
September 27, 1995 -- Item 5. Other Events
</TABLE>
86
<PAGE>
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, on January 12, 1996.
THE COOPER COMPANIES, INC.
By: /S/ A. Thomas Bender
...................................
A. THOMAS BENDER
PRESIDENT, CHIEF EXECUTIVE
OFFICER AND DIRECTOR
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities indicated on the dates set forth opposite their
respective names.
<TABLE>
<CAPTION>
SIGNATURE CAPACITY DATE
- ------------------------------------------ -------------------------------------------- -------------------
<S> <C> <C>
/s/ ALLAN E. RUBENSTEIN Chairman of the Board of Directors January 12, 1996
.........................................
ALLAN E. RUBENSTEIN
/s/ A. THOMAS BENDER President, Chief Executive Officer and January 12, 1996
......................................... Director
A. THOMAS BENDER
/s/ ROBERT S. WEISS Executive Vice President, Treasurer and January 12, 1996
......................................... Chief Financial Officer
ROBERT S. WEISS
/s/ STEPHEN C. WHITEFORD Vice President and Corporate Controller January 12, 1996
.........................................
STEPHEN C. WHITEFORD
/s/ MARK A. FILLER Director January 12, 1996
.........................................
MARK A. FILLER
/s/ MICHAEL H. KALKSTEIN Director January 12, 1996
.........................................
MICHAEL H. KALKSTEIN
/s/ MOSES MARX Director January 12, 1996
.........................................
MOSES MARX
/s/ DONALD PRESS Director January 12, 1996
.........................................
DONALD PRESS
/s/ STEVEN ROSENBERG Director January 12, 1996
.........................................
STEVEN ROSENBERG
</TABLE>
87
STATEMENT OF DIFFERENCES
------------------------
The British pound sign shall be expressed as 'L'
The trademark symbol shall be expressed as 'tm'
The registered trademark symbol shall be expressed as 'r'
<PAGE>
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
LOCATION
OF EXHIBIT
IN SEQUENTIAL
EXHIBIT NUMBERING
NUMBER DESCRIPTION OF DOCUMENT SYSTEM
- ------- -------------------------------------------------------------------------------------------- -------------
<C> <S> <C>
3.1 -- Restated Certificate of Incorporation, as partially amended, incorporated by reference to
Exhibit 4(a) to the Company's Registration Statement on Form S-3 (No. 33-17330) and
Exhibits 19(a) and 19(c) to the Company's Quarterly Report on Form 10-Q for the Fiscal
Quarter ended April 30, 1988..............................................................
3.2 -- Certificate of Amendment of Restated Certificate of Incorporation dated September 21,
1995......................................................................................
3.3 -- Amended and Restated By-Laws, incorporated by reference to Exhibit 3.2 to the Company's
Report on Form 8-A dated January 18, 1994.................................................
4.1 -- Second Supplemental Indenture, dated as of January 6, 1994, between the Company and
Bankers Trust Company, as successor trustee, with respect to the 10 5/8% Convertible
Subordinated Reset Debentures due 2005, incorporated by reference to Exhibit 4.3 to the
Company's Report on Form 8-A dated January 18, 1994.......................................
4.2 -- Indenture, dated as of January 6, 1994, between the Company and IBJ Schroder Bank & Trust
Company, as trustee, with respect to the 10% Senior Subordinated Secured Notes due 2003,
incorporated by reference to Exhibit 4.8 to the Company's Report on Form 8-A dated January
18, 1994..................................................................................
4.3 -- Pledge Agreement, dated January 6, 1994, by the Company in favor of IBJ Schroder Bank &
Trust Company, as Trustee, incorporated by reference to Exhibit 4.9 to the Company's
Report on Form 8-A dated January 18, 1994.................................................
4.4 -- Rights Agreement, dated as of October 29, 1987, between the Company and The First
National Bank of Boston, incorporated by reference to Exhibit 4.1 to the Company's Current
Report on Form 8-K dated October 29, 1987.................................................
4.5 -- Amendment No. 1 to Rights Agreement, dated as of June 14, 1993, between the Company and
The First National Bank of Boston, incorporated by reference to Exhibit 10.4 to the
Company's Quarterly Report on Form 10-Q for the fiscal quarter ended April 30, 1993.......
4.6 -- Amendment No. 2 to Rights Agreement, dated as of January 16, 1995, between the Company
and The First National Bank of Boston, incorporated by reference to Exhibit 4.6 to the
Company's Annual Report on Form 10-K for the fiscal year ended October 31, 1994...........
4.7 -- Certificate of Designation, Preferences and Rights of Series A Junior Participating
Preferred Stock of The Cooper Companies, Inc., incorporated by reference to Exhibit 4.10
of the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 1989....
10.1 -- 1988 Long Term Incentive Plan, Amended and Restated as of January 16, 1995, incorporated
by reference to Exhibit 10.1 to the Company's Annual Report on Form 10-K for the fiscal
year ended October 31, 1994...............................................................
10.2 -- Turn-Around Incentive Plan, incorporated by reference to Exhibit 10.2 to the Company's
Annual Report on Form 10-K for the fiscal year ended October 31, 1994.....................
10.3 -- Severance Agreement entered into as of June 10, 1991, by and between CooperVision, Inc.
and A. Thomas Bender, incorporated by reference to Exhibit 10.26 to Amendment No. 1 to the
Company's Annual Report on Form 10-K for the fiscal year ended October 31, 1992...........
10.4 -- Letter dated March 25, 1994, to A. Thomas Bender from the Chairman of the Compensation
Committee of the Company's Board of Directors, incorporated by reference to Exhibit 10.4
to the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 1994....
10.5 -- Employment Agreement dated as of December 1, 1991, by and between Robert S. Holcombe and
the Company, incorporated by reference to Exhibit 10.27 to Amendment No. 1 to the
Company's Annual Report on Form 10-K for the fiscal year ended October 31, 1992...........
10.6 -- Letter Agreement dated November 16, 1994, by and between Robert S. Holcombe and the
Company, incorporated by reference to Exhibit 10.6 to the Company's Annual Report on Form
10-K for the fiscal year ended October 31, 1994...........................................
</TABLE>
88
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
LOCATION
OF EXHIBIT
IN SEQUENTIAL
EXHIBIT NUMBERING
NUMBER DESCRIPTION OF DOCUMENT SYSTEM
- ------- -------------------------------------------------------------------------------------------- -------------
<C> <S> <C>
10.7 -- Letter Agreement dated October 3, 1995, by and between Robert S. Holcombe and the
Company...................................................................................
10.8 -- Severance Agreement entered into as of April 26, 1990, by and between Nicholas J.
Pichotta and the Company..................................................................
10.9 -- Letter Agreement dated November 1, 1992, by and between Nicholas J. Pichotta and the
Company...................................................................................
10.10 -- Employment Agreement entered into as of May 27, 1992, by and between Mark R. Russell and
Hospital Group of America, Inc., incorporated by reference to Exhibit 10.20 to Form 10-K-A
dated February 27, 1995...................................................................
10.11 -- Letter Agreement dated June 18, 1993, by and between Mark R. Russell and Hospital Group
of America, Inc., incorporated by reference to Exhibit 10.21 to Form 10-K-A dated February
27, 1995.
10.12 -- Letter Agreement dated January 11, 1995, by and between Mark R. Russell and Hospital
Group of America, Inc., incorporated by reference to Exhibit 10.22 to Form 10-K-A dated
February 27, 1995.........................................................................
10.13 -- Severance Agreement entered into as of August 21, 1989, by and between Robert S. Weiss
and the Company, incorporated by reference to Exhibit 10.28 to Amendment No. 1 to the
Company's Annual Report on Form 10-K for the fiscal year ended October 31, 1992...........
10.14 -- 1990 Restricted Stock Plan for Non-Employee Directors of The Cooper Companies, Inc.,
incorporated by reference to the Company's Proxy Statement dated June 15, 1990............
10.15 -- 1996 Long Term Incentive Plan for Non-Employee Directors of The Cooper Companies, Inc.,
incorporated by reference to the Company's proxy statement for its 1996 Annual Meeting of
Stockholders..............................................................................
10.16 -- Exchange Agreement, dated June 12, 1992 by and between the Company and Cooper Life
Sciences, Inc., incorporated by reference to Exhibit 28(d) to the Company's Current Report
on Form 8-K dated June 12, 1992...........................................................
10.17 -- Settlement Agreement, dated June 12, 1992, by and between the Company and Cooper Life
Sciences, Inc., incorporated by reference to Exhibit 28(e) to the Company's Current Report
on Form 8-K dated June 12, 1992...........................................................
10.18 -- Exchange Agreement, dated June 14, 1993, between the Company and Cooper Life Sciences,
Inc., incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form
10-Q for the fiscal quarter ended April 30, 1993..........................................
10.19 -- Registration Rights Agreement, dated June 14, 1993, between the Company and Cooper Life
Sciences, Inc., incorporated by reference to Exhibit 10.3 to the Company's Quarterly
Report on Form 10-Q for the fiscal quarter ended April 30, 1993...........................
10.20 -- Settlement Agreement, dated June 14, 1993, between the Company and Cooper Life Sciences,
Inc., incorporated by reference to Exhibit 10.5 to the Company's Quarterly Report on Form
10-Q for the fiscal quarter ended April 30, 1993..........................................
10.21 -- Amendment No. 1 to Settlement Agreement of June 14, 1993, dated as of January 16, 1995,
between the Company and Cooper Life Sciences, Inc., incorporated by reference to exhibit
10.14 to the Company's Annual Report on Form 10-K for the fiscal year ended October 31,
1994......................................................................................
10.22 -- Agreement dated as of September 28, 1993, among Medical Engineering Corporation,
Bristol-Myers Squibb Company and the Company, incorporated by reference to Exhibit 10.1 to
the Company's Current Report on Form 8-K dated October 1, 1993............................
11 -- Calculation of Net Income per Common Share...............................................
21 -- Subsidiaries.............................................................................
23 -- Consent of KPMG Peat Marwick LLP.........................................................
27 -- Financial Data Schedule.
</TABLE>
89
<PAGE>
<PAGE>
STATE OF DELAWARE
OFFICE OF THE SECRETARY OF STATE
------------------------
I, Edward J. Freel, Secretary of State of the State of Delaware, do hereby
certify the attached is a true and correct copy of the Certificate of Amendment
of 'The Cooper Companies, Inc.', filed in this office on the twenty-first day of
September, A.D. 1995, at 9 o'clock a.m.
A certified copy of this Certificate has been forwarded to the Kent County
Recorder of Deeds for recording.
<TABLE>
<S> <C>
EDWARD J. FREEL
[SECRETARY'S OFFICE SEAL] -----------------------------------
Edward J. Freel, Secretary of State
AUTHENTICATION: 7648348
DATE: 09-21-95
</TABLE>
0888137 8100
950215639
<PAGE>
<PAGE>
CERTIFICATE OF AMENDMENT
OF RESTATED CERTIFICATE OF INCORPORATION
OF
THE COOPER COMPANIES, INC.
(PURSUANT TO SECTION 242 OF THE GENERAL
CORPORATION LAW OF THE STATE OF DELAWARE)
The Cooper Companies, Inc., a corporation duly organized and existing under
the laws of the State of Delaware (the 'Corporation'), does hereby certify as
follows:
1. The name of the Corporation is The Cooper Companies, Inc.
2. The Restated Certificate of Incorporation is hereby amended by
changing Article IV(a) thereof so that, as amended, such Article IV(a)
shall read in its entirety as follows:
(a) Number of Shares. The total number of shares of all classes of
stock which the Corporation shall have authority to issue is 21,000,000,
consisting of (i) 20,000,000 shares of Common Stock ('Common Stock'),
each share having a par value of $.10, and (ii) 1,000,000 shares of
Preferred Stock ('Preferred Stock'), each share having a par value of
$.10.
3. The Restated Certificate of Incorporation is hereby amended by
adding Paragraph (c) to Article IV thereof, which paragraph shall read in
its entirety as follows:
(c) Simultaneously with the effective date of this amendment (the
'Effective Date'), each share of the Company's Common Stock, par value
$.10 per share, issued and outstanding immediately prior to the
Effective Date (the 'Old Common Stock') shall automatically and without
any action on the part of the holder thereof be reclassified as and
changed into one-third ( 1/3) of a share of the Company's Common Stock,
par value $.10 per share (the 'New Common Stock'), subject to the
treatment of fractional share interests as described below. Each holder
of a certificate or certificates which immediately prior to the
Effective Date represented outstanding shares of Old Common Stock (the
'Old Certificates', whether one or more) shall be entitled to receive
upon surrender of such Old Certificates to American Stock Transfer and
Trust Company (the 'Exchange Agent' or 'Transfer Agent') for
cancellation, a certificate or certificates (the 'New Certificates',
whether one or more) representing the number of whole shares of the New
Common Stock formerly represented by such Old Certificates so
surrendered, are reclassified under the terms hereof. From and after the
Effective Date, Old Certificates shall represent only the right to
receive New Certificates (and, where applicable, cash in lieu of
fractional shares, as provided below) pursuant to the provisions hereof.
No certificates of scrip representing fractional share interests in New
Common Stock will be issued, and no such fractional share interest will
entitle the holder thereof to
<PAGE>
<PAGE>
vote, or to any rights of a stockholder of the Company. In lieu of any fraction
of a share, a certificate or certificates evidencing the aggregate of all
fractional shares otherwise issuable (rounded, if necessary, to the next highest
whole share) shall be issued to the Exchange Agent or its nominee, as agent for
the accounts of all holders of Common Stock otherwise entitled to have a
fraction of a share issued to them in connection with the Reverse Split. Sales
of fractional interest will be effected by the Exchange Agent or its nominee as
soon as practicable on the basis of prevailing market prices of the Common Stock
on the New York Stock Exchange at the time of sale. After the Reverse Split
Effective Date, the Exchange Agent will pay to such stockholders their pro rata
share of the net proceeds derived from the sale of their fractional interest
upon surrender of their stock certificates. If more than one Old Certificate
shall be surrendered at one time for the account of the same stockholder, the
number of full shares of New Common Stock for which New Certificates shall be
issued shall be issued shall be computed on the basis of the aggregate number of
shares represented by the Old Certificates so surrendered. In the event that the
Company's Transfer Agent determines that a holder of Old Certificates has not
tendered all of his certificates for exchange, the Transfer Agent shall carry
forward any fractional share until all certificates of that holder have been
presented for exchange such that payment for fraction shares to any one person
shall not exceed the value of one share. If any New Certificate is to be issued
in a name other than that in which the Old Certificates surrendered for exchange
are issued, the Old Certificates so surrendered shall be properly endorsed and
otherwise in proper form for transfer, and the person or persons requesting such
exchange shall affix any requisite stock transfer stamps to the Old Certificates
surrendered, or provide funds for their purchase, or establish to the
satisfaction of the Transfer Agent that such taxes are not payable. From and
after the Effective Date, the amount of capital represented by the shares of the
New Common Stock into which and for which the shares of the Old Common Stock are
reclassified under the terms hereof shall be the same as the amount of capital
represented by the shares of Old Common Stock so reclassified, until thereafter
reduced or increased in accordance with applicable law.
4. Such Amendments of the Restate Certificate of Incorporation have
been duly adopted in accordance with the provisions of Section 242 of the
General Corporation Law of the State of Delaware. The Board of Directors of
the Corporation adopted resolutions setting forth these Amendments,
declaring their advisability and calling for submission of such Amendments
to the stockholder of the Corporation for vote at the Corporation's 1995
Annual Meeting of Stockholders. The stockholders approved such Amendments
at the Annual Meeting of Stockholders held on September 20, 1995.
<PAGE>
<PAGE>
IN WITNESS WHEREOF, the Corporation has caused this certificate to be
signed by A. Thomas Bender, its President and Chief Executive Officer, and
attested by Marisa F. Jacobs, its Secretary, this 21 day of September, 1995.
THE COOPER COMPANIES, INC.
By: A. THOMAS BENDER
-------------------------
A. Thomas Bender
President and
Chief Executive Officer
ATTEST:
By: MARISA F. JACOBS
------------------------
Marisa F. Jacobs
Secretary
<PAGE>
<PAGE>
[The Cooper Companies Logo] The Cooper Companies, Inc.
1 Bridge Plaza, Sixth Floor
Fort Lee, NJ 07024 USA
201-585-5100
201-585-5355 Fax
October 3, 1995
Robert S. Holcombe
547 Brook Avenue
River Vale, NJ 07642
Dear Bob:
In view of the decision to close the Fort Lee office, this letter sets
forth the agreement between us with respect to the termination of your
employment with The Cooper Companies, Inc. ('Cooper'). As used in this letter,
'Employment Agreement' shall refer to the Employment Agreement, dated as of
December 1, 1991, between you and Cooper, as amended on November 16, 1994. Each
capitalized term used herein which is not otherwise defined shall have the
meaning assigned to it in the Employment Agreement. To the extent there is any
inconsistency between the Employment Agreement and this letter agreement, the
provisions of this letter agreement shall be controlling. This letter shall also
constitute the Notice of Termination called for under Section 4(c) of the
Employment Agreement.
By signing this agreement, you acknowledge that you were advised by the
Company to consult with another attorney before signing, that you negotiated the
agreement and that this agreement accurately sets forth the terms of our
agreement regarding termination of your employment. Should you decide to sign
the agreement, you will have a period of seven calendar days following your
execution of the agreement in which to revoke your consent, which revocation
must be in writing signed by you.
1. Termination. (a) The termination of your employment with Cooper shall be
effective April 30, 1996 (the 'Termination Date'). Subject to the last sentence
of this subparagraph (a) and to subparagraph 1 (b) below, you shall continue to
fully and faithfully perform those duties assigned to you by Cooper in your
current capacity as Senior Vice President and General Counsel and continue to
receive your Annual Salary at your current rate and all other rights and
benefits to which you are entitled under your Employment Agreement until the
close of business on the Termination Date. Notwithstanding the foregoing, from
March 1, 1996 through and including April 30, 1996, you shall work at the rate
of 18.75 hours per week and shall receive an Annual Salary payable at a rate
equal to 50% of your current Annual Salary.
(b) Should you notify the Company in writing at least 30 days before its
effectiveness of a decision to end your employment prior to the Termination
Date, you shall continue to receive your Annual Salary through such earlier
termination date at the rate currently in effect (or 50% of that rate if
subsequent to February 29, 1996) and all other rights and benefits to which you
are entitled. All of the severance benefits described in Section 2 below shall
remain due to you on exactly the same terms as described therein except that
provision of the same shall begin on the early
<PAGE>
<PAGE>
Robert S. Holcombe
October 3, 1995
Page 2
termination date, rather than on April 30, 1996. Upon delivery of the notice
provided for herein, such early termination date shall become the new
Termination Date.
2. Benefits. (a) Your employment has been terminated by Cooper without
Cause, thereby entitling you to all of the benefits specified in Section 5(c) of
the Employment Agreement.
(b) On the Termination Date, Cooper shall deliver to you a check in payment
of all accrued but unused vacation time less all amounts required to be withheld
in connection with ordinary tax withholding rules and regulations.
(c) Following the Termination Date, Cooper will facilitate the transfer of
any funds in which you are vested under the Cooper 401(k) Plan.
(d) All rights with respect to options or restricted stock issued under the
1988 Long Term Incentive Plan shall be governed by the provisions of such Plan,
the various Option Certificates and Restricted Stock Agreements issued in
accordance with such Plan and the Turn-Around Incentive Plan.
(e) With respect to your 1995 and pro rata 1996 Incentive Payment Plan
bonuses, in view of the changed circumstances all of your MBOs will be deemed to
have been achieved and there will be no negative distinction made in comparison
with other senior Cooper executives when determining the amount of your bonus
payments.
(f) In full satisfaction of Cooper's obligations to you under Section
5(c)(iii) of the Employment Agreement, Cooper shall pay you on the Termination
Date a lump sum retirement benefit in the amount of $48,330.60.
3. Release. On the Termination Date, you will execute and deliver to Cooper
a General Release in the form attached hereto.
4. Return of Records. You hereby agree and confirm that, on or prior to the
Termination Date, you will return to the Company all documents containing
Non-Public Information relating to the Company or entities in or with which the
Company has, or has contemplated or is contemplating any investment or other
transaction which you obtained during your employment with Cooper. As used
herein, 'Non-Public Information' shall mean any information relating to the
Company, its investments and acquisitions and proposed investments and
acquisitions, and entities affiliated with any of the foregoing that you have
acquired by reason of your employment with the Company, except for (A)
information which is in the public domain at the time of receipt by you, and (B)
information which, after receipt thereof by you, becomes part or the public
domain through no improper act or omission of yours.
<PAGE>
<PAGE>
Robert S. Holcombe
October 3, 1995
Page 3
5. Remaining Agreement. Except as modified by the terms of this letter
agreement, all of the terms and conditions of your Employment Agreement shall
remain in full force and effect.
6. Notice. Notices to be given hereunder shall be deemed given if made in
accordance with Section 10 of the Employment Agreement, provided that the
address to be used for the Company shall be: 6140 Stoneridge Mall Road,
Pleasanton, CA 94588, and the address to be used for you shall be your address
as specified on the first page of this letter, or such other address as either
party shall specify in a written notice given to the other in accordance with
such Section 10 and this provision.
You hereby confirm and acknowledge that you have read this letter agreement
and fully understand the provisions contained herein. If the foregoing sets
forth your understanding of our agreement, please sign in the space provided
below-v for your signature, whereupon this letter shall become a binding
agreement.
This letter agreement will be governed by the laws of the State of
California (without giving effect to its choice of law provisions).
Very truly yours,
THE COOPER COMPANIES, INC.
By: ROBERT L. WEISS
------------------------------
ACCEPTED AND AGREED as
of the date first written above
ROBERT S. HOLCOMBE
- ------------------------------------
Robert S. Holcombe
<PAGE>
<PAGE>
SEVERANCE AGREEMENT
This AGREEMENT, entered into as of April 26, 1990, by and between NICHOLAS
J. PICHOTTA (the 'Employee') and THE COOPER COMPANIES, INC., a Delaware
corporation (together with its subsidiaries referred to herein as the
'Company'),
W I T N E S S E T H:
WHEREAS the Company recognizes that the Employee's contribution to the
betterment of the Company has been substantial; and
WHEREAS the Company believes it to be important both to the Company's
future prosperity and to its general interests to obtain assurance concerning
the continuation of the Employee's employment and to provide the Employee with
incentives:
NOW, THEREFORE, in consideration of the mutual covenants herein contained,
the parties agree as follows:
1. Term of Agreement.
This Agreement shall be in effect from the date hereof until the earliest
of the following:
1
<PAGE>
<PAGE>
(a) The date when the Employee ceases to be employed by the Company, if no
severance benefit is provided under this Agreement as a result of the employment
termination; or
(b) The date when all obligations of the parties under this Agreement have
been satisfied, if the Employee ceases to be employed by the Company and a
severance benefit is provided under this Agreement as a result of the employment
termination.
2. Employment and Compensation.
(a) The Company agrees to employ the Employee during the Employment Period
(as hereinafter defined) as Vice-President of Corporate Development of
CooperVision, Inc. (together with its predecessor, CooperVision Ophthalmic
Products, Inc., hereinafter referred to as 'CVI'), reporting to the Co-Chairmen
of the Board of Directors of the Company and to the President of CVI, and the
Employee agrees to be so employed by the Company, all subject to the terms and
conditions of this Agreement.
(b) Annual Base Salary: During the Employee's employment hereunder, the
Company shall pay the Employee, through its wholly-owned subsidiary, CVI, a
salary at the rate of not less than $140,000 (One Hundred Forty Thousand
Dollars) per annum ('Annual Base Salary'), payable in equal regular installments
on the 15th and last day of each month. The Board of Directors of the Company
may from time to time, in its sole
2
<PAGE>
<PAGE>
and absolute discretion, increase the Employee's Annual Base Salary. Any such
increased salary shall become the Annual Base Salary on and after the effective
date of such increase.
(c) Incentive Payment Plan: The Employee shall be eligible to participate
in the CVI Incentive Payment Plan ('IPP') at the 35% award level. Such IPP bonus
shall be payable to the Employee if and only if (i) the Board of Directors of
the Company shall have established criteria for the earning of an IPP bonus by
CVI employees and (ii) such criteria shall have been achieved and IPP bonuses
shall have been paid thereunder to other eligible CVI employees.
(d) Restricted Stock Grant:
(i) The Company agrees to submit for stockholder approval, not later
than at the next annual stockholders meeting of the Company, a new incentive
stock plan. Promptly following the approval of such plan, the Employee shall be
granted the right to purchase 40,000 shares of restricted common stock of the
Company at a purchase price of $0.10 per share (the 'Restricted Shares'), to be
purchased and held in accordance with the terms of such incentive stock plan
(the 'Plan'). The restrictions on the Restricted Shares shall be removed as set
forth in Section 2(d)(ii) hereof.
(ii) The restrictions on the Restricted Shares shall be removed in the
following percentages of the total number of such shares, provided the average
closing price of the Company's common stock over a consecutive thirty day period
3
<PAGE>
<PAGE>
achieves the indicated stock price during the Employment Period:
<TABLE>
<CAPTION>
STOCK PRICE % UNRESTRICTED
----------- --------------
<S> <C>
$4.43 20%
5.22 40%
6.16 60%
7.27 80%
8.58 100%
</TABLE>
Promptly following the last day of the Employment Period, the Employee shall
sell to the Company, and the Company shall repurchase, at $0.10 per share all
the Restricted Shares from which restrictions shall not have been removed
pursuant to this Section 2(d) during the Employment Period. Notwithstanding the
foregoing, upon a resignation following a Change in Control, pursuant to Section
5 hereof, all restrictions shall be removed from the Restricted Shares and the
certificates evidencing such shares promptly shall be delivered to the Employee.
The Employee agrees to execute a restricted stock agreement with respect to the
Restricted Shares in a form reasonably acceptable to counsel to the Company.
(e) Relocation Expenses and Loan: The Employee agrees to relocate to the
State of Connecticut for the purpose of establishing a new headquarters for CVI.
The Company shall reimburse the Employee for the reasonable expense associated
with such relocation in accordance with the Company's Employee Transfer Expense
Policy dated August 21, 1989; except that, with respect to such relocation to
Connecticut, the Employee waives any right, pursuant to Section IV.C of such
policy or otherwise, to reimbursement by the Company of any loss incurred
4
<PAGE>
<PAGE>
upon the sale of the Employee's house in California. Upon such relocation, the
Company shall pay to Employee a one-time lump sum transition allowance in the
amount of $33,600 (Thirty-three Thousand Six Hundred Dollars). Upon such
relocation, the Company agrees to offer to the Employee a relocation housing
loan in an amount up to $90,000 secured by either (i) a valid and enforceable
first lien of mortgage upon the home purchased with such funds; or (ii) a valid
and enforceable second lien of mortgage upon the home purchase with such funds,
provided that such second lien is permitted by the terms of any first lien and
that the total indebtedness secured by the home purchased shall not exceed 85%
of the lesser of the purchase price or the appraised value therefor. The loan
shall bear interest at the Prime Rate of interest charged by the Chase Manhattan
Bank, as from time to time adjusted, with interest only to be paid quarterly in
arrears and principal and unpaid interest, if any, due in full on the 120th day
following Date of Termination. The Employee shall execute a loan agreement and
such other document as shall reasonably be required by the Company, all in form
acceptable to counsel for the Company. Such documents shall provide, inter alia,
that the Company may offset any unpaid principal and interest against any
severance benefit or compensation due upon termination, if any.
(f) Automobile Allowance: From and after the date upon which the Employee
relocates pursuant to Section 2(e) and continuing through the Date of
Termination, the Company shall pay to the Employee an automobile allowance of
$300 per month
5
<PAGE>
<PAGE>
and shall reimburse the Employee for the reasonable operating cost associated
with the business use of such automobile.
(g) Benefits: During the Employment Period, the Employee shall participate
in all employee benefit plans and receive such fringe benefits as are from time
to time made generally available to CVI's senior management including, without
limitation, life insurance, accidental death and dismemberment insurance,
surgical, medical and hospital expense benefits, long-term disability plans,
Stock Purchase Savings and Retirement Income Plans. Upon presentation of
appropriate documentation, the Company shall reimburse the Employee for all
proper expenses incurred by him in the performance of his duties, in accordance
with the policies and procedures established by the Company.
(h) Sales Bonus: The Company agrees to submit to the Board of Directors for
approval a program for the payment of a sale bonus (the 'Sale Bonus') to CVI
Headquarters Staff, to be earned only upon the closing of a sale by the Company
of CVI to a third party buyer. If approved, such Sale Bonus would total, in the
aggregate for all eligible employees of CVI and of the Company, an amount equal
to 1% (one percent) of the Sale Price, as hereinafter defined. Promptly
following the approval of such program, the Employee shall assist the President
of CVI in submitting for approval to the Co-Chairmen of the Company a list of
proposed eligible employees of CVI and the Company, together with the proposed
percentage of the aggregate pool to be allocated to each eligible employee. For
purposes hereof,
6
<PAGE>
<PAGE>
the 'Sale Price' shall be deemed to be the total consideration paid in cash and
securities for CVI, inclusive of all long-term debt, if any, assumed by the
purchaser. Securities, if any, included in the Sale Price shall be valued at the
fair market value therefor on the date of closing.
3. Involuntary Termination Without Cause.
If the Company terminates the Employee's employment without Cause, the
Company shall pay the Employee a severance benefit in an amount equal to 200% of
the Employee's Annual Base Salary and shall deliver to the Employee all
certificates evidencing those of the Restricted Shares from which restrictions
shall have been removed prior to the Date of Termination pursuant to Section
2(d). Promptly following such termination, the Employee shall sell to the
Company, and the Company shall repurchase at $0.10 per share, all of the
Restricted Shares from which restrictions shall not have been removed prior to
the Date of Termination. For purposes of this Agreement, a termination without
cause shall include but not be limited to the Employee ceasing to be employed by
the Company as a result of the Employee's continuing in the employ of a
division, subsidiary or other business unit of the Company that has been sold,
transferred or otherwise conveyed to a third party. The Company shall give the
Employee not less than 90 days' advance notice in writing of any termination
without Cause.
7
<PAGE>
<PAGE>
4. Resignation for Good Reason.
If the Employee terminates his employment for Good Reason then, following
the Date of Termination, the Company shall pay the Employee a severance benefit
in an amount equal to 200% of the Employee's Annual Base Salary and shall
deliver to the Employee all certificates evidencing those of the Restricted
Shares from which restrictions shall have been removed prior to the Date of
Termination pursuant to Section 2(d). Promptly following such termination, the
Employee shall sell to the Company, and the Company shall repurchase at $0.10
per share, all of the Restricted Shares from which restrictions shall not have
been removed prior to the Date of Termination.
5. Resignation After Change in Control.
If the Employee terminates his employment without Good Reason within 90
days after a Change in Control, the Company shall pay the Employee a severance
benefit in an amount equal to 150% of the Employee's Annual Base Salary; in
addition, all restrictions shall be removed from the Restricted Shares and the
certificates, evidencing such shares shall be delivered to the Employee promptly
following the Date of Termination.
8
<PAGE>
<PAGE>
6. Resignation With Notice.
If the Employee terminates his employment other than pursuant to Section 4,
5 or 7 hereof, and provided that the Employee shall have given the Company not
less than 90 days' advance written notice of such termination, then the Company
shall pay to the Employee a severance benefit in an amount equal to 25% of the
Employee's Annual Base Salary and the Company shall have no further obligations
to the Employee under this Agreement other than for those benefits provided
under the Company's Retirement Income and Stock Purchase Savings Plan or those
benefits, if any, which the Company is required by law to provide
notwithstanding any agreement to the contrary. Promptly following such
resignation, the Employee shall sell to the Company, and the Company shall
repurchase at $0.10 per share, all the Restricted Shares from which restrictions
shall not have been removed prior to the Date of Termination.
7. Relocation.
If the Company notifies the Employee that his principal workplace will be
moved to any location more than 50 miles from his present principal workplace
except to any location maintained as the headquarters of any business unit
acquired by the Company or by CVI and the Employee elects not to relocate, then
the Employee's employment shall terminate on the relocation date specified in
the notice referred to in this
9
<PAGE>
<PAGE>
Section 7 and the Company shall pay the Employee a severance benefit in an
amount equal to 150% of the Employee's Annual Base Salary and shall deliver to
the Employee all certificates evidencing those of the Restricted Shares from
which restrictions shall have been removed prior to the Date of Termination
pursuant to Section 2(d). Promptly following such termination, the Employee
shall sell to the Company, and the Company shall repurchase at $0.10 per share,
all of the Restricted Shares from which restrictions shall not have been removed
prior to the Date of Termination. The Company shall give the Employee not less
than 90 days' advance notice of any relocation described in this Section 7. The
Employee shall consent to or decline the relocation within 90 days of receipt of
notice. The Employee hereby consents to the relocation of his principal
workplace to the Sate of Connecticut as set forth in Section 2(e), or to another
headquarters location maintained by any business unit acquired by the Company or
by CVI, and hereby waives any right to benefits pursuant to this Section 7 on
account of such relocations. Following any relocation of the Employee pursuant
to this Section 7, the location of the CVI corporate headquarters in Connecticut
or of the afore-referenced headquarters location maintained by any business unit
acquired by the Company or by CVI shall be deemed to be Employee's principal
workplace for the purpose of this Section 7.
10
<PAGE>
<PAGE>
8. DEATH
If the Employee's employment shall be terminated by reason of his death,
the Company shall pay to such person as the Employee shall have designated in a
notice filed with the Company or, if no such person shall have been designated,
to the Employee's estate, a severance benefit in an amount equal to 200% of the
Employee's Annual Base Salary and shall deliver to the Employee all certificates
evidencing those of the Restricted Shares from which restrictions shall have
been removed prior to the Date of Termination pursuant to Section 2(d). Promptly
following such termination, the Employee shall sell to the Company, and the
Company shall repurchase at $0.10 per share, all of the Restricted Shares from
which restrictions shall not have been removed prior to the Date of Termination.
9. TERMINATION FOR CAUSE.
If the Company terminates the Employee's employment for Cause, the Company
shall pay to the Employee his Annual Base Salary through the Date of Termination
and the Company shall have not further obligations to the Employee under this
Agreement other than for those benefits provided under the Company's Retirement
Income and Stock Purchase Savings Plan or those benefits, if any, which the
Company is required by law to provide notwithstanding any agreement to the
contrary. Promptly following such termination, the Employee shall sell to
11
<PAGE>
<PAGE>
the Company, and the Company shall repurchase at $0.10 per share, all the
Restricted Shares from which restrictions shall not have been removed prior to
the Date of Termination.
10. PAYMENT OF SEVERANCE BENEFIT.
(a) Election. If the Employee becomes entitled to a severance benefit under
the preceding sections of this Agreement, he may elect whether such benefit is
to be paid in a lump sum under Subsection (b) below or in installments under
Subsection (c) below. Such an election shall be submitted to the Company in
writing within five business days after the Date of Termination. If the Employee
fails to submit a timely written election to the Company, such benefit shall be
paid in a lump sum under Subsection (b) below.
(b) Lump Sum. A benefit payable under this Subsection (b) shall be paid in
a single lump sum within 10 business days after the Date of Termination.
(c) Installments. A benefit payable under this Subsection (c) shall be paid
by continuing the Employee's Annual Base Salary in accordance with the Company's
regular payroll practices until such benefit is exhausted, commencing with the
period next following the last payroll period during which the Employee was
employed by the Company.
(d) Withholding. All payments made under this Agreement shall be subject to
reduction to reflect any
12
<PAGE>
<PAGE>
withholding taxes or other amounts required by applicable law or regulation.
(e) Death. Any amount payable under this Section 10 after the Employee's
death shall be paid to the beneficiary or beneficiaries designated by him for
this purpose in writing or, if there is no surviving beneficiary, to his estate.
11. GROUP INSURANCE.
(a) General. If the Employee becomes entitled to a benefit payable under
Section 3, 4, 5, or 7 hereof the Employee's participation (including dependent
coverage) in the life, accident, disability, health and dental insurance plans
of the Company, shall be continued, or equivalent benefits provided by the
Company at no cost to the Employee until the earlier of 24 months following the
Date of Termination or the date the Employee becomes covered by equivalent
benefits by a subsequent employer;
(b) Coordination with COBRA Coverage. For purposes of determining the
required duration of any contribution coverage under the Company's health care
plans mandated by law, the period of any continued coverage under this Agreement
following the termination of the Employee's employment shall be counted as all
or part of such required duration.
13
<PAGE>
<PAGE>
12. OTHER BENEFITS
If the Employee becomes entitled to a benefit under Section 3, 4, 5 or 7,
he shall also receive the following benefits:
(a) The Employee shall be entitled to receive a pro rata share of any
amounts payable, if any, under the CVI Headquarters Incentive Payment Plan
approved by the Board of Directors of the Company, based on the number of
months the Employee served as an employee during the fiscal year completed
or already underway, payable if and when other participants in the Plan
receive payment from the Company thereunder.
(b) The Employee shall fully vest in all benefits due under the
Company's Retirement Income Plan or, if prohibited by the terms thereof,
shall be entitled to receive benefits substantially equivalent to the
benefits accrued thereunder. Whether benefits are substantially equivalent
for purposes of the preceding sentence shall be determined without regards
to the tax consequences thereof.
(c) The Company shall continue to pay to the Employee, for a period of
90 days from the Date of Termination, the automobile allowance described in
Section 2 hereof.
14
<PAGE>
<PAGE>
13. NO MITIGATION REQUIRED.
The Employee shall not be required to mitigate the amount of any benefit
provided under this Agreement by seeking new employment or otherwise.
14. COMPETITIVE ACTIVITY.
During the Employment Period and for a further period of one year
thereafter, the Employee shall not:
(a) Participate, without the written consent of the Board of Directors
or a person authorized thereby, in the management or control of, or act as
an executive for or employee of, any business operation or any enterprise
if such operation or enterprise engages in substantial competition with any
material line of business at the time actively conducted by the Company or
any of its subsidiaries, divisions, affiliates or new business or business
units including, without limitation, CVI (collectively, the 'Companies');
provided, however, that the foregoing shall not include the mere ownership
of not more than five percent of the equity securities of any enterprise or
the participation in an investment banking firm or otherwise engaging in
investment banking activities and in that capacity serving or advising
enterprises in competition with the Companies;
(b) Solicit, in competition with the Companies, any person who is a
customer of the business conducted by the
15
<PAGE>
<PAGE>
Companies or of any business in which the Companies are substantially engaged at
any time during the Employment Period; and
(c) Induce or attempt to persuade any employee of the Companies to
terminate his or her employment relationship in order to enter into
competitive employment.
15. UNAUTHORIZED DISCLOSURE.
During the Employment Period and for a further period of ten years
thereafter, the Employment shall not, except as required by any court or
administrative agency, without the written consent of the Board of Directors or
a person authorized thereby, disclose to any person, other than an employee of
the Company or a person to whom disclosure is reasonably necessary or
appropriate in connection with the performance by the Employee or his duties to
the Company, any confidential information obtained by him while in the employ of
the Company with respect to any of the Company's inventions, processes,
customers, methods of distribution, methods of manufacturing, attorney-client
communications, pending or contemplated acquisitions, other trade secrets, or
any other material which the Company is obliged to keep confidential pursuant to
any confidentiality agreement or protective order; provided, however, that
confidential information shall not include any information now known or which
becomes known
16
<PAGE>
<PAGE>
generally to the public (other than as a result of an unauthorized disclosure by
The Employee) or any information of a type not otherwise considered confidential
by a person engaged in the same business or a business similar to that conducted
by the Companies.
16. SCOPE OF COVENANTS; REMEDIES.
The following provisions shall apply to the covenants contained in Section
14 and 15 hereof;
(a) The covenants contained in Sections 14(a) and 14(b) shall apply
within the territories in which any of the Companies are actively engaged
in the conduct of business during the Employment Period including, without
limitation, the territories in which customers are then being solicited;
(b) Without limiting the right of the Company to pursue all other
legal and equitable remedies available for violation by the Employee of the
covenants contained in Sections 14 and 15 hereof, it is expressly agreed by
the Employee and the Company that such other remedies cannot fully
compensate the Company for any such violation and that the Company shall be
entitled to injunctive relief to prevent any such violation or any
continuing violation thereof;
(c) Each party intends and agrees that if, in any action before any
court or agency legally empowered to enforce the covenants contained in
Sections 14 and 15 hereof, any term,
17
<PAGE>
<PAGE>
restriction, covenant or promise contained therein is found to be unreasonable
and accordingly unenforceable, then such term, restriction, covenant or promise
shall be deemed modified to the extent necessary to make it enforceable by such
court or agency; and
(d) The covenants contained in Sections 14 and 15 hereof shall survive
the conclusion of the Employment Period.
17. MISCELLANEOUS PROVISIONS.
(a) Limitation on Severance Benefits. The severance benefits set forth
in Sections 3, 4, 5, 6, 7 and 8 of this Agreement shall be mutually
exclusive. Nothing contained herein shall be construed to permit the
payment of severance benefits under more than one of said Sections 3, 4, 5,
6, 7 and 8.
(b) Excess Parachute Cap. In the event that any payments or benefits
received or to be received by the Employee pursuant to this Agreement in
connection with a Change in Control as defined herein or upon the
termination of the Employee's employment would not be deductible to the
Company, in whole or in part, as a result of Section 280G of the Internal
Revenue Code, then such payments or benefits shall be reduced by the
minimum amounts necessary so that no portion thereof is not deductible. Any
determination with regard to whether or not any such payment or benefits
would be deductible as a result of Section 280G shall be made by tax
counsel
18
<PAGE>
<PAGE>
selected by the Company's independent auditors, in accordance with the
principles of Section 280c.
(c) Delivery of Notice. All notices, requests, demands and other
communications made pursuant to this Agreement shall be in writing and shall be
deemed duly given (a) if delivered by hand, and the time delivered or (b) if
mailed, at the time mailed at any general or branch United States Post Office
enclosed in a registered or certified postpaid envelope addresses to the
respective parties as follows:
If to the company:
The Cooper Companies, Inc.
3145 Porter Drive
Palo Alto, California 94304
Att: Corporate Secretary
with a copy to:
250 Park Avenue
6th Floor
New York, New York 10177
Att: General Counsel
If to The Employee:
c/o The Cooper Companies, Inc.
3145 Porter Drive
Palo Alto, California 94304
with a copy to:
------------------------------------
------------------------------------
or to such other address as either party may have previously furnished to the
other in writing in the manner set forth
19
<PAGE>
<PAGE>
above, provided that such notice of change of address shall only be effective
upon receipt.
(d) Waiver. No provision of this Agreement shall be modified, waived or
discharged unless the modification, waiver or discharge is agreed to in writing
and signed by the Employee and the company. No waiver by either party of any
breach of, or of compliance with, any condition or provision shall be construed
as a waiver of any breach of, or compliance with, any other condition or
provision or of the same condition or provision at another time.
(e) Assignment and Successors. Neither party shall assign any right or
delegate any obligation hereunder without the other party's written consent, and
any purported assignment or delegation by a party hereto without the other
party's written consent shall be void. The Company shall require any successor
(whether direct or indirect and whether by purchase, lease, merger,
consolidation, liquidation or otherwise) to all or substantially all of the
company's business and/or assets, by an agreement in substance and form
satisfactory to the Employee, to assume this Agreement in the same manner and to
the same extent as the Company would be required to perform it in the absence of
a succession. The Company's failure to obtain such agreement prior to the
effectiveness of a succession shall be a breach of this Agreement and shall
entitle the Employee to all of the compensation and benefits to which he would
have been entitled hereunder if the Company had involuntarily terminated his
employment without Cause on the
20
<PAGE>
<PAGE>
date when such succession becomes effective. For all purposes under this
Agreement, the term 'Company' shall include any successor to the Company's
business and/or assets which executes and delivers the assumption agreement
described in the preceding sentence of this Subsection (d) or which becomes
bound by this Agreement by operation of law. This Agreement and all rights of
the Employeee hereunder shall inure to the benefit of, and be enforceable by,
the Employee's personal or legal representatives, executors, administrators,
successors, heirs, distributees, devisees and legatees.
(f) Whole Agreement. No agreements, representations or understandings
(whether oral or written and whether express or implied) which are not expressly
set forth or incorporated in this Agreement have been made or entered into by
either party with respect to the subject matter hereof. Effective as of the date
hereof, this Agreement supersedes any prior employment or severance agreement
between the Employee and the Company.
(g) Choice of Law. The validity, interpretation, construction and
performance of this Agreement shall be governed by the laws of the State of New
York.
(h) Severability. The invalidity of enforceability of any provision or
provisions of this Agreement shall not affect the validity or enforceability of
any other provision hereof, which shall remain in full force and effect.
21
<PAGE>
<PAGE>
18. Definitions.
(a) 'Cause' shall mean (i) gross misconduct injurious to the company, as
determined in a written opinion rendered to the Company's board of directors by
the Company's outside counsel, (ii) conduct by the Employee constituting or
competitive activity in violation of Section 14; or (iii) the willful making by
the Employee of any unauthorized disclosure in violation of Section 15.
(b) 'Change in Control' shall mean that: (i) a sufficient number of
individuals who were not nominated by management are elevated to the board of
directors of the Company to constitute 50% or more of the Company's board of
directors; (ii) the Company's stockholders adopt a plan of liquidation; (iii) a
third party, pursuant to a tender offer to the Company's stockholders, acquires
at least a majority of the shares of Common Stock of the company; or (iv) none
of Gary A. Singer, Bruce D. Sturman, or another member of the Singer family
shall continue to serve as Chairman or Co-Chairman of the Board of Directors of
the Company.
(c) 'Good Reason' shall mean (i) any assignment to the Employee of any
duties, other than those assigned to him on the date of this Agreement, which
are not mutually acceptable to the parties hereto, (ii) any removal of the
Employee from, or any failure to reelect the Employee to, any of the positions
held by him on the date of this Agreement, except in connection with the
termination of the Employee's employment for Cause, or
22
<PAGE>
<PAGE>
(iii) a reduction in the Employee's rate of compensation or fringe benefits.
(d) 'Employment Period' shall be that period commencing on the date hereof
and continuing until the Date of Termination.
(e) 'Date of Termination' shall mean (i) if the Consultant's employment is
terminated by his death, the date of his death; (ii) in the case of a
termination by the Company pursuant to Section 9, the date specified in the
notice of termination; (iii) in the case of a termination by the Company other
than pursuant to Section 9, the date specified in the notice of termination
which date shall be at least 90 days after the date of such notice; (iv) in the
case of a termination by the Employee, the date specified in the notice of
termination, which date shall be at least 90 days after the date of such notice.
IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the
case of the Company by its duly authorized officer, as of the day and year
first above written.
NICHOLAS J. PICHOTTA
-----------------------------
Nicholas J. Pichotta
THE COOPER COMPANIES, INC.
BY STEVEN G. SINGER
-----------------------------
Steven G. Singer
23
<PAGE>
<PAGE>
[The Cooper Companies Logo] The Cooper Companies, Inc.
50 Park Avenue, Sixth Floor
New York, NY 10177 USA
212-557-2690
November 1, 1992
Mr. Nicholas J. Pichotta
The Cooper Companies, Inc.
2 Corporate Drive, Suite 600
Shelton, CT 06484
Dear Nick:
Reference is made to your Severance Agreement with The Cooper Companies,
Inc. (the 'Company') entered into as of April 26, 1990 (the 'Severance
Agreement'). The purpose of this letter is to amend and supplement the Severance
Agreement to reflect (i) your recent promotion to the position of Chairman and
Chief Executive Officer of CooperSurgical, Inc. ('CSI'), a subsidiary of the
Company, and (ii) the satisfaction of the Company's potential obligations, if
any, under Section 5 of the Severance Agreement. Capitalized terms in this
letter, unless otherwise defined herein, shall have the same meanings as those
set forth in the Severance Agreement.
The Company and the Employee hereby ratify and confirm the Severance
Agreement in all respects except as hereby amended, effective as of October 1,
1992, as follows:
Section 2(a) is hereby amended to read in its entirety as follows:
'(a) The Company agrees to employ the Employee during the Employment Period
(as hereinafter defined) as Vice President of the Company, and as Chairman
and Chief Executive Officer of CooperSurgical, Inc. ('CSI'), reporting to
the Chief Operating Officer of the Company, and the Employee agrees to be so
employed, all subject to the terms and conditions of this Agreement.'
The first sentence of Section 2(b) is hereby amended to read as follows:
'(b) Annual Base Salary: Effective October 1, 1992, the Company shall pay
the Employee, through its subsidiary, CSI, a salary at the rate of not less
than $190,000 (One Hundred Ninety Thousand Dollars) per annum ('Annual Base
Salary'), payable in equal regular installments on the 15th and last day of
each month.'
<PAGE>
<PAGE>
Mr. Nicholas J. Pichotta
The Cooper Companies, Inc.
Page 2
November 1, 1992
The first sentence of Section 2(c) is hereby amended to read as follows:
'(c) Incentive Payment Plan: The Employee shall be eligible to participate
in the CSI Incentive Payment Plan ('IPP') at the 40% award level.'
The references to 'CVI' in the second sentence of said Section 2(c) shall
be changed to 'CSI'.
Section 2(d) is hereby deleted in its entirety and the following
substituted therefor:
'(d) Restricted Shares: The restrictions on the unvested 24,000 shares of
restricted common stock of the Company granted to the Employee on July 12,
1990, shall be removed in two equal installments of 12,000 shares on January
4, 1993, and January 3, 1994, provided the Employment Period shall not have
earlier terminated. The Employee agrees to execute an amendment to his
restricted stock agreement with respect to said restricted shares, in a form
reasonably acceptable to counsel to the Company, effecting such removal of
restrictions. There shall be no change in the schedule for removal of
restrictions on the 16,000 shares of restricted common stock of the Company
granted to the Employee on February 11, 1992.'
Section 2(e) is hereby deleted in its entirety and the following
substituted therefor:
'(e) Forgiveness of Relocation Housing Loan: On January 15, 1993, the
Company shall cancel and forgive (provided that the Employment Period shall
not have earlier terminated) the principal of and all accrued interest on
the Employee's $90,000 relocation housing loan provided by the Company.
Promptly following such forgiveness and cancellation, the Company shall
prepare and cause to be recorded a discharge of mortgage or other
appropriate instrument to evidence the removal of the Company's lien on the
Employee's residence.'
Section 2(g) is hereby amended by changing the reference to 'CVI's' in the
first sentence thereof to 'CSI's'.
<PAGE>
<PAGE>
Mr. Nicholas J. Pichotta
The Cooper Companies, Inc.
Page 3
November 1, 1992
Section 2(h) is hereby deleted in its entirety and the following
substituted therefor:
'(h) Deferred Compensation: In addition to the Employee's Annual Base
Salary, the Company shall pay to the Employee (subject to appropriate
withholdings and provided that the Employment Period shall not have earlier
terminated) $62,000 (Sixty-Two Thousand Dollars) of Deferred Compensation
payable in twenty-four equal installments of $2,583.33 (Two Thousand Five
Hundred Eighty-Three Dollars and Thirty-Three Cents) on the first day of
each month commencing November 1, 1992 until October 1, 1994.'
Section 3 is hereby amended to read in its entirety as follows:
'3. Termination Without Cause or for Good Reason.
If the Company terminates the Employee's employment without Cause, or if the
Employee terminates his employment for Good Reason, the Company shall pay
the Employee a severance benefit in an equal amount to the applicable
percentage of the Employee's Annual Base Salary set forth below:
<TABLE>
<CAPTION>
DATE OF TERMINATION % OF ANNUAL BASE SALARY
- ------------------------------------------------------------------- -----------------------
<S> <C>
Prior to April 1, 1993 50.0%
During April, 1993 58.3%
During May, 1993 66.7%
During June, 1993 75.0%
During July, 1993 83.3%
During August, 1993 91.7%
After September 1, 1993 100.0%
</TABLE>
The Company shall deliver to the Employee all certificates evidencing those
restricted shares of the Company's common stock owned by the Employee from
which restrictions shall have been removed prior to the Date of Termination
pursuant to Section 2(d) or the applicable restricted stock agreement.
Promptly following such termination, the Employee shall sell to the Company,
and the Company shall repurchase at $0.10 per share, all of the restricted
shares of the Company's common stock owned by the Employee from which
restrictions shall not
<PAGE>
<PAGE>
Mr. Nicholas J. Pichotta
The Cooper Companies, Inc.
Page 4
November 1, 1992
have been removed prior to the Date of Termination. For purposes of this
Agreement, a termination without Cause shall include but not to be limited to
the Employee ceasing to be employed by the Company as a result of the Employee's
continuing in the employ of a division, subsidiary or other business unit of the
Company that has been sold, transferred or otherwise conveyed to a third party.
The Company shall give the Employee not less than 90 days advance notice in
writing of any termination without Cause.'
Section 4 is hereby deleted in its entirety and the following substituted
therefor:
'4. Resignation or Termination After Change in Control.
If (i) within 90 days after a Change in Control the Employee terminates his
employment without Good Reason, the Company shall pay the Employee a
severance benefit in an amount equal to 100% of the Employee's Annual Base
Salary, or (ii) within six months after a Change of Control the Company
terminates the Employee's employment without Cause, the Company shall pay
the Employee a severance benefit in an amount equal to 150% of the
Employee's Annual Base Salary; in addition, in either such case, all
restrictions shall be removed from the 24,000 shares of restricted common
stock of the Company referred to in Section 2(d) and the certificates
evidencing such shares shall be delivered to the Employee promptly following
the Date of Termination.'
Section 5 is hereby deleted in its entirety and the following substituted
therefor:
'5. 'Catch-Up' Provision.
Notwithstanding any other provision of this Agreement, if, prior to October
1, 1994, either (a) the Employee's employment is terminated by the Company
without Cause following a Change in Control or (b) Steven G. Singer ceases
to be the Chief Operating Officer of the Company and such position is filled
with someone other than A. Thomas Bender or the Employee, then, in addition
to any severance benefit to which the Employee may be entitled hereunder,
(i) the Company shall be obligated to pay the Employee an amount equal to
the differ-
<PAGE>
<PAGE>
Mr. Nicholas J. Pichotta
The Cooper Companies, Inc.
Page 5
November 1, 1992
ence between $62,000 and the aggregate of all amounts of Deferred Compensation
previously received by the Employee pursuant to Section 2(h) hereof, (ii) if
such termination occurs prior to January 3, 1994, the restrictions shall be
removed from all of the Employee's 24,000 shares of restricted common stock of
the Company referred to in Section 2(d) hereof, and (iii) if such termination
occurs prior to January 15, 1993, the Employee's relocation housing loan shall
nonetheless be canceled and forgiven as provided in Section 2(e) hereof.'
The reference to 'Section 4, 5 or 7' in the first sentence of Section 6
shall be changed to 'Section 3, 4 or 7'.
The addresses set forth in Section 17(c) shall be amended to read as
follows:
If to the Company:
The Cooper Companies, Inc.
250 Park Avenue
Sixth Floor
New York, NY 10177
Attention: Chief Operating Officer
with a copy to:
The Cooper Companies, Inc.
250 Park Avenue
Sixth Floor
New York, NY 10177
Attention: General Counsel
If to the Employee:
c/o The Cooper Companies, Inc.
2 Corporate Drive
Shelton, CT 06484
with a copy to:
Nicholas J. Pichotta
300 Chestnut Hill Road
Wilton, CT 06897
<PAGE>
<PAGE>
Mr. Nicholas J. Pichotta
The Cooper Companies, Inc.
Page 6
November 1, 1992
Section 18(b) is hereby amended by inserting 'or' at the end of clause (ii)
thereof, by deleting '; or ' at the end of clause (iii) and
all of clause (iv) thereof, and by inserting a period in lieu of such deletion
at the end of clause (iii) thereof.
In consideration of your entering into this amendment of the Severance
Agreement, the Company has paid you the sum of One Hundred Thousand Dollars
($100,000), less applicable withholdings, and you hereby release the Company
from any and all claims for payment of any amounts that might otherwise be
claimed by or payable to you based on a Change in Control of the Company or any
other provision of the Severance Agreement that might have resulted in a
liability of the Company to you prior to the date hereof.
If the foregoing is acceptable to you please sign where indicated below and
return a copy of this letter to me.
Sincerely,
STEVEN G. SINGER
---------------------------------
Steven G. Singer
Executive Vice President
and Chief Operating Officer
Agreed to and accepted:
NICHOLAS J. PICHOTTA
- ---------------------
Nicholas J. Pichotta
<PAGE>
<PAGE>
EXHIBIT 11
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
CALCULATION OF NET INCOME (LOSS) PER COMMON SHARE
<TABLE>
<CAPTION>
Years Ended October 31,
-----------------------
1995 1994 1993
---- ---- ----
(In thousands, except per share figures)
<S> <C> <C> <C>
Primary:
Income (loss) from continuing operations before
extraordinary items(1)........................... $ 115 $(4,786) $(34,392)
Discontinued operations:
Loss on sale of operations....................... - - (13,657)
------- -------- --------
Income (loss) before extraordinary items......... 115 (4,786) (48,049)
Extraordinary items.............................. - - 924
------- -------- ---------
Net income (loss)................................ 115 $(4,786) $(47,125)
======= ======== =========
Weighted average number of common shares
outstanding...................................... 11,576 10,193 10,035
======= ======= ========
Primary net income (loss) per common share:
Continuing operations........................... .01 (0.47) $ (3.43)
Discontinued operations:
Loss on sale of operations...................... - - (1.36)
------ -------- --------
Income (loss) before extraordinary items........ .01 (0.47) (4.79)
Extraordinary items............................. - - 0.09
------- -------- ---------
Net income (loss) per common share.............. $0.01 $ (0.47) $ (4.70)
====== ======== =======
Fully diluted:
Income (loss) from continuing operations
before extraordinary items(1).................... $ 115 $(4,786) $(34,392)
Discontinued operations:
Loss on sale of operations...................... - - (13,657)
------- -------- ---------
Income (loss) before extraordinary items........ 115 (4,786) (48,049)
Extraordinary items on a fully diluted basis.... - - 924
------- --------- --------
Net income (loss) on a fully diluted basis...... $ 115 $(4,786) $ (47,125)
======= ======== =========
Weighted average number of common shares
outstanding.................................... 11,576 10,193 10,035
======= ======= =========
Total common shares assuming full dilution..... 11,615 10,193 10,035
Fully diluted net income (loss) per common share:
Continuing operations.......................... $ 0.01 $ (0.47) $ (3.43)
Discontinued operations:
Loss on sale of operations..................... - - (1.36)
------- --------- ---------
Income (loss) before extraordinary items........ 0.01 (0.47) (4.79)
Extraordinary items............................. - - 0.09
------- -------- ---------
Net income (loss) per common share on a fully
diluted basis................................... $ 0.01 $(0.47) $(4.70)
======= ======== =========
</TABLE>
- ----------------
(1) After dividend requirements on Senior Exchangeable Redeemable Restricted
Voting Preferred Stock of $320 in 1993 and after dividend requirements on
Series B Preferred Stock of $89 in 1994.
<PAGE>
<PAGE>
SUBSIDIARIES OF
THE COOPER COMPANIES, INC.
A DELAWARE CORPORATION
<TABLE>
<CAPTION>
JURISDICTION OF
NAME INCORPORATION
- ---- -------------
<S> <C>
The Cooper Healthcare Group, Inc. Delaware
CooperVision Pharmaceuticals, Inc. Delaware
CooperVision, Inc. New York
CooperVision Inc. Canada
Hospital Group of America, Inc. Delaware
Hospital Group of Delaware, Inc. Delaware
Hospital Group, Inc. Delaware
Residential Centers of Delaware, Inc. Delaware
Hospital Group of Illinois, Inc. Illinois
Hospital Group of Louisiana, Inc. Louisiana
Hospital Group of New Jersey, Inc. New Jersey
Hampton Learning Center, Inc. New Jersey
HGNJ, Inc. New Jersey
CooperSurgical, Inc. Delaware
HBH Medizintechnik GmbH Germany
The Cooper Real Estate Group, Inc. Delaware
NOTE: Except for CooperSurgical and its 52% owned subsidiary, HBH
Medizintechnik GmbH, each subsidiary is wholly-owned either by
The Cooper Companies, Inc. or by the wholly-owned subsidiary under
which it is indented in the list above. In the case of CooperSurgical, Inc.,
97.5% of the company is owned by The Cooper Companies, Inc. and the remaining
2.5% is owned by members of CooperSurgical's Medical Advisory Board.
<PAGE>
</TABLE>
<PAGE>
ACCOUNTANT'S CONSENT
The Board of Directors
The Cooper Companies, Inc.
We consent to incorporation by reference in the Registration Statement Nos.
33-50016 and 33-11298 on Form S-3 and Registration Statement Nos. 33-27938,
33-36325 and 33-36326 on Form S-8 of The Cooper Companies, Inc. of our reports
dated December 11, 1995, relating to the consolidated balance sheets of The
Cooper Companies, Inc. and subsidiaries as of October 31, 1995 and 1994 and the
related consolidated statements of operations, stockholders' equity (deficit)
and cash flows for each of the years in the three-year period ended October 31,
1995, and all related schedules, and the consolidated balance sheets of Hospital
Group of America, Inc. and subsidiaries as of October 31, 1995 and 1994 and the
related consolidated statements of operations, stockholders' equity (deficiency)
and cash flows for each of the years in the three-year period ended October 31,
1995, and related schedule, and of our report dated December 4, 1995 relating to
the balance sheets of CooperSurgical, Inc. as of October 31, 1995 and 1994 and
the related statements of operations, stockholders' equity (deficit) and cash
flows for each of the years in the three-year period ended October 31, 1995, and
related schedule, which reports appear in the October 31, 1995 Annual Report on
Form 10-K of The Cooper Companies, Inc.
San Francisco, California
January 11, 1996
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> OCT-31-1995
<PERIOD-START> NOV-01-1994
<PERIOD-END> OCT-31-1995
<CASH> 11,207
<SECURITIES> 0
<RECEIVABLES> 19,958
<ALLOWANCES> 2,241
<INVENTORY> 9,570
<CURRENT-ASSETS> 41,228
<PP&E> 46,597
<DEPRECIATION> 12,535
<TOTAL-ASSETS> 91,992
<CURRENT-LIABILITIES> 39,613
<BONDS> 43,490
<COMMON> 1,158
0
0
<OTHER-SE> (2,907)
<TOTAL-LIABILITY-AND-EQUITY> 91,992
<SALES> 55,296
<TOTAL-REVENUES> 97,090
<CGS> 17,549
<TOTAL-COSTS> 58,003
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 2,300
<INTEREST-EXPENSE> 4,741
<INCOME-PRETAX> 230
<INCOME-TAX> 115
<INCOME-CONTINUING> 115
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 115
<EPS-PRIMARY> .01
<EPS-DILUTED> .01
<PAGE>
